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Abstract
The Centers for Medicare and Medicaid Services (CMS) instituted the Hospital Readmission
Reduction Program (HRRP) to reduce the frequency of heart failure (HF) 30-day hospital
readmissions. To meet the needs of patients with end-stage HF, palliative care (PC) is promoted
to provide additional support to patients and reduce unnecessary hospital readmission. While PC
is a plausible and logical intervention, effectiveness in achieving a reduction in readmissions has
not been assessed in an HF population with adequate controls to assess confounding. The goal of
this research was to assess the effectiveness of palliative care for HF (HFPC) consult to effect
change in 90-day hospital readmissions in a propensity-matched model that adequately controls
for mortality at a single-site 526-bed tertiary-care facility. Index hospitalization for live HF
discharges: Oct 1 - Dec. 31, 2019, n =250. Propensity matching aided in achieving a more
homogeneous population with less variability and ensured a greater likelihood of observing an
accurate and valid assessment of the outcome of interest. Results were statistically significant,
demonstrating a strong association between HFPC consult and 90-day hospital readmission in a
propensity-matched population. Logistic regression showed a statistically significant association
between HFPC and 90-day hospital readmission, p < .001. The logit transformation of the HFPC
factor, OR 4.3, 95% CI [1.8 - 10.6]. Survival analysis demonstrated that time to readmission
happens more frequently in patients who have an HFPC consult; readmissions occur earlier in
the post-discharge period and are strongly skewed to the immediate 30-day post-discharge
period. Further, more than 50% of HF patients who have an HFPC consult experience a hospital
readmission within 30 days of discharge, and more than 75% of HF patients who have an HFPC
consult will have a hospital readmission within 90 days of discharge. This dissertation study
demonstrated that while HFPC may be an important aspect of continuity of care and care

planning for HF patients, it has a strong negative association with the objective of reducing
hospital readmissions. HFPC consult predicted earlier hospital readmissions in this HF
population with high morbidity, approaching end-of-life.
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Chapter 1: Introduction
Introduction
The Centers for Medicare and Medicaid Services (CMS) instituted the Hospital
Readmission Reduction Program (HRRP) to reduce the frequency of heart failure (HF) 30-day
hospital readmissions. To fill the health care needs of patients with end-stage heart failure,
palliative care (HFPC) and hospice referrals are promoted to provide additional support to
patients, in addition to their primary care and specialist physicians, and reduce unnecessary
hospital readmission. While HFPC is a plausible and logical intervention, effectiveness in
achieving a reduction in readmissions has not been assessed in a heart failure population with
adequate controls to assess potential sources of confounding and interaction. This dissertation
study demonstrated the error of this assumption.
Patients must have a diagnosis of end-stage heart failure to be eligible for referral to
palliative care (PC). Patients with end-stage heart failure are intuitively expected to have a higher
rate of mortality compared to patients without a diagnosis of end-stage heart failure. These
factors suggest that patients eligible for HFPC would be at higher risk for increased mortality
events than patients not eligible for HFPC services; thus, any evidence supporting HFPC as an
intervention to reduce hospital readmission should control mortality. However, most
administrative datasets used for health services research do not capture mortality.
Currently, hospital-readmission metrics include all patients diagnosed with HF who are
readmitted within a 30-day time period in their numerator, with the denominator including all
patients discharged with a diagnosis of HF. If the patient experiences a mortality event in the 30day period after hospital discharge, there is no opportunity for readmission, and the mortality
event does not accrue to the numerator of the admitting hospital readmission metric. Studies, to
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date, have evaluated the efficacy of palliative care to achieve a reduction in hospital
readmissions but have not evaluated this potential for significant differential mortality. Thus, not
accounting for mortality in follow-up studies evaluating the effectiveness of HFPC (Palliative
Care for Heart Failure) may result in significant ascertainment bias. If differential mortality is
present but unquantified and mortality is more prevalent in the HFPC group, a Type I error will
occur, or a significant intervention effect will be found when, in truth, there is no intervention
effect.
This investigation evaluated the potential for differential mortality in the relationship
between 90-day HF hospital readmission and eligibility for referral to HFPC with a thorough
mortality follow-up of all patients admitted for HF. This investigation assessed the mortalityadjusted, propensity-matched (severity-adjusted) relationship between HFPC consult and 90-day
hospital readmission in patients with a diagnosis of end-stage heart failure (HF) in the current
context of administrative mandates that aim to reduce the frequency of HF hospital readmissions.
Problem Statement
Heart failure is the most common discharge diagnosis in the United States, affecting 5.1
million people annually (Arora et al., 2017; Fasolino & Phillips, 2016). Of the estimated 900,000
COVID-19 hospitalizations that occurred through November 2020, 12% of hospitalizations were
attributable to heart failure (O’Hearn et al., 2021). The Centers for Medicare and Medicaid
Services (CMS) implemented components of the 2010 Affordable Care Act with the introduction
of the Hospital Readmission Reduction Program (HRRP) and publicly reported hospital 30-day
all-cause risk-standardized mortality rates and 30-day all-cause risk-standardized readmission
rates for acute myocardial infarction (AMI), heart failure (HF), and pneumonia (Krumholz et al.,
2013). In October 2012, CMS introduced penalties and reduced Medicare payments for excess
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readmissions in a broad array of inpatient hospitalizations, specifically HF, based on a ratio of
predicted versus expected 30-day readmissions (Medicare, 2017). According to Davis et al.
(2017), a higher than expected rate of 30-day readmissions following HF hospitalization can
negatively impact hospital performance measures and incur reimbursement penalties. A myriad
of interventions has since been proposed to decrease the number of HF readmissions (Bradley et
al., 2013). The introduction of palliative care to end-stage organ failure patients is new and has
received increasing attention worldwide in the last decade (Ng et al., 2016).
Research evaluating the effectiveness of a PC consult in the setting of acute
hospitalization for HF as an intervention to decrease 30-day hospital readmission has shown
mixed results and methodological limitations. A broad array of guidelines promote its adoption,
while the literature has demonstrated poor reproducibility of the reliability of an HFPC consult to
effectively reduce hospital readmissions (Chuang & Fausto, 2014; Chuang et al., 2017; Nelson et
al., 2011; O’Connor et al., 2015; Wiskar et al., 2017). Retrospective studies have been limited by
a lack of validation studies assessing sensitivity and specificity of the PC consultation coding
(ICD9-V66.7) and ascertainment bias with an inability to measure differential mortality (Hua et
al., 2017; Wiskar et al., 2017). Prospective studies have been limited by low enrollment and loss
to follow-up, leading to the study being underpowered, with unintended crossover and limited
PC staffing resources to sustain the intervention (Sidebottom et al., 2015; Szekendi et al., 2016).
The goal of this dissertation study was to assess the effectiveness of HFPC consult to effect
change in 90-day hospital readmissions in a propensity-matched model that adequately controls
for mortality at a single-site 526-bed tertiary-care facility.
Heart Failure
The impetus for HFPC arises from issues pertaining to the incidence, prevalence, and
cost of HF, which is the most common discharge diagnosis in the United States, affecting more
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than five million patients annually (Arora et al., 2017; Fasolino & Phillips, 2016). By 2030, with
prevalence remaining stable, more than eight million patients in the United States will have HF,
with expected three-year mortality rates as high as 50% among Medicare beneficiaries after an
HF admission (Heidenreich et al., 2013). Even if prevalence remains constant for age, sex, race,
or ethnicity, rising costs and technological innovation are expected to increase the total direct
medical costs of HF from $21 billion to $53 billion. Inclusive of indirect costs, total expenditure
is projected to increase from $31 billion to $70 billion in 2030 (Heidenreich et al., 2013).
Readmissions
The impetus for HFPC arises out of issues relating to hospital readmission rates.
Readmission rates were first introduced in 1953 to characterize risk among neuropsychiatric
patients discharged from the Department of Veterans Affairs (VA) hospitals (Jenkins et al.,
1953). In 2009, CMS began to publicly report hospital 30-day all-cause risk-standardized
mortality rates and 30-day all-cause risk-standardized readmission rates for AMI, HF, and
pneumonia (Centers for Medicare and Medicaid Services, 2015; Krumholz et al., 2013). The
2010 Affordable Care Act implemented the HRRP on the premise that a hospital’s scope of
responsibility should include post-discharge care coordination (Centers for Medicare and
Medicaid Services; Chin et al., 2016).
In October 2012, CMS began reducing Medicare payments for inpatient hospitalizations
based on a ratio of predicted versus expected 30-day readmissions for AMI, HF, pneumonia,
Chronic Obstructive Pulmonary Disease(COPD), hip or knee replacement, and CABG surgery
(Centers for Medicare and Medicaid Services, 2015). More than the expected 30-day
readmissions following HF hospitalization negatively impacts hospital performance measures
and reimbursement (Davis et al., 2017). A myriad of interventions have since been proposed to
decrease the number of HF readmissions, some criticized as encouraging inappropriate care
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strategies to achieve a reduction in readmission rates (Bradley et al., 2013; Woolhandler &
Himmelstein, 2016). However, whether HFPC is an appropriate care strategy to achieve these
aims has not been fully evaluated.
CMS implemented thirty-day readmission rates despite limited evidence supporting 30day readmission rates as an indicator of between-hospital variation in the quality of care (Chin et
al., 2016; National Quality Forum, 2016). The team that developed the metrics noted low
intracluster correlation coefficients (ICC) of 4.8-5.3% for mortality measures and 1.5-2.6% for
readmission measures (Chin et al., 2016). ICCs represent the proportion of risk explained by
hospitals (between-hospital variation) compared to the total risk in the population (all variation;
Chin et al., 2016). This poor correlation was further evaluated by Chin et al. (2016), who found a
sharp and consistent reduction in the readmission ICC after the seventh-day post-discharge,
suggesting that a significant proportion of the presumed hospital quality signal at 30 days may be
attributed to other characteristics of the individual and community setting of care. These
characteristics include the socioeconomic and demographic profile of the hospital’s patient
population, the hospital’s resource availability, and patient social support or mental health issues
(Chin et al., 2016; Pandey et al., 2017).
Other HF studies have likewise failed to demonstrate a strong association between inhospital quality of care and 30-day readmission rates (Fischer et al., 2015). The goal of the
selection of 30-day readmission rates as an indicator of quality relates more to encouraging
hospitals to assume responsibility for post-discharge adherence and primary care follow-up
rather than hospital quality of care. In addition, it is to represent a public policy intended to shift
responsibility to the hospital provider to promote a more cohesive shared responsibility for
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continuity of care (Chin et al., 2016). Time to readmission intervals was an important
consideration for this investigation and the determination of HFPC effectiveness.
Hospitals with the greatest burden of readmissions are more likely to be penalized for
higher readmission rates, raising questions of whether CMS readmissions penalties are equitably
and justly applied for hospitals with a high prevalence of socially or medically complex patients
(Pandey et al., 2017). A recent evaluation of readmissions for AMI, a condition related to HF,
found an inequitable burden of readmission among hospitals serving patient populations with
higher levels of social disadvantage and higher illness acuity (Pandey et al., 2017). Inequity is an
important consideration in the evaluation of HFPC, which is also prone to similar inequities.
AdventHealth Tampa was chosen as the site for this investigation primarily because of its
advocacy of PC services to the HF population.
Studies have established a temporal decline in HF readmissions but have been criticized
as confounded by changes in coding rather than improvements in care (Desai et al., 2016; Jha,
2015; Zuckerman et al., 2016). Emerging evidence has also demonstrated the potentially harmful
effects of the HRRP with increased mortality associated with continuing implementation
(Dharmarajan et al., 2017; Fonarow et al., 2017; Gupta et al., 2017; Krumholz et al., 2013).
There are emerging calls for HRRP outcome metrics to be reevaluated to align with evidence
that acute care and discharge quality metrics do not appear to influence readmissions. Hospital
readmissions are often attributable to individual and community aspects of care, indicating the
need to identify better quantified strategies that can reliably meet patients’ needs and effectively
manage morbidity, leading to unnecessary hospital readmission. Alternative explanations of
decreasing HF readmission trends are an important consideration of efficacy in evaluating HFPC
and its relationship to reducing 90-day hospital readmissions. This dissertation study also
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assessed the differential time to readmission for patients who have an HFPC consult compared to
those who do not. The study will contribute to the evidence on the effectiveness of palliative care
to meet these diverse patient needs and reduce hospital readmission. Specifically, this research
assessed the effectiveness of palliative care for HF (HFPC) consult to effect change in 90-day
hospital readmissions in a propensity-matched model that adequately controls for mortality.
Palliative Care
The expansion of palliative care programs beyond cancer to end-stage organ failure
patients is new and has received increasing widespread attention worldwide in the last decade
(Ng et al., 2016). A key element of hospital interest in palliative care is the risk adjustment it
affords, the presence of a coded palliative care consult (V667) or hospice referral on the
electronic medical record of the patient admitted with HF increases the expected count of HF
readmissions in CMS quality calculations and creates a greater opportunity for the hospital to
have a less than the expected count of HF readmissions, which translates into a higher quality
score for the admitting hospital (Trivette, 2017).
PC has shown an ability to reduce readmission rates in mixed patient populations (Nelson
et al., 2011; O’Connor et al., 2015). Preceding implementation of HRRP, Kaiser Permanente
researchers conducted a prospective pre versus post-intervention with a fully constituted PC
team. They found a statistically significant 2 reduction in six-month readmissions from 1.15 to 0.7
readmissions per patient (Nelson et al., 2011). After implementing HRRP, University of
Pennsylvania researchers conducted a retrospective review of PC consults and reported a
protective effect3 for 30-day hospital readmission (O’Connor et al., 2015). Both studies were
limited by a study population that relied on the presence of a PC consult request, creating a
2
3

p =.025
OR 0.66, p < 0.001, 95% CI [0.55 - 0.78]
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significant risk of selection bias, in that patients most likely to adhere to PC guidance were
selected and therefore likely to bias the observed results.
Furthermore, mortality was not assessed; this added an ascertainment bias. Ascertainment
bias and the significant potential for confounding by mortality were important elements
controlled for in this investigation in establishing the effectiveness of HFPC to reduce 90-day
hospital readmissions. A broad array of stakeholders have also produced consensus statements
that support the introduction of palliative care for HF (American Academy of Hospice Palliative
Medicine, Center to Advance Palliative Care, Hospice Palliative Nurses Association, Last Acts
Partnership & National Hospice Palliative Care Organization, 2004; Davies & Higginson, 2004;
Goodlin et al., 2004; Jaarsma et al., 2009; Yancy et al., 2013). These guidelines also identify
several challenges, including defining criteria for appropriateness for HFPC consultation,
barriers to referral, consistency of service delivery, and HFPC team resources.
Another factor that influences the consistent adoption of palliative care in the acute care
environment is the broad variability in the hospital-level perceived appropriateness for an HFPC
consult. Even though overall eligibility for an HFPC consult is consistently high, with 18.8% of
the total inpatient population determined to be eligible, HFPC consult rates for eligible patients
varied widely from 12.5% - 58.8%, but not achieving 100% referral of eligible patients
(Szekendi et al., 2016). Evaluating variation in appropriateness by diagnosis, Szekendi et al.
(2016) found that patients with poor prognosis cancer were appropriate for a PC consult 100% of
the time, while patients with advanced HF (Class IV, LVAD, or EF <35%) were appropriate just
33% of the time. Demonstrating similar challenges to appropriately identify patients for a PC
consult in the setting of a complex chronic condition, patients with a diagnosis of COPD
(oxygen-dependent or FEV1 <30%) received an appropriate referral just 32% of the time. This
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variation in appropriateness for PC consultation by diagnostic criteria demonstrates the
confusion of non-PC clinicians who are primarily familiar with the system of palliative care that
focuses on cancer end-of-life care. The hospital site for this investigation was specifically chosen
because it has been a consistent, strong proponent of PC services to the HF population.
Another important factor is the consistency of delivery of PC services. Of those
appropriate for referral, a minority (31.6%) received a referral and actual delivery of any PC
services (Szekendi et al., 2016). A further 29.8% received a referral but no PC services, and the
remaining 60.9% of those appropriate for a referral received neither a referral nor services
(Szekendi et al., 2016). A physician order is often necessary to operationalize PC or hospice
referral but is not sufficient to ensure completed service delivery. AdventHealth Tampa has
eliminated this barrier by implementing a site policy enabling activation of a nurse-initiated
HFPC consult request. There is also considerable variation in the definition of what services are
included in a palliative care consult for HF (Szekendi et al., 2016). Other work has suggested
that HFPC focused primarily on symptom control did not decrease readmissions 4 compared to
HFPC focused on advanced care planning and goals5 (O’Connor et al., 2015). Poor consistency
of service delivery complicates the ability of the non-PC clinician to be confident in the services
that may be provided if an HFPC consult is requested and likewise for researchers determining
effectiveness (Szekendi et al., 2016). The consistency of service delivery at AdventHealth
Tampa via a site policy enabling nurse-activated HFPC consult requests minimizes the potential
bias of this issue. The resources available on the HFPC team are also variable and may include a
PC physician, an inpatient PC RN, a social worker, a bioethicist, and hospital chaplain;

4
5

OR 1.05, p =0.684, 95% CI [0.82 - 1.35]
OR 0.36, p < 0.001, 95% CI [0.27 - 0.48]
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alternatively, it may comprise a palliative care RN only, or there may be no team available
(Nelson et al., 2011).
Lastly, validating completed service delivery is complicated by variable hospital coding
practices, defined as documentation of an ICD-9 V66.7 palliative care encounter, ranging from
0-100%, limiting the accuracy and reliability of administrative data (Szekendi et al., 2016). This
evidence demonstrates important methodological issues: (a) consistency of referral to PC
services, (b) consistency of availability of PC services, (c) reliability of completed service
delivery, (d) consistency and reproducibility of PC services provided, and (e) reliability of
accurately assessing the delivery of PC services. AdventHealth Tampa minimizes these
methodological issues respectively by (a) enabling nurse-activated HFPC consult requests, (b)
partnerships that ensure consistency of availability of PC services, (c) reliability of completed
consult on the medical record, (d) consistency and reproducibility of PC services provided, albeit
limited to this single site which may not be generalizable to the broader population of hospitals,
and (e) reliability of the completed consult is verifiable within the body of the medical record.
While the reliability of the model of services for HFPC is an important aspect of HFPC service
delivery, the scope of services provided is beyond the scope of this investigation.
A third factor is the reliability of the model of services for HFPC that is significantly
different from cancer-focused end-of-life care compared to an end-organ failure trajectory of
decline (Jaarsma et al., 2009). The trajectory of decline associated with end-organ dysfunction,
such as HF, demonstrates a more gradual loss of function interrupted by acute exacerbations that
cause sudden precipitous losses in function without a full return to baseline over time; this
indicates a need to reevaluate the underlying assumptions that have been developed from a
primarily cancer-focused end of life care model and applied to HF management to decrease
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readmissions (Jaarsma et al., 2009). The scope of services provided for cancer-focused PC would
be expected to be substantively different than the scope of services for HFPC. In addition, PC
efficacy based on previously mixed patient populations cannot be reliably generalized to the
population of patients with HF demonstrating different trajectories of decline. While the model
of services for HFPC is important, it is beyond the defined scope of this investigation.
A fourth factor is the major barriers that exist in initiating a physician-ordered referral for
palliative care: (a) there is typically no standard definition of palliative care within the
organization, resulting in subjective criteria and wide variation amongst clinicians; (b) HFPC is
erroneously associated with end of life care and life expectancy of two weeks or less; (c)
educational opportunities for non-PC clinicians to gain skills in primary palliative care are
infrequent and rarely mandatory; (d) subspecialist physicians with longstanding patient
relationships retain a desire to maintain that relationship and provide subspecialist management
that may not be met by a HFPC clinician; and (e) an internal psychological conflict that exists for
both patients and clinicians in the perception of referral to HFPC indicates a choice for end of
life care and the seemingly competing interest to seek advanced specialty care and pursue access
to advanced cutting edge therapies, for example, “giving up” versus “doing everything”
(Szekendi et al., 2016). While these human factors issues are important, they are beyond the
scope of this investigation.
Despite these challenges, several recent studies have sought to establish the effectiveness
of HFPC to reduce hospital readmission. A large post-HRRP longitudinal analysis using the
Agency for Healthcare Quality and Research (AHRQ) Nationwide Readmission Database (NRD)
that compiles all hospital admissions for patients from 22 states and tracks patients throughout
the year found that propensity-matched HF patients with a primary diagnosis of HF (ICD9
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428.xx) who received an HFPC consult were 58% less likely to be readmitted for HF, 6 and 54%
were less likely to be readmitted for any cause7 during the nine-month follow-up period (Wiskar
et al., 2017). Noting the inherent susceptibility of administrative datasets to diagnostic and
procedure coding errors, the authors noted a limitation for this study was the absence of
validation in an HF population that coding of a PC visit actually occurred and relied on previous
validation of PC coding in a stroke population with a sensitivity of 81% and specificity of 97%
(Wiskar et al., 2017). A second validation study in a mixed patient population at a single center
noted problems assessing the validity of the V66.7 code for documentation of PC consultation
with a poor sensitivity of 53.9% and specificity of 75.1% (Hua et al., 2017).
Montefiore Medical Center researchers further evaluated the effectiveness of HFPC with
a retrospective cohort study and, in a reversal of their findings from an earlier 2014 study, found
that while fewer patients with a completed palliative care consult were readmitted, compared to
those with a consult ordered but not completed, the difference was not statistically significant 8
(Chuang & Fausto, 2014; Chuang et al., 2017). The researchers noted an important limitation in
their studies was an inability to control for mortality that may produce a differential assessment
of the readmission outcome; patients with HFPC consultation or hospice referral may die,
resulting in fewer readmissions in the HFPC cohort. Allina Health investigators executed a
randomized intervention for patients appropriate for HFPC but noted no statistically significant
change in readmission within 30 days9 (Sidebottom et al., 2015). Interpretation of results was
limited by an underpowered sample size, crossover, and losses to follow-up if readmission
occurred outside of the hospital system (Sidebottom et al., 2015). While not reflective of a US
6
7
8
9

9.3% versus 22.4%, p < 0.01
29.0% versus 63.2%, p < 0.01
43% and 53%, respectively, x2 =1.9, p =0.171
HR 1.43, 95% CI [0.5 - 4.1]
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health care system or population, the challenge of reducing HF readmissions with HFPC has also
been evaluated in international settings in Hong Kong with a randomized intervention that noted
the absence of a statistically significant difference10 (Wong et al., 2016). These studies reflect the
limitations found in previous studies that showed important confounders that were controlled for
in this investigation of HFPC and its effectiveness at decreasing 90-day hospital readmission.
Relevance and Significance
This dissertation study is relevant to the development of evidence in several key health
care areas of interest, including heart failure, hospital readmissions, and palliative care. Heart
failure prevalence is increasing; administrative pressures to reduce hospital readmissions show
no sign of weakening, and alternative strategies like palliative care require an evidence-based
and methodologically rigorous evaluation of outcomes. This study assessed whether a hospitalgenerated referral to palliative care services could reduce 90-day hospital readmissions for heart
failure in a propensity-matched model after controlling for mortality.
Research Question and Hypotheses
This dissertation study addressed the following research questions and hypotheses:
RQ1: Will a hospital-generated referral to palliative care services reduce 90-day hospital
readmissions for heart failure in a propensity-matched model after controlling for mortality?
H0: There is no significant difference in 90-day readmissions in HF patients receiving
HFPC consultation versus patients not receiving HFPC consultation after controlling for
mortality and severity.
H1: The increased level of resources, education, facilitated decision-making, and future
health planning would enable patients to better understand their symptoms and improve health

10

20.9% versus control 29.3%, x2 =4.41, p =0.79
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behaviors through a better understanding of the health system that will allow them to seek health
care services in less hospital-oriented settings and ultimately decrease hospital readmissions.
H1a: There is a statistically significant difference in 90-day readmissions in HF patients
receiving HFPC consultation versus patients not receiving HFPC consultation after controlling
for mortality and severity.
To answer the research question, appropriate measures were abstracted to assess the
impact of previously unaddressed confounders that carry a significant risk of ascertainment bias
(e.g., mortality). The research question also ensured the comparison of similar risk characteristics
by using a propensity-matched model (e.g., comparing hospital readmissions of patients with HF
with similar acuity). This investigator assumes that a better understanding of the health system
will enable patients to seek health care services in less hospital-oriented settings and ultimately
decrease hospital readmissions.
Definition of Terms
AMI

Acute myocardial infarction

ACA

Affordable Care Act

ACE

Angiotensin Converting Enzyme inhibitors

AMA

Against Medical Advice

ARB

Angiotensin Receptor Blocker

CABG

Coronary artery bypass graft surgery

CMS

Centers for Medicare and Medicaid Services

COPD

Chronic Obstructive Pulmonary Disease

CRT

Cardiac Resynchronization Therapy device

EF%

Ejection Fraction Percent
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HF

Heart Failure

HFPC

Heart Failure Palliative Care

HRR

Hospital readmission rates

HRRP

Hospital Readmission Reduction Program

IABP

Intra-Aortic Balloon Pump

ICD

Implantable Cardiac Defibrillator

ICD-10

International Statistical Classification of Diseases and
Related Health Problems, 10th revision

PC

Palliative Care

PMHx

Past Medical History

SNF

Skilled Nursing Facility

SPSS

Statistical Package for the Social Sciences

Summary
Recent administrative mandates from the Centers for Medicare and Medicaid Services
embodied in the Hospital Readmission Reduction Program aim to reduce the frequency of heart
failure 30-day hospital readmissions. To fill the health care needs of patients with end-stage heart
failure, palliative care referrals are promoted to provide additional support to patients in addition
to their primary care and specialist physicians. As a result, patients have an improved
understanding of their disease, improving disease management and thereby decreasing hospital
utilization, thus reducing hospital 30-day readmissions after an index HF hospitalization.
Heart failure is the most common discharge diagnosis in the United States, affecting 5.1
million annually (Arora et al., 2017; Fasolino & Phillips, 2016). CMS implemented components
of the 2010 Affordable Care Act with the introduction of the HRRP and initiated public reporting
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of key hospital metrics for mortality and readmission rates for AMI, HF, and pneumonia
(Krumholz et al., 2013). In October 2012, penalties were introduced, and Medicare payments for
inpatient hospitalizations were reduced based on a ratio of predicted versus expected 30-day
readmissions (Medicare, 2017). HFPC for end-stage organ failure patients is widely promoted as
an effective intervention and has received increasing attention worldwide in the last decade (Ng
et al., 2016). As noted, research evaluating the effectiveness of HFPC consultation or hospice
referral in the setting of acute hospitalization for HF as an intervention to decrease 30-day
hospital readmission has yielded mixed results and methodological limitations (Chuang &
Fausto, 2014; Chuang et al., 2017; Hua et al., 2017; Nelson et al., 2011; O’Connor et al., 2015;
Sidebottom et al., 2015; Szekendi et al., 2016; Wiskar et al., 2017).
The hypothesis of this investigation was that the increased level of resources, education,
facilitated decision-making, and future health planning would enable patients to better
understand their symptoms and improve health behaviors through a better understanding of the
health system that will allow them to seek health care services in less hospital-oriented settings
and ultimately decrease hospital readmissions. This investigation assessed the effectiveness of
palliative care referral to reduce 90-day hospital readmissions for heart failure. The research
question measured the impact of potentially important mortality confounding, and it used a
propensity-matched model to ensure comparison of similar risk characteristics. This research
also assessed the mortality-adjusted relationship between HF propensity-matched cohorts and
90-day hospital readmission in the current context of administrative mandates that aim to reduce
the frequency of HF hospital readmissions.
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Chapter 2: Review of the Literature
Historical Review of the Literature Contributing to the Topic
A comprehensive historical review of the literature pertaining to this investigation of
HFPC and 90-day hospital readmission requires an in-depth understanding of the literature
associated with heart failure, hospital readmissions, and palliative care. It also requires an
understanding of the factors that contribute to the societal and individual burden of heart failure,
including (a) an assessment of the literature pertaining to the incidence, prevalence,
pathogenesis, and disease progression of heart failure, (b) a review of the development and
evolution of the hospital readmission metric and associated administrative mandates, (c) an
understanding of the symptomatic burden of disease for patients. Moreover, a complete historical
review of the literature for this investigation requires an understanding of the factors that
contribute to the issues pertaining to HF readmissions, including (a) an appreciation of the
economic burden for hospitals related to HF hospital readmission, (b) a recognition of the
posited emergence of increased mortality associated with downward trends of HF readmission
subsequent to initiation of the administrative mandates, (c) the challenges involved with
identifying effective alternative strategies to reduce HF readmissions, and (d) an understanding
of the complexities of medical management when implementing a comprehensive strategy to
reduce HF readmission. Lastly, a full review of the literature pertaining to this investigation
requires an understanding of the definition and evolution of palliative care, including (a) the
variation in the trajectory of disease that requires careful consideration when applying a service
traditionally developed to provide care for terminal cancer patients, (b) the breadth of
recommendations and position statements that advocate for the use of palliative care in patients
with HF, and (c) trends and barriers for implementation of HFPC consistently and reliably.
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Historical Review of the Literature Relating to HF
A comprehensive historical review of the literature pertaining to the investigation of
HFPC and 90-day hospital readmission requires an understanding of the factors that contribute to
the societal and individual burden of heart failure, including (a) an assessment of the literature
pertaining to the incidence, prevalence, pathogenesis and disease progression of heart failure, (b)
a review of the development and evolution of the hospital readmission metric and associated
administrative mandates, and (c) an understanding of the symptomatic burden of disease for
patients. The sustained incidence, increasing prevalence, and significant lifetime risk create the
strong imperative to improve all aspects of care associated with the diagnosis of HF. The
prevalence of risk factors in the US population, the increasing prevalence of obesity and
diabetes, the associated cost for care, and potentially significant increases in the future cost of
care for patients with HF indicate a significant imperative to improve the care and management
of individuals with HF. The challenges of a clinical syndrome with high mortality, complex
medical management of multiple comorbidities, and challenges with identifying interventions
with associated mortality benefit create the imperative for identifying new strategies for
improved management of patients with HF.
Diagnosis and Case Definition of HF
HF is a complex clinical syndrome comprised of cardiac and pulmonary signs and
symptoms, including paroxysmal nocturnal dyspnea, orthopnea, neck vein distension, rales,
cardiomegaly, jugular venous pressure elevation, ankle edema, dyspnea on exertion, and pleural
effusion (Dunlay & Roger, 2014).
Incidence and Prevalence of HF
The current incidence of HF is based on data from 2005 to 2014 from the National Heart,
Lung, and Blood Institute’s (NHLBI) Atherosclerosis Risk in Communities (ARIC) study’s
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community surveillance and demonstrates 1,000,000 incident cases annually in individuals > 55
years of age (Huffman et al., 2013). Incident cases are also highly skewed towards older adults,
with rates for White males per 1,000 person-years estimated at 32 cases over the age of 75, 11
for ages 65 -74, and 3.9 for ages 55-64 (Benjamin et al., 2018). Temporal trends in incidence
suggested an overall decline in HF incidence between 2000 and 2010, while earlier studies
indicated that the incidence of HF has remained largely stable over time (Barker et al., 2006;
Gerber et al., 2015; Levy et al., 2002; McCullough et al., 2002).
In 2018, 6.5 million (2.5%) Americans >20 years of age were estimated to have a
diagnosis of HF based on 2011 to 2014 National Health and Nutrition Examination Survey
(NHANES) data, representing a 12% increase in prevalence from 2012, and consistent with the
model projecting a prevalence of 8.5 million (3%) of Americans by 2030 (Benjamin et al., 2018;
Heidenreich et al., 2013). Projections estimate a 46% increase in the prevalence of HF from 2012
to 2030 due to the aging of the population and improvements in the delivery of care that improve
survival (Benjamin et al., 2018; Heidenreich et al., 2013). Prevalence is highly skewed towards
older adults, with 14.1% of men over the age of 80, 6.2% of men 60-79, 1.4% of men age 40-59,
and just 3% of men age 20-39 identified as cases. Prevalence data is based on self-report,
calculated based upon a response of “yes” to the question of ever having congestive heart failure
during the NHANES data collection (Benjamin et al., 2018). NHANES data are likely to
underestimate actual prevalence as found in even a small sample. When asked to self-report “Do
you have HF?” eight of 94 (8.5%) responded “no” (Gilotra et al., 2017).
Temporal trends in incidence and prevalence may be affected by variability in the
reliability of diagnostic criteria used to diagnose HF, the reliability of other methodologies that
rely on self-report or billing codes for the diagnosis of HF, and methodologies that rely on the
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occurrence of a hospitalization event to identify a quantifiable case of HF (Dunlay & Roger,
2014). Incidence and prevalence estimates are also affected by the population examined, with
Medicare beneficiaries demonstrating higher incidence rates compared to young populations.
Moreover, lifetime risk is high, with 20-45% of individuals age 45 to 95 estimated to acquire a
diagnosis of HF. Lifetime risk of HF was similar amongst White (32-39%) and Black (24-36%)
females. Disparate lifetime risk of HF was estimated in White men (30-42%) versus Black men
(20-29%) due to competing mortality risks for Black men (Huffman et al., 2013). The sustained
incidence, increasing prevalence, and significant lifetime risk create the strong imperative to
improve all aspects of care, including effective measures to prevent excess hospital readmission
associated with the diagnosis of HF.
Risk Factor Prevalence and Cost of HF
Risk factors for HF are common, with at least one risk factor present in up to 33% of the
US adult population (Benjamin et al., 2018). Coronary artery disease, hypertension, diabetes
mellitus, obesity, and smoking are responsible for 52% of incident HF cases (Heidenreich et al.,
2013). Lack of optimal control of blood pressure, cholesterol, diabetes, smoking, and body mass
is estimated to account for 88.8% of incident HF events (Dunlay & Roger, 2014). Racial
disparities and dietary and lifestyle factors are also significant contributors to HF risk
(Heidenreich et al., 2013). Demographic risk factors include older age, male sex, ethnicity, and
low socioeconomic status (Heidenreich et al., 2013). Dunlay and Roger (2014) reported that the
risk factor prevalence of hypertension, hyperlipidemia, and smoking has declined, while the
prevalence of obesity and diabetes has risen.
Associated total cost for HF in 2012 was estimated to be $30.7 billion, of which 68% was
attributable to direct medical costs. Heidenreich’s model also projects a 127% increase in total
cost to $69.7 billion by 2030 (Heidenreich et al., 2013). Notably, potential costs could rise as
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much as $160 billion in direct cost alone by 2030 (Heidenreich et al., 2013). Hospitalizations
(including readmissions) are prevalent after an HF diagnosis, with 83% of patients hospitalized
at least once and 43% hospitalized at least four times, and represent a substantial portion (75%)
of the cost of HF care (Dunlay & Roger, 2014; Heidenreich et al., 2013). Total individual
lifetime costs were $109,541,11 with the majority accumulated during hospitalizations (mean
$83,980 per person; Dunlay et al., 2011).
Other factors that affect cost include the use of long-term care facilities and the impact of
advanced heart failure therapies. Discharges to a skilled nursing facility (SNF) increased among
Medicare beneficiaries from 6.8% in 1980-84 to 13.4% between 2000-2004 (Dunlay & Roger,
2014). Further, 24.1% of Medicare beneficiaries in an evidence-based prevention program were
discharged to an SNF after an HF hospitalization (Dunlay & Roger, 2014). More than 50% of HF
hospitalizations to SNF expire within one year (Dunlay & Roger, 2014). Advanced heart failure
therapies such as organ transplants and left ventricular assist devices (LVAD) are costly, and
eligible patients represent only a small fraction of all US cases of those living with HF (Dunlay
& Roger, 2014). The prevalence of risk factors in the US population, the increasing prevalence
of obesity and diabetes, the associated cost for care, and potentially significant increases in the
future cost of care for patients with HF indicate a significant imperative to improve the care and
management of individuals with HF. Interventions such as HFPC may address the burden of
disease and decrease costs predominantly by decreasing hospital readmissions.
Mortality and Comorbidity
After the initial diagnosis of HF, survival is 72-75% at one year and 35-52% at five years,
which has significantly improved in recent decades, nonetheless indicating a diagnosis with

11

95% CI [$100,335 - 118,946]
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substantially high mortality rates (Dunlay & Roger, 2014). While efficacious for symptom
management, established HF treatment alternatives such as diuretics, ultrafiltration, vasodilators,
inotropes, and spironolactone have demonstrated no mortality benefit in large, well-conducted
clinical trials (Rayner-Hartley et al., 2018). Multiple comorbidities in HF constitute a significant
burden of medical complexity in HF populations: renal insufficiency, atrial fibrillation, and
COPD or asthma, and increase the complexity of medical management (Rayner-Hartley et al.,
2018).
A recent review of characteristics of patients attending the ED for HF noted an increased
prevalence of previous coronary artery bypass graft (CABG) or percutaneous coronary
intervention (PCI), hypertension, peripheral vascular disease (PVD), stroke, and diabetes in
patients less than 80 years compared to those older than 80 (Claret et al., 2016). Older patients
were more likely to present with additional comorbidities such as atrial fibrillation, dementia,
and chronic renal failure (Claret et al., 2016). The challenges of a clinical syndrome with high
mortality, complex medical management of multiple comorbidities, and challenges with
identifying interventions with associated mortality benefit create the imperative for identifying
new strategies, such as HFPC, for improved management of patients with HF.
Summary
The sustained incidence, increasing prevalence, and significant lifetime risk of HF create
the strong imperative to improve all aspects of care associated with the diagnosis of HF. The
prevalence of risk factors in the US population, the increasing prevalence of obesity and
diabetes, the associated cost for care, and potentially significant increases in the future cost of
care for patients with HF indicate a significant imperative to improve the care and management
of individuals with HF. The challenges of a clinical syndrome with high mortality, complex
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medical management of multiple comorbidities, and challenges with identifying interventions
with associated mortality benefit create the imperative for identifying new strategies, such as
palliative care to prevent HF hospital readmission, to improve management of patients with HF.
Historical Review of the Literature Relating to Hospital Readmission for HF
A complete historical review of the literature for this investigation of whether HFPC is an
effective intervention to reduce 90-day hospital readmissions requires an in-depth understanding
of the numerous factors that contribute to the issues pertaining to HF readmissions, including (a)
the emergence of the hospital readmission metric, (b) the economic burden of readmission for
hospitals, (c) risk factors associated with hospital readmission, (d) the burden of symptoms for
HF patients, (e) HF readmission rate trends since the implementation of HRRP, (f) mortality
trends associated with hospital readmission initiatives, and (g) an understanding of the
complexities of HF medical management that must be considered when identifying an effective
strategy to reduce HF readmissions. These factors create the impetus for developing innovative
approaches to manage the HF patient population with HFPC consults that may serve as an
effective method to reduce 90-day HF hospital readmissions.
The Hospital Readmission Metric
The earliest published literature on HF recognized the elements of the process of care,
adequate patient education during discharge instructions, and prompt follow-up (Lewis, 1978). In
the mid-1980s, the prevalence of HF was identified as a significant cause of hospital
readmission; within a 6-month period after index hospitalization, 36% of patients with a primary
diagnosis of HF experienced a hospital readmission (Gooding & Jette, 1985). Dunlay and Roger
(2014) reported that heart failure is the leading cause of hospitalization among Medicare
beneficiaries and has the highest 30-day readmission rate (~25%) of any diagnosis. Greater than
50% will be readmitted within one year; multiple readmissions are common and are associated
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with high mortality (Dunlay & Roger, 2014). To create new strategies, CMS implemented
incentives to encourage hospitals to address the issue.
Readmission rates were first introduced in 1953 to characterize risk among
neuropsychiatric patients discharged from the Department of Veterans Affairs (VA) hospital
(Jenkins et al., 1953). In 2005, to promote quality and manage costs, the Hospital Compare
website was launched, introducing the metrics and proposed methodology for public reporting of
hospital quality metrics (DeVore et al., 2016). In 2009, the American College of Cardiology
(ACC) and the Institute for Healthcare Improvement (IHI) launched the Hospital to Home (H2H)
initiative targeting a goal of reducing 30-day hospital readmission by 20% by December 2012
(American College of Cardiology & Institute for Healthcare Improvement, 2009). On July 9,
2009, CMS began to publicly report hospital 30-day all-cause risk-standardized mortality rates
and 30-day all-cause risk-standardized readmission rates for AMI, HF, and pneumonia (Centers
for Medicare and Medicaid Services, 2015; Krumholz et al., 2013). The 2010 Affordable Care
Act implemented the HRRP on the premise that a hospitals’ scope of responsibility should
include post-discharge care coordination (Centers for Medicare and Medicaid Services, 2015;
Chin et al., 2016). On October 1, 2012, CMS Medicare introduced penalties and started to reduce
payments for inpatient hospitalizations if a hospital demonstrated a higher than expected versus
predicted 30-day readmissions for multiple diagnoses, specifically identifying HF readmissions
(Centers for Medicare and Medicaid Services, 2015; Davis et al., 2017).
The CMS implemented 30-day readmission rates based on hierarchical logistic regression
models that were derived from Medicare claims data and adjusted for variation in hospital
volume and case mix (McIlvennan et al., 2015). The metric was implemented despite limited
evidence supporting the 30-day interval as an indicator of between-hospital variation in the
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quality of care (Chin et al., 2016; National Quality Forum, 2016). Intracluster correlation
coefficients (ICC) represent the proportion of risk explained by hospitals (between-hospital
variation) compared to the total risk in the population (all variation). Poor 30-day readmission
correlation was noted with ICC values of 4.8-5.3% for mortality measures and 1.5-2.6% for
readmission measures. Further time-dependent analysis demonstrated a sharp reduction in the
readmission ICC after the seventh day post-discharge,12 suggesting that a significant proportion
of the presumed hospital quality signal at 30 days may be attributed to characteristics of the
individual or community setting of care such as the socioeconomic and demographic profile of
the hospital’s patient population, the hospital’s resource availability, patient social support, or
mental health issues (Chin et al., 2016; Pandey et al., 2017).
Similar findings were noted in a longitudinal review of index HF admissions from 2006
to 2009 in Australia with non-statistically significant interhospital ICC for 30-day unplanned
readmission of 0.0125,13 and statistically significant patient-level factors of age and comorbidity
were more predictive of unplanned 30-day hospital readmission (Korda et al., 2017). In a large
meta-analysis of hospital process indicators, 30-day readmissions were not associated with
adherence to any of the CMS required hospital process indicators, indicating that the causation of
readmissions lies outside of the purview of the acute hospital admission (Fischer et al., 2015;
Pandey et al., 2017). Thus, it follows that selection of 30-day readmission rates as an indicator of
quality is to encourage hospitals to assume responsibility for post-discharge adherence and
primary care follow-up and likely represents a public policy intended to shift responsibility from
individual care providers to systems of care, such as that embodied by multidisciplinary HFPC,
to promote a more cohesive shared responsibility for continuity of care (Chin et al., 2016).
12
13

78%, 49% and 76% among patients admitted with AMI, HF and pneumonia respectively
p =0.24
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The development of readmission metrics is flawed as a measure of hospital quality of
care. These metrics are more likely to represent administrative priorities to promote improved
systems of care that include both individual and community aspects of care. HFPC may
contribute to improved continuity of care and thereby result in fewer unplanned hospital
readmissions.
Burden of Readmission for Hospitals
A recent evaluation of adherence to AMI acute and discharge performance measures
showed an inequitable burden of readmission among hospitals serving patient populations with
higher levels of social disadvantage and higher illness acuity (Pandey et al., 2017). Compared to
White patients and non-minority serving hospitals, Black patients and minority-serving hospitals
demonstrated an increased risk of all-cause readmission for HF14 in a large analysis of more than
three million Medicare recipients, notably prior to initiation of HRRP (Joynt et al., 2011).
Consequently, hospitals with a high prevalence of socially or medically complex patients carry
the greatest burden of readmissions and are more likely to be penalized, raising questions of
whether CMS readmissions penalties are equitably and justly applied (Joynt & Jha, 2013; Pandey
et al., 2017).
Hospitals with the highest readmission rates are more likely than hospitals with lower
readmission rates to care for patients who are (1) younger, Black, not married, less educated,
retired, (2) have fewer total assets, lower household income, and a Medicare disability, (3) are
Medicaid enrolled, (4) have an absence of supplemental health insurance, a current smoking
status, multiple comorbidities, depression, lower cognition, lower self-rated health, fewer
household residents, and multiple difficulties with activities of daily living (ADLs), mobility and
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OR 1.04, 9 `5% CI [1.03 - 1.06] and 1.14, 95% CI [1.11 - 1.17]
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agility (Barnett et al., 2015; Freedland et al., 2016). Hospitals that serve a higher percentage of
patients enrolled in both Medicare and Medicaid (dual-enrolled) were 20% more likely to have
excess readmissions using the CMS methodology than hospitals that served a lower percentage
of patients with dual-enrolled statuses, indicating that hospitals that serve a more disadvantaged
population are disproportionately subject to payment reduction penalties under HRRP; this
difference was reduced to 0 by adjusting for individual dual eligibility status and hospital share
of patients with dual eligibility (Gu et al., 2014). The equity issues described herein are the
subject of broad debate and represent issues beyond the defined scope of this investigation but
are nonetheless a necessary background to understand the complications associated with
emerging HFPC initiatives.
Previous studies among patients with HF have likewise failed to demonstrate a strong
association between in-hospital quality of care and 30-day readmission rates (Fischer et al.,
2015). Studies have established a temporal decline in HF readmissions but may be confounded
by changes in coding rather than improvements in care (Desai et al., 2016; Jha, 2015; Zuckerman
et al., 2016). The evidence suggests there is an emerging imperative for HRRP outcome metrics
to be reevaluated to align with the evidence that acute care and discharge quality metrics do not
appear to influence readmissions, and hospital readmissions are often attributable to individual
and community aspects of care. The hospital burden of care is disproportionately distributed.
Hospitals with the highest readmission rates tend to bear the responsibility for sicker, poorer, less
educated patients with fewer social supports. These hospitals are also more likely to incur
payment reduction penalties for excess 30-day HF readmissions. These issues are relevant to this
investigation in that if health systems are encouraged to divert resources to ensure HFPC referral
and access to services, HFPC must be established as an effective intervention to reduce 90-day
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hospital readmissions, especially for health systems that already struggle with caring for the
highest risk patients in a situation of limited resources.
Trends in HF Readmissions Since HRRP
An annotated detailed summary of findings pertaining to HF readmission rates is
included in Appendix A1. In summary, initial support for the introduction of the HRRP was
strong, identifying multiple reasons for excessive 30-day readmission rates that, if properly
managed during the inpatient admission, may reduce readmission rates 15 (Berenson et al., 2012).
The HRRP also embeds accountability in the system, as hospitals are no longer able to abdicate
responsibility for patients after they leave but instead remain accountable for what happens to
patients in the post-discharge period, resulting in improved discharge planning and care
coordination (Jha, 2015). However, caution was also advised that the implementation of the
HRRP may have unintended consequences for the care of vulnerable populations and older
adults (Gu et al., 2014; Naylor et al., 2012). Ultimately, HFPC may bridge the gaps between
hospital discharge and primary care physician follow-up.
A 2000-2011 community study of Olmsted County, MN residents, identified rates of
readmission that were highest during the first 30 days then decreased precipitously after. A
minority were readmission for heart failure (17%). More often, the reason for hospitalization was
another cardiovascular (32%) or non-cardiovascular (51%) cause (Chamberlain et al., 2017). The
authors noted that in order to reduce hospitalizations in patients with HF, an integrated approach
focusing on comorbidities is required (Chamberlain et al., 2017). HFPC may be the modality to
achieve this integration.
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hospital-acquired infections and other complications, premature discharge, failure to
coordinate and reconcile medication, inadequate communication among hospital personnel,
patients, caregivers and poor planning for care transitions
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HF Mortality Trends
HF mortality trends are an important aspect of this study because the dependent variable,
HFPC consult, seeks to impact the post-discharge period, and differential mortality may affect
the assessment of the outcome of interest—90-day hospital readmission. The causes attributable
to mortality surrounding HF hospitalization are not well understood. One hypothesis is that
hospitalization events are uniquely followed by a time-dependent, transient, biologic vulnerable
state for all patients, characterized by hemodynamic and neurohormonal abnormalities and endorgan damage (Dunlay et al., 2010; Gheorghiade et al., 2012). Temporal changes in mortality
risk before and after HF readmission demonstrate a net increase in predicted mortality risk 16 after
readmission with a nadir at 90 days, demonstrating a persistent mortality risk that never returns
to pre-readmission levels (Cook et al., 2016).
A single state review of readmissions between 1998-2001 found a 12-month mortality
rate of 41% with a 30-day readmission versus a mortality rate of 27% amongst propensitymatched patients without a 30-day readmission (Arundel et al., 2016). Evaluating patient
characteristics and a marked 37% net increase in mortality post HF readmission in a global,
randomized clinical trial identified characteristics associated more often with a patient’s
individual clinical risk profile rather than risk relative to hospitalization itself (Cook et al., 2016).
Korda et al. (2017) observed statistically significant associations with patient-level
characteristics of age and severe comorbidities for 30-day hospital readmission versus hospitallevel characteristics. Simply put, 30-day readmission captures the patient with worsening clinical
symptoms requiring admission rather than the hospitalization itself being causative to the
resulting mortality risk (Cook et al., 2016). Palliative care may provide the needed transition and
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HR 37%, 95% CI [23% - 53%]
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continuity of care to address the observed increase in mortality risk associated with
hospitalization.
Readmission Trends and Associated Mortality
Results are mixed with regard to readmission trends and associated mortality and
annotated results; an annotated summary can be found in Appendix A2. Early evidence assessing
mortality outcomes since the implementation of HRRP showed absent or non-statistically
significant trends (Bergethon et al., 2016; DeVore et al., 2016). However, early caution was
raised about the potential consequences of the HRRP with concerns about the metric itself,
suggesting a risk of shifting hospital expenditures to focus on reducing readmissions at the
expense of more urgent quality improvement efforts and introducing punitive measures for
readmission in hospitals that have achieved low mortality rates with higher readmission rates
(Joynt & Jha, 2012). In a comprehensive review of the HRRP program, 30-day readmission rates
for HF were unchanged over time while noting a statistically significant increase in mortality
after implementation of public reporting (DeVore et al., 2016).
Emerging evidence has demonstrated the potentially harmful if unintended effects of the
HRRP, with emerging evidence of increased mortality associated with continuing
implementation (Bueno et al., 2010; Dharmarajan et al., 2017; Fonarow et al., 2017; Gupta et al.,
2017; Krumholz et al., 2013). In a secondary analysis of previously published results on
readmission and mortality, researchers identified a statistically significant negative correlation
between the longitudinal trend in mortality rates and readmission rate 17 (Krumholz et al., 2009;
Krumholz et al., 2013). The caution offered by the authors that the “relationship was only modest
and not throughout the entire range of performance” (p. 590) is of interest; however, stratified
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r2 =-0.17, 95% CI [-0.20 to -0.14]
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analysis revealed consistent statistically significant inverse correlations regardless of key hospital
characteristics of teaching status, ownership status, safety net status, or geographic location
(Krumholz et al., 2013). A comparison of mortality trends pre- and post-intervention identified
no statistically significant differences between hospitals participating in the Premier Hospital
Quality Incentive Demonstration (HVBP hospitals) and hospitals not participating (non-HVBP
hospitals), which were more likely to include small, private, non-teaching critical access
hospitals in the South and Midwest exempt from CMS penalties (Figueroa et al., 2016). While
there was no statistically significant difference in mortality trend between HVBP and non-HVBP
hospitals, both categories witnessed a reversal in the observed mortality trend for HF with rates
declining in the pre-intervention period18 and statistically significant increases of 0.02 and 0.03,
respectively, in the post-intervention period (Figueroa et al., 2016). If findings of increased
mortality in the post-discharge period are accurate, HFPC may provide the needed transition and
continuity of care to minimize mortality differences.
Controversy continues on the validity of the association of the HRRP with mortality
evaluated in a cross-sectional study with poor baseline performers in HF quality metrics
demonstrating a decrease in mortality19 while all other hospitals demonstrated an increase in
mortality20 (Chatterjee & Joynt Maddox, 2018). A large retrospective cohort study inclusive of
3.2 million HF hospitalizations evaluating the four periods of HRRP implementation identified
consistent increases in 30-day post-discharge mortality 21 (Wadhera et al., 2018). A second large
retrospective cohort study using similar sampling methodology and time period identified four
18

-0.7 for HVBP hospitals and -0.11 for non-HVBP hospitals
13.5 to 13.0%
20
10.9 to 12.0%
21
0.27%, 0.49% and 0.52% for the respective intervals of baseline change prior to HRRP
announcement, change after HRRP announcement but prior to implementation, and change after
HRRP implementation
19
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million HF hospitalizations. A key difference was the inclusion of inpatient mortality events,
which included an additional 800,000 cases accounted for by a calculated 2% mortality rate of
cases not included in the study population of Wadhera et al.’s (2018) research (Khera et al.,
2018). Thirty-day post-discharge mortality increased between 2006 and 2014; however, the
researchers qualified that finding with the observation that 30-day post-discharge mortality also
increased prior to the announcement of the HRRP, which suggests that observed increases are
expected (Khera et al., 2018).
In addition, in their final presentation of results, the authors combined the decreasing
trend of in-hospital mortality with the increasing trend of 30-day post-discharge mortality to
illustrate their conclusion that there was no statistically significant overall change in HF
mortality as measured by the composite of post-admission mortality (Khera et al., 2018). In
summary, the authors make a dualistic argument that there are no statistically significant
increases in overall post-admission mortality. If that argument is not sufficient, the observed
increases are wholly attributable to the natural and expected increases in overall HF mortality.
Mortality remained a significant source of variability and was an important confounder for this
evaluation of the impact of HFPC on 90-day hospital readmissions.
HRRP has been moderately successful at reducing hospital readmissions after an index
HF admission. It is also likely that the reduction in HF hospital readmissions is associated with
an increase in HF mortality. Studies to date have not stratified the HF population to determine
what subgroups are at the highest risk for increased mortality, but it is intuitive to propose that
those with Stage III, IV HF or meeting eligibility criteria for a palliative care referral would be
most likely to be at highest risk. An annotated summary of studies pertaining to HF readmission
rates and mortality can be found in Appendix A2.
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Risk Factors for Readmission
Risk factors for readmission identified in previous studies include:


comorbidities of diabetes, chronic lung disease, renal failure, or electrolyte
imbalance. Fifty percent of readmissions were due to a cardiac cause, pulmonary
causes (13%), renal causes (9%), smoking status, alcohol intake, depression, and
lower cognition score.



characteristics of the hospital stay and disposition, including patients with a
prolonged hospital admission greater than one week and patients discharged to an
SNF or home with a nurse



interventions during the acute hospitalization, including transfusion during the index
admission



demographic characteristics of older age, less education



economic characteristics of fewer total assets, lower household income, Medicare
primary insurance or Medicaid enrollment, absence of supplemental health insurance,
and absence of prescription drug coverage.



social isolation, including no living children, no living siblings, no friends living
nearby and infrequent contact with friends, poor self-rated health, difficulties with
activities of daily living (ADLs), decreased mobility and decreased agility (Arora,
Patel, et al., 2017; Barnett et al., 2015; Freedland et al., 2016; Mirkin et al., 2017).

These studies demonstrate the scope required of a program to effectively reduce hospital
readmissions and reflect the necessary scope of socioeconomic, health literacy, and psychosocial
considerations that need to be considered in efforts to successfully address hospital readmissions
(Barnett et al., 2015). Hospital-focused interventions alone can contribute little, while
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interventions like palliative care offer a broader scope to address the highly variable patient
circumstances that need to be addressed. These elements represent important co-factors for this
investigation and are represented within the demographic and severity characteristics included in
this investigation.
Patient Drivers of HF Hospital Readmission
Patient perception of symptoms and the reasons for hospital readmission are important to
understanding the issues that improve the self-management of HF and decrease unnecessary
hospital readmission. HFPC may directly affect patient perception of symptoms to seek hospital
readmission. Hospital admission for HF is associated with fatigue, drowsiness, dyspnea, anxiety,
decreased well-being, and edema. In one review, up to 58% of patients reported that symptoms
had not improved an average of four days after hospital discharge compared to admission (Khan
et al., 2015).
Patient-identified reasons for HF admission include worsening heart failure, dietary
nonadherence, or other worsening medical condition; only a small proportion (4%) did not know,
had no access to a provider, or reported a medication issue (Gilotra et al., 2017). Physician
perspective agreed with patient perceptions on issues of dietary nonadherence, but physicians
were much more likely to identify a medication issue as a major reason for HF admission.
Patients identified three major themes relating to reasons for hospital readmission: a lack of
caregiver support and personal motivation to provide self-care: “I can’t take care of myself, and I
can’t find anybody who can provide care” (p. 539), acceptance of condition and desire for
aggressive care: “I ain’t going nowhere, and I’m fighting” (p. 539), and access to care and poor
quality of care: “I have problems, medical, psychological, financial and every day I’m out, it gets
worse” (p. 539; Enguidanos et al., 2015).
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Perception of illness related to personal control and treatment beliefs about the necessity
of medications versus adverse effects have been noted to be significantly associated with
medication adherence, which is a critical aspect of care for the success of interventions that aim
to reduce hospital readmissions (Turrise, 2016). In the Journal of the American Medical
Association (JAMA) forum, Jha (2015) eloquently advocated that “during an acute illness,
patients prioritize survival, maintaining functional status, cognitive clarity, being treated with
dignity, and reducing pain. Reducing hospital readmission, while important, is likely a lower
priority for patients” (p. 1681).
Perception of symptoms, medication and dietary adherence, perceived social support,
cognitive and economic capabilities to provide self-care, perception of illness, and access to care
influence an individual’s ability to provide self-care sufficient to appropriately reduce
unnecessary hospital readmission. HFPC may directly affect patient perceptions of these cofactors and influence subsequent health-seeking behaviors, giving patients the confidence to
accurately interpret their symptoms and thereby avoid unnecessary hospital readmissions.
Strategies for Reducing HF Readmissions
Interventions that have demonstrated the potential to decrease hospital readmissions
include (a) the development of risk prediction models, (b) optimizing medical therapy, and (c)
health system strategies (Ziaeian & Fonarow, 2016). A myriad of interventions have since been
proposed to decrease the number of HF readmissions and may encourage inappropriate care
strategies to achieve a reduction in readmission rates (Bradley et al., 2013; Woolhandler &
Himmelstein, 2016). HFPC is typically considered a health system strategy that may provide the
needed transition and continuity of care to optimize compliance with medical therapy.
Validated risk prediction models have shown poor discrimination in their ability to
predict hospital readmission—c-statistic range 0.55 - 0.65 (Burke et al., 2017; Kansagara et al.,
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2011; Krumholz et al., 2016). Cognitive testing as a part of routine clinical care during
hospitalization has shown greater predictive performance of hospital readmission, and inclusion
of cognitive testing in other models improved predictive accuracy (Patel et al., 2015). Inclusion
of measures of health literacy and functional and cognitive status may improve predictive
models, but further validation is required (Ziaeian & Fonarow, 2016).
Optimizing medical therapy may include advanced heart failure interventions such as
cardiac resynchronization therapy, ultrafiltration, and left ventricular assist devices; however,
they are costly, and eligible patients represent only a small fraction of all US cases living with
HF (Al-Khazaali et al., 2016; Dunlay & Roger, 2014). Cost-effective medication management
may include digoxin, beta-blockers, aldosterone inhibitors, angiotensin-converting enzyme
(ACE) inhibitors, angiotensin receptor blockers (ARB), or a new combination product Sacubitril
or Valsartan that has shown efficacy in managing HF (Khder et al., 2017; Ziaeian & Fonarow,
2016). Remote monitoring, whether by telephone or via embedded impedance technology in ICD
or CRT devices, did not improve outcomes or reduce readmissions but increased admissions due
to increased monitoring (Chaudhry et al., 2010; Jayaram et al., 2017; Krumholz et al., 2016).
Implantable pulmonary artery sensors that wirelessly transmit pulmonary artery pressure
measurements offer the potential to reduce HF readmissions up to 58% in a single-blind trial but
are reliant on the fidelity of data and timely response to information (Abraham et al., 2011).
Statistically significant health system strategies to reduce hospital readmissions include
partnering with community physicians, local hospitals, nursing responsibility for medication
reconciliation, arranging follow-up appointments before discharge, a process to send discharge
summaries directly to the patient’s primary physician, and assigning staff to follow-up on test
results that return after patient discharge (Bradley et al., 2013). The issue remains that while each
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intervention contributed statistically significant reductions to HRR, the effect size was limited,
ranging from -0.18% to -0.34% (Bradley et al., 2013).
Effective interventions to reduce HF readmissions must include medical management,
early reassessment, health literacy, assessment of neuropsychological status, financial means,
and assessment of functional status (Sperry et al., 2015). Current fragmented strategies cannot
deliver a comprehensive scope of services required to decrease hospital readmissions and
improve patient outcomes. HFPC may be a plausible and feasible health system strategy to
improve compliance with treatment interventions and thereby decrease 90-day hospital
readmissions.
Summary
The development of readmission metrics is flawed as a measure of hospital quality of
care. Readmission metrics are more likely to reflect administrative priorities to promote the
development of improved systems of care that incorporate individual and community aspects of
care more likely to contribute to improved continuity of care and result in fewer unplanned
hospital readmissions. HFPC may be a plausible and feasible modality of care delivery to
achieve the objective of reduced HF hospital readmission. The hospital burden of care is
disproportionately distributed, and hospitals with the highest readmission rates carry the
responsibility for sicker, poorer, less educated patients who have fewer social supports. These
hospitals are also more likely to incur payment reduction penalties for excess 30-day HF
readmissions.
Mortality risk increases after hospital readmission and never returns to pre-admission
levels. Palliative care may provide the needed transition and continuity of care to address the
observed increase in mortality risk associated with hospitalization. HRRP has been moderately
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successful at reducing hospital readmissions after an index HF admission. It is also likely that the
reduction in HF hospital readmissions is also associated with an increase in HF mortality.
Studies to date have not stratified the HF population to determine what subgroups are at the
highest risk for increased mortality, but it is intuitive to propose that those with Stage III, IV HF
or meeting eligibility criteria for a palliative care referral would be most likely to be at highest
risk. Assessment of mortality is a previously unassessed and yet high-risk source of confounding
and is a key aspect of this investigation.
The scope required of a program to effectively reduce hospital readmissions should
include components that address socioeconomic, health literacy, and psychosocial
considerations. Perception of symptoms, medication and dietary adherence, perceived social
support, cognitive and economic capabilities to provide self-care, perception of illness, and
access to care influence an individual’s ability to provide self-care sufficient to appropriately
reduce unnecessary hospital readmission. Effective interventions should include medical
management, early reassessment, health literacy, assessment of neuropsychological status,
financial means, and assessment of functional status. Current fragmented strategies cannot
deliver a comprehensive scope of services required to decrease hospital readmissions and
improve patient outcomes. Hospital-focused interventions alone can contribute little, while
interventions like palliative care offer a broader scope to address the highly variable patient
circumstances that need to be addressed.
This study assessed the effectiveness of the entry point of access to palliative care
services, the initial palliative care consult. Whether palliative care consultation resulted in the
delivery of a sufficiently broad scope of interventions to meet palliative care standard of practice
is beyond the scope of this research. This dissertation study assumed that appropriate PC
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interventions are delivered at the discretion of the PC provider individualized to the needs of
each patient. Future research efforts on service delivery of palliative care should assess the
elements that are evidenced-based and consistently delivered, how they are documented as
complete, how progress is measured and the ideal timeline for service delivery. This study
focused on the entry point to service delivery to determine whether the presence of a single PC
consult alone, as defined and required by CMS, could result in a reduction in hospital
readmissions.
Historical Review of the Literature Relating to HFPC
Lastly, a full review of the literature pertaining to this investigation requires an
understanding of the definition and evolution of palliative care, including (a) the variation in the
trajectory of disease that requires careful consideration when applying a service traditionally
developed to provide care for terminal cancer patients, (b) the breadth of recommendations and
position statements that advocate for the use of palliative care in patients with HF, and (c) trends
and barriers for implementation of HFPC consistently and reliably.
Definition of Palliative Care
Palliative care is defined by the US Department of Health and Human Service (HHS),
Centers for Medicare & Medicaid Services (CMS) and the National Quality Forum (NQF) as
“patient and family-centered care that optimizes quality of life by anticipating, preventing, and
treating suffering” (Braun et al., 2016). A comprehensive palliative care intervention includes
assessment and management of physical symptoms, psychosocial and spiritual concerns, and
advance care planning (National Consensus Project, 2018). Palliative care throughout the
continuum of illness involves addressing physical, intellectual, emotional, social, and spiritual
needs and facilitates patient autonomy, access to information, and choice (Dahlin, 2013). The
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simplified definition proposed in the 4th Edition of the National Consensus Project (NCP)
clinical practice guideline for quality palliative care embodies three elements: (a) comprehensive
physical, emotional, spiritual, and social assessment, (b) skilled management of pain and other
distressing symptoms, and (c) expert communication about what is most important to patients
and families and implementing care plans to achieve those goals (National Consensus Project,
2018). Unlike hospice, palliative care is offered simultaneously with medical treatment (Gelfman
et al., 2017).
The palliative care movement began in the 1970s as a grassroots community hospice
movement aimed at caring for cancer patients in their homes (Adler et al., 2009). Medicare
added hospice services to its benefits in 1982 (Connor, 2007). The trajectory of declining health
in HF is very different from the trajectory of declining health associated with cancer. As such,
the model of palliative care services that has been developed to meet the needs of patients with
cancer may not translate well to meet the needs of patients with HF (Murray & Sheikh, 2008).
Unlike cancer, HF exacerbations are unpredictable, advanced therapies are expensive and limited
in their availability, and outcomes remain uncertain (Gelfman et al., 2017). Palliative care
treatment models for HF have vastly improved in specificity and complexity and recognize the
specific pathophysiologic changes and variable trajectory of declining physical function unique
to HF (Goodlin, 1997, 2005, 2009; Morrison & Meier, 2004). In 2005, the American College of
Cardiology and American Heart Association guidelines for the first time included
recommendations that included discussion with patients and families about prognosis for
functional capacity and survival, advance directives, palliative care and hospice care (Hunt,
American College of, & American Heart Association Task Force on Practice, 2005).
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This perspective on a new approach to HFPC is seen in the earliest investigations
evaluating PC, suggesting a broader approach to chronic illnesses, noting that “the transition
model of hospice care does not serve HF patients well, as most do not want to choose between
curative treatment and symptom relief. A broader model of palliative medicine would offer
aggressive symptom management and comprehensive care to the large percentage of outpatients
with advanced illness who are still pursuing aggressive management or cure of their disease”
(Rabow et al., 2004, p. 83).
Hospice Care. Palliative care and hospice care are separate and distinct concepts that are
often mistakenly used interchangeably but have important differences. Palliative care is a
broadly inclusive term describing all aspects of care that focus on improving quality of life and
symptom control over curative therapy. Hospice is a defined subset of palliative care patients
with an imminently life-limiting illness and has important implications for health insurance
benefits (McIlvennan & Allen, 2016). This distinction is important, as bias persists among
patients and providers that palliative care referral is equivalent to hospice care and is a major
barrier to provider referrals and patient uptake of referral (Kavalieratos et al., 2014). This
perception has driven efforts to rebrand HFPC as an intervention for patients with ‘advanced’ HF
versus ‘end-stage’ HF and attempts to reduce the pernicious stereotype that palliative care is an
option only of last resort (Kavalieratos et al., 2016).
Guidelines. The advocacy for palliative care to be made available to advanced HF
patients is broadly advocated and embodied in numerous guidelines and consensus statements
from:


World Health Organization (Davies & Higginson, 2004)
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American Academy of Hospice Palliative Care Medicine (American Academy of
Hospice Palliative Medicine, 2004)



Consensus statement on palliative and supportive care in advanced heart failure
(Goodlin et al., 2004)



European Society of Cardiology (Jaarsma et al., 2009)



Canadian Cardiovascular Society (McKelvie et al., 2011)



Centers for Medicare & Medicaid Services (Centers for Medicare & Medicaid
Services)



American Heart Association scientific statement (Allen et al., 2012)



International Society for Heart and Lung Transplantation (Feldman et al., 2013)



Centers for Medicare & Medicaid Services decision memo for ventricular assist
devices (Centers for Medicare & Medicaid Services, 2013)



Joint Commission for the Accreditation of Hospital Organizations ("Modified:
Ventricular assist device destination therapy requirements, 2014")



Heart Failure Society of America (Fang et al., 2015)



American Heart Association and Heart Failure Society of America: HF in Skilled
Nursing Facilities (Jurgens et al., 2015)



Geriatrics Section of the American College of Cardiology (Kirkpatrick et al., 2016)



American Heart Association (Braun et al., 2016; Heidenreich et al., 2013)



American Stroke Association (Braun et al., 2016)



American College of Cardiology (Yancy et al., 2017; Yancy et al., 2013)



National Consensus Project (National Consensus Project, 2018)
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Despite the prevalence of guidelines and consensus statements, the evidence to establish
the efficacy and effectiveness of palliative care to improve outcomes in HF is preliminary; a US
national strategy for palliative care does not exist and remains an unrealized opportunity to
improve value in health care (Meier, 2011; Meier et al., 2017). Highlighting the paucity of
literature available to cardiologists, a review of the literature from 2009-2013 quantifying
publications on HFPC found only 11 (0.1%) articles in the predominant cardiology journals on
the topic of HF with PC as the main topic and an additional six (0.0%) with palliative care as a
specific mention (Xie et al., 2017). Palliative care journals performed marginally better, with 47
(1.2%) of PC articles listing HF as a main topic and another 17 articles (0.4%) listing HF as a
significant mention (Xie et al., 2017). Representation of the topic in cardiology conference
proceedings demonstrated similar poor performance, with only 21 (1.2%) HF seminar sessions
and 17 (0.4%) poster presentations listing PC as a main topic (Xie et al., 2017). This
performance is largely driven by the absence of funding for HFPC, with <0.1% of federal
funding for HF allocated to research on PC, only 21 (0.7%) grants funded with HFPC as a main
topic, and another 13 (0.4%) with PC as a significant mention from the 2,921 HF grants funded
by federal sources from 2009-2013, despite its prevalence and emphasis in a broad array of
guidelines and consensus statement (Xie et al., 2017).
In 2017, only one paper evaluating HFPC was selected for presentation at the annual
assembly of the American Association of Palliative and Hospice Medicine (AAHPM) and the
Hospice and Palliative Nurses Association (HPNA) as a study with significant potential for
impact on hospice and palliative care practice. The study was subsequently evaluated as having a
high risk of bias. Additionally, it was conducted in a very different health care setting in Hong
Kong (Gelfman et al., 2017; Kavalieratos et al., 2017; Taylor et al., 2017). In 2016, a National
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Institutes of Health, National Palliative Care Research Center sponsored workshop was convened
to outline the current research base, identify knowledge gaps and research priorities (Gelfman et
al., 2017). The summary statement of the current evidence from the newly formed Improve
Palliative Care Therapies for Patients with Heart Failure and Their Families (IMPACT-HF2)
workgroup concluded that the current state of the science for palliative care in HF is limited, and
further evidence is required to: (1) better understand advanced HF patients’ limiting symptoms
and focus treatment on their relief, (2) better characterize and address the needs of the caregivers
of advanced HF patients, (3) improve patient and family understanding of HF disease trajectory
and importance of advance care planning, and (4) determine the best models of palliative care,
including models for those who want to continue life-prolonging therapies (Gelfman et al.,
2017). This research proposal addressed research priority #2 of the NIH, NPCRC to better
characterize and address the needs of the caregivers of advanced HF patients by evaluating an
area of key interest to caregivers regarding whether palliative care consultation in a general
medical population can reduce 90-day hospital HF readmission without increasing mortality.
Trends of Palliative Care Utilization
There has been a significant trend of increased HFPC over time, with utilization trends in
veterans with severe heart failure increasing from 6% to 10% from 2007 to 2013. Overall, 51%
of patients with HF died within one year of hospitalization. Patients seen by PC had a 1-year
mortality of 72.8% compared to 49.5% among those who were not seen by PC 22 (Mandawat et
al., 2016). Fromme et al. (2006) emphasized that the observed reduction in hospital readmission
rates was undoubtedly lower because of the differential mortality that occurred within the

22

p < 0.001
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palliative care consultation group. Outcomes demonstrating the benefit of PC utilization should
consider this differential mortality; however, studies to date have failed to do so.
Access to PC programs is variable across the United States, with the lowest prevalence of
PC programs found in the South-Central regions. Even among hospitals with 300 or more beds,
12% of hospitals in the South did not have a current palliative care program (Dumanovsky et al.,
2016). The resulting unmet need for palliative care in US hospitals was quantified with an
observed extreme hospital-level variation from 12% to more than 90% of eligible patients
receiving palliative care referral or services (Szekendi et al., 2016).
Enrollment in PC programs has also demonstrated marked variability. Patients enrolled in
PC are more likely to be White, older, female, exhibit multiple comorbidities, access acute care
services such as ER visits, hospitalizations, and ICU admission, and be receiving services in a
long-term care setting than patients with cancer (Bain et al., 2009; Cheung et al., 2013;
Setoguchi et al., 2010). A more in-depth evaluation of racial differences noted a persistent
disparity over time, with non-White individuals eligible for hospice services 20% less likely to
enroll and more likely to disenroll23 in services compared to Whites (Unroe et al., 2012). NonWhites accessing PC services were more likely than Whites to be younger, exhibit a higher
frequency of comorbidity, reside in a state with Medicaid buy-in, and live in a non-rural location
(Unroe et al., 2012). The perceptions associated with PC among patients self-described as
familiar with PC services include many negative perceptions about it being a service to provide
“comfort to dying patient and family,” “for dying patients,” or “comfort care.” Increasingly
positive perceptions include “team effort towards the patient to provide everything the patient
needs,” “semi holistic approach to care,” or “pain relief, patient comfort, support for family.”

23

11.6% versus 7.2%
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Others have perceived PC as an assistive service described as “help with day-to-day activities,
not in a hospital setting,” “visiting nurse who gives medications,” or “home care for elderly and
sick” (Khan et al., 2015, p. 1713-1714). Among patients eligible for PC services, only 22%
reported familiarity; however, 68% were interested in receiving PC services, which indicates that
there is potential to address unmet needs associated with HF that is not being effectively
managed by existing patient management systems (Khan et al., 2015).
Barriers and Supports for implementation of HFPC
In a recent multisite, retrospective, point prevalence study, the majority of patients
appropriate for referral (60.9%) received neither referral nor services and identified barriers to
referral, including (a) no standard definition of palliative care, even within organizations
resulting in subjective referral criteria and variation in clinical practice patterns, (b) specialist
reluctance to refer because of long-standing patient relationships and desire to retain patient
management, (c) variable educational opportunities available to clinicians to acquire skills in
primary palliative care, and (d) a perceived conflict that has the provider motivated to provide
advanced specialty care and patient acceptance of not “doing everything” (Szekendi et al., 2016,
p. 363). This variation in referral patterns has remained consistent over time, as demonstrated in
a 2007 benchmarking study that assessed adherence to quality improvement metrics for palliative
care and found wide variability in the provision of key performance measures that varied from
0% to 100% (Twaddle et al., 2007).
Factors propelling the adoption of HFPC services include (a) increasing referrals over
time as HFPC teams develop relationships with frontline physicians and caregivers become
aware of the value of HFPC services, (b) impression that HFPC teams should be reserved for the
management of complex symptom management and when difficult patient and family dynamics
arise, (c) support from hospital leadership who view HFPC as aligning with the achievement of
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strategic goals to reduce readmissions, (d) increasing public awareness among patients and
providers, and (e) increased focus on the hospital mission to provide patient-centered care
(Szekendi et al., 2016). Of note is the paucity of research demonstrating efficacy or effectiveness
as a factor promoting the adoption of HFPC services. Several studies have focused on
demonstrating the benefit of HFPC for the hospital system and reductions in hospital
readmissions, length of stay, and overall cost reduction (Bharadwaj et al., 2016; Lukas et al.,
2013).
HFPC has been advocated to alleviate the symptom and psycho-social burden associated
with advanced HF (Alpert et al., 2017; Dahlin, 2013). Compared to patients receiving cancer PC,
HFPC patients experience a similar panel of symptoms, including (in declining rate of
frequency) fatigue, anorexia, dyspnea, pain, insomnia, depression, anxiety, constipation,
agitation, diarrhea, and nausea (Kavalieratos et al., 2014). Symptoms that were improved by HF
hospitalization include nausea, anorexia, dyspnea, depression, edema, and decreased well-being;
symptoms unmet by the hospitalization included pain, fatigue, drowsiness, and anxiety and may
represent an opportunity to improve patient outcomes with services that are available and fall
within the purview of HFPC services (Khan et al., 2015). While many symptoms improved
during hospitalization—fatigue (60%), anorexia (28%), dyspnea (25%), pain (20%), insomnia
(18%), depression (18%), and anxiety (13%)—they remained as major sources of unresolved
symptom in HFPC patients (Kavalieratos et al., 2014).
Summary
A model of palliative care that recognizes the specific pathophysiologic changes and
variable trajectory of declining physical function unique to HF is offered simultaneously with
medical treatment, which embodies (a) comprehensive physical, emotional, spiritual, and social
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assessment, (b) skilled management of pain and other distressing symptoms, and (c) expert
communication about what is most important to patients and families and implementing care
plans to achieve those goals. Despite the prevalence of guidelines and consensus statements, the
evidence to establish the efficacy and effectiveness of palliative care to improve outcomes in HF
is preliminary. A US national strategy for palliative care does not exist due to the nascent
emergence of the palliative care physician specialty and high geographic variability of PC
services and PC providers. It remains an unrealized opportunity to improve value in health care.
This research addressed (a) the paucity of research demonstrating the effectiveness of HFPC to
reduce hospital readmissions and (b) research priority #2 of the NIH, NPCRC, to better
characterize and address the needs of the caregivers of advanced HF patients by evaluating an
area of key interest to caregivers regarding whether palliative care consultation in a general
medical population can reduce 90-day hospital HF readmission without increasing mortality.
Outcomes demonstrating the benefit of HFPC utilization must consider the ascertainment bias of
differential mortality; however, studies to date have failed to do so.
Research Literature Specific to HFPC
As discussed in the preceding historical review of the literature on heart failure, hospital
readmissions, and palliative care, the increasing prevalence of HF coupled with the increasing
cost associated with care, the complicated burden of HF symptoms, and comorbidities in the
context of increasing regulatory and financial pressures to decrease hospital readmissions have
promoted the adoption of novel strategies such as the adaptation of palliative care treatment
models in the HF patient population. This section provides a more current review of the literature
specifically pertaining to palliative care for patients with HF (HFPC) in a policy environment,
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promoting a reduction in hospital readmissions for HF, and describes the theoretical framework
of this investigation.
Readmissions
According to Dharmarajan et al. (2013), 20-25% of hospitalized HF patients will be
readmitted within 30 days. Seventy percent of hospitalized HF patients will be readmitted within
one year. Two-thirds of HF patients readmitted within 30 days will be readmitted for a condition
other than HF. Evidence of the efficacy of palliative care consults to reduce readmissions for HF
often cite palliative care studies that were performed in mixed populations, with heart disease
representing only a small (5%-16%) proportion of the study population (Enguidanos et al., 2012;
Fromme et al., 2006; Lukas et al., 2013). A retrospective observational review of palliative care
enrolled by traditional referral patterns identified a statistically significant decreased 30-day
hospital readmission rate of 14% for HF patients compared to non-enrolled subjects with a
hospital readmission rate of 40% (Brian Cassel et al., 2016). The former reflects a rate similar to
contemporaneously observed readmission rates post-HRRP implementation, while the latter
reflects a rate significantly above general readmission rates observed for HF (Zuckerman et al.,
2016). Resource use was significantly less in a retrospective observational study of palliative
care enrollees compared to a propensity-matched cohort of HF patients predominantly driven by
a reduced number of hospitalizations and length of stay (Brian Cassel et al., 2016).
Establishing the Goals of Care
Palliative care for HF has a primary objective to focus on improving quality of life rather
than focusing on improving survival alone through medical interventions. The aim is to alleviate
physical and psychological symptoms, support spiritual concerns, and create the opportunity to
discuss goals of care (Teixeira et al., 2016). Inpatient palliative care consultation has been
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demonstrated to decrease the frequency of procedures near the end of life, decrease the length of
stay, and decrease hospital and overall costs of care, such as pharmacy and imaging (Adler et al.,
2009).
Resuscitation preferences in HF have been noted to change over the course of the disease,
with 75% of patients electing do-not-resuscitate status before death, yet marked discordance
exists between patients’ primary recovery goals and treating clinicians’ goals who often do not
effectively elicit patients’ needs, concerns and expectations regarding their care (Dunlay et al.,
2014, Figueroa, 2016). In a recent single-site review at a large academic medical center, 20% of
patients hospitalized with HF indicated a resuscitation preference that differed from what had
been ordered by clinicians in the same hospitalization (Young et al., 2017). Guidelines routinely
recommend discussions about prognosis and patient preferences for goals of care, advance care
planning, surrogate decision making, and social and spiritual support; however, a cross-sectional
analysis of a cohort study identified 32% had not discussed prognosis, 24% had not discussed
what to expect in the future with respect to their HF diagnosis, 54% had not discussed advance
care planning, and 77% had not discussed religion or spirituality preferences (Gordon et al.,
2017). Shared decision-making and future care planning are essential elements of HFPC and
routinely employ communication methods with demonstrated effectiveness, such as motivational
interviewing (Meyers & Goodlin, 2016; Riegel et al., 2016).
Systematic Reviews and Randomized Clinical Trials
Multiple systematic reviews specifically relevant to the topic of HFPC have compiled the
limited evidence available and largely focus on the prevalence of bias in much of the existing
literature and the previously reviewed findings gleaned from the few remaining well-conducted
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studies with minimal risk of bias (Diop et al., 2017; Fischer et al., 2015; Kane et al., 2015;
Kavalieratos et al., 2016; Kavalieratos et al., 2017; Maciver & Ross, 2018; Singer et al., 2016).
The systematic reviews and randomized clinical trials that have contributed to the
evidence on HFPC are summarized in an annotated table found in Appendix A3. Only one study
has been rated as having a low risk of bias. The mixed results and methodological issues present
in these studies demonstrate the preliminary status of the evidence to guide assessment, patient
management, and effective treatment interventions to achieve desired patient outcomes for
decreasing symptom burden, improving quality of life, and optimizing resource utilization with
decreasing hospital readmissions without increasing the risk of mortality. Previous evidence
reviewed has demonstrated evidence for the potential of increased mortality associated with
decreased hospital readmissions. Any policy that improves resource utilization should not come
at the cost of increased risk of mortality. It is an important aspect of palliative care research to
provide evidence that palliative care not only improves symptom burden, quality of life, and
decreased hospital readmission but does so with no increased risk.
Alternatively, HFPC may be the only safe and effective way to decrease hospital
readmissions with the home-based services of PC. The hypothesis of this investigation was that
the increased level of resources, education, facilitated decision-making, and future health
planning would enable the patient to better understand their symptoms and improve health
behaviors through a better understanding of the health system, and enable the patient to seek
health care services in less hospital-oriented settings to ultimately decrease hospital
readmissions. Also, this research evaluated whether or not an HFPC consult is associated with
hospital readmission at 90 days after controlling for mortality. If an HFPC consult is associated
with decreasing hospital readmissions after controlling for mortality, this would indicate a
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positive finding and evidence of efficacy for HFPC consultation (reject the null hypothesis). If an
HFPC consult is not associated with decreasing hospital readmissions after controlling for
mortality, this would indicate a negative finding for HFPC consultation (fail to reject the null
hypothesis). No study to date has evaluated patient outcomes in a propensity-matched cohort to
evaluate the effect that mortality may have on the rate of hospital readmissions.
Sidebottom et al. (2015) demonstrated non-significant differences in mortality in a
population with marked differential loss to follow-up with 80% of intervention arm patients not
completing intervention follow-up. Brannstrom and Boman (2014) and Rogers et al. (2017)
found non-significant differences in survival or mortality at follow-up in resource-intensive
health services environments atypical for health services in much of the United States. In the
absence of such resource-intensive health services, it is intuitive that HFPC may be the only
resource available to HF patients to achieve the outcomes of decreasing hospital readmission
without increasing mortality. To attempt to decrease hospital readmissions without additional
self-care support would intuitively be a significant risk of increased mortality, especially in the
setting of observed increases in mortality associated with HRRP efforts to decrease hospital
readmissions for HF.
Retrospective Studies
The most frequent method of investigation of HFPC has been the retrospective cohort
analysis. The findings from this approach have also had the highest frequency of mixed findings.
Two recent large studies, conducted at large academic medical centers, produced directly
contradicting findings (Chuang et al., 2017; Wiskar et al., 2017). Chuang et al. (2017) identified
no reduction in risk of 30-day hospital readmission in the HFPC group compared to a propensity-
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matched control group24. Wiskar et al. (2017) identified a significant reduction in hospital
readmission for HF25 and all-cause readmission26 at nine-month follow-up. There were key
differences in these two studies, the former, a single-site academic medical center, the latter, a
linked nationwide analysis; the former monitored follow-up for 30 days and the latter for 90 days
(Chuang et al., 2017; Wiskar et al., 2017). Both studies matched on severity using validated
comorbidity indices. Neither study evaluated the effect of mortality despite differential mortality
(39% - 37%) and differential average time to death (136-262 days) in the HFPC group compared
to controls in the former study, an analysis that was perhaps unnecessary, given the existing
absence of an observed association; in the latter study, mortality was not assessed, which was a
significant limitation to the findings (Chuang et al., 2017; Wiskar et al., 2017).
A previous study at a single-site large academic medical center identified statistically
significant reductions in 30-day hospital readmission, with rates for HFPC recipients showing
10.3%27 versus usual care at 15%28 (O'Connor et al., 2015). The authors acknowledged that at
least some of the effect size might have been due to hospice referrals; mortality was not assessed
in the cohort (O'Connor et al., 2015). In addition, the observed readmission rates were
substantially different from rates in later retrospective studies and other studies evaluating HF
readmission rates alone, suggesting fundamental differences in admission practice or
ascertainment bias (Chuang et al., 2017; Desai et al., 2016; Wiskar et al., 2017). Earlier
retrospective studies were predominantly descriptive in nature, included HF in a mixed

24
25
26
27
28

respectively, 50.8% and 36.0%
9.3% vs. 22.4%, p < 0.01
29.0% vs. 63.2%, p < 0.01
95% CI [8.9% - 12.0%]
95% CI [14.4% - 15.4%]
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population, and evaluated implementation strategies for advance care planning and hospice use
(Bekelman et al., 2011; Connor et al., 2007; Enguidanos et al., 2012; Schellinger et al., 2011).
Prospective and Before-After Intervention Studies
The majority of prospective studies have been small studies of HFPC models of care to
test the feasibility of a planned future larger intervention study (Bekelman et al., 2014; DionneOdom et al., 2014). One prospective case-control study is notable for its specific methodology
using multiple validated measures of comorbidity, symptoms, depression, and quality of life at
baseline and 90-day follow-up, with statistically significant improvements noted in each of the
domains measured (Evangelista et al., 2012). Patients were excluded if they were currently
receiving or had planned HFPC services; limitations noted included the small groups, lack of
randomization, and the case-control method to test association without the ability to evaluate
causality (Evangelista et al., 2012).
Several non-randomized before-after HFPC intervention trials have been published
describing the phased implementation of HFPC for advanced HF at single sites of inpatient and
outpatient care (Bailey et al., 2005; Nelson et al., 2011; Pattenden et al., 2013). The bias of the
historical control in the setting of rapid evolution and advocacy for the implementation of HFPC
from published guidelines is significant (Gordis, 2009). One before-after HFPC intervention trial
evaluated the effectiveness of a single RN versus an interdisciplinary team consisting of a
physician, bioethicist, social worker, RN, and hospital chaplain. The study noted a 20%
reduction in six-month hospital readmissions, p =0.025, with a calculated Bayesian probability of
readmission of 73% for each individual in the former group, while the latter group had a
calculated Bayesian probability of readmission of 33% (Nelson et al., 2011).
Cross-sectional Studies
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Other studies have included descriptive cross-sectional prevalence studies defining the
availability of PC services, quantifying the unmet patient need for palliative care services, and
resource utilization (Blecker et al., 2011; Szekendi et al., 2016; Twaddle et al., 2007). These
analyses have identified significant gaps in the human resource and organizational capacity to
deliver HFPC to eligible patients. A point prevalence study of 33 hospitals identified 18.8% of
the inpatient populations as appropriate for palliative care referral. Of those deemed appropriate,
39.1% received a palliative care referral or services, with wide variation in service delivery
ranging from 12% to more than 90% (Szekendi et al., 2016). These findings indicate a sizable
unmet need for PC services in general, which increases the demand for additional PC resource
demands; the evidence supports the efficacy of the HFPC intervention to achieve the outcome
desired-decreased hospital readmissions.
In a review of 35 major US teaching hospitals, 12 (35%) did not have PC consultation
available (Twaddle et al., 2007). The level of performance achieved on key performance
measures rivaled that of hospitals where PC consultation was available but not utilized or
requested late in the hospitalization. Hospitals with no PC consultation available achieved an
average of 53.8% successful completion of key performance measures, while hospitals with PC
consultation achieved 69.3% adherence to key performance measures when PC was received
compared to 59.8% when it was not received (Twaddle et al., 2007). These findings demonstrate
that PC services may be successfully delivered to the HF patient even in the absence of a specific
PC consultation service, indicating the potential for innovative program design that maximizes
the reach and utility of PC practitioners. These findings are also important to the definition of
what constitutes delivery of PC. The definition is limited to the presence or absence of a
requested PC consultation to the completion versus non-completion of a requested PC
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consultation or delivery of the PC services, regardless of whether or not such services are
provided in the context of a formal PC consultation.
Qualitative Studies
A limited number of studies have evaluated questions important to the practice of PC,
such as goal definition and assessment of PC service delivery (Schellinger et al., 2018; Schwarz
et al., 2012). Evaluating a mixed population comprising 68% with a primary diagnosis of HF,
Schellinger et al. (2018) identified 13 unique domains that are essential to whole-person care.
These findings provide an essential guide to achieving a comprehensive, holistic PC assessment
that goes beyond the focus on physical, disease-specific, problem-oriented medical care.

Cost-effectiveness Studies
Cost-effectiveness for HFPC has not been evaluated in the United States. Sequential
studies evaluating the cost-effectiveness of PC indicate that pooled diagnostic categories were
statistically significant, while stratification demonstrated a stronger association with cancer
versus non-cancer diagnoses (May et al., 2014; May et al., 2018). In a statistical analysis
accounting for multiple comparisons, statistically significant cost-effectiveness only remained
among non-cancer patients with an Elixhauser comorbidity index > 4, indicating that PC is costeffective for those with non-cancer diagnoses with four or more multiple comorbidities
(Elixhauser et al., 1998; May et al., 2018; Moore et al., 2017). Cost-effectiveness for home-based
HFPC has been clearly established in Sweden, with statistically significant reductions in MD
visits, emergency transport, and hospital care (Sahlen et al., 2016). Costs were increased for
nurse visits and other primary health care visits, which resulted in non-significance for total
combined costs. However, despite non-significant changes in costs, there was also a statistically
significant increase in quality-adjusted life years, contributing to an overall favorable outcome
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for the cost-effectiveness determination (Sahlen et al., 2016). The limitation for generalizability
of these findings to the United States is the fundamental differences in the health system
priorities, health care preferences, and priorities of the United States versus Sweden. Whether
HFPC is cost-effective in the US health system remains undetermined.
Theoretical Framework
The theoretical framework for this research is nested within the foundational science of
signal detection theory (Goldstein, 1999). The process of sensation and perception can be
separated into the physiological process of neural transmission and the psychological process of
perception, recognition, and action (Goldstein, 1999). The psychological process that prompts
behavior is best described by Leventhal’s Common-sense model of self-regulation of health and
illness (CSM). Leventhal’s Common-sense model is broadly used throughout the HFPC
literature (Dionne-Odom et al., 2014; Horne et al., 2013; Turrise, 2016).
Signal Detection Theory
The sensations of sight, hearing, smell, taste, and touch inform our perceptions through
established physiological pathways, but also through the cognitive influences formed by an
individuals’ ability to remember and recognize grouping patterns, context, previous knowledge,
familiarity with the method of delivery, and expectations based on culture, past experiences, and
memory (Goldstein, 1999). The physiological pathways of sight, hearing, and touch are
augmented by the chemical senses of taste and smell that form the individual’s ability to perceive
their presence and position in this world (Goldstein, 1999). The physiologic pathway comprises a
distal stimulus (diagnosis of HF), a proximal stimulus (symptoms of HF), transduction
(transformation of sensory input to electrical energy), and neural processing (transmission to
neuronal pathways). The subsequent psychological process comprises the elements of perception
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(interpretation of symptoms), recognition (contextual meaning of symptoms), and action
(outcome of the perceptual process; Goldstein, 1999).
Signal detection theory is the theoretical basis of measuring perception. It has two
essential components, the ‘signal,’ which is the stimulus presented to the subject, and ‘noise,’
which is all the other stimuli in the environment that can sometimes be mistaken for a signal
because the signal is usually very faint (Goldstein, 1999). This describes the complexities of the
chronically ill HF patient struggling to differentiate signals of worsening disease from the noise
of chronic illness with incredible accuracy. For example, in a signal detection experiment, an
individual must interpret the presence or absence of a signal in the context of varying
background noise. An individual who is motivated, intrinsically or extrinsically, to identify as
many signals as possible will be a liberal responder and demonstrate a high sensitivity, low
specificity, and a high false-positive rate of activation (Goldstein, 1999). An individual who is
motivated to be ‘sure’ of the presence of a signal before responding will be a conservative
responder and demonstrate a lower sensitivity, higher specificity, and a lower false-positive rate
of activation (Goldstein, 1999).
An important and directly applicable aspect of the theory is that if the payoff or reward
for identifying a signal is high, all subjects will become liberal responders and demonstrate a
high sensitivity and consequently high false-positive rate of activation, precisely the motivational
system that is in place for the care and management of patients with HF (Goldstein, 1999). A
high-valued reward (health) will be realized if the patient can identify as many signals as
possible indicating a problem with their underlying disease that prompts them to seek expert
opinion via medical care. Simultaneously, government and insurers provide incentives to health
systems and health care providers to provide optimal care within existing resources that will limit
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the need for hospital resources, to be ‘gatekeepers’ for hospital readmission, and from the
patient’s perspective, limit access to the reward.
Varying the reward in a signal detection experiment will yield a ROC curve that would
enable the investigator to determine whether individual responses exhibit the same or
significantly different sensitivity to the signal regardless of their inherent high or low responder
tendency. However, in an experiment with HFPC, it would be unethical to vary the reward, and
as such, a natural or observational study design is required. In this type of study design, a
response that can be evaluated is the presence or absence of 90-day hospital readmission for HF.
By providing improved coping mechanisms, HFPC may improve the accuracy of perceived
signals (symptoms), thus decreasing unnecessary health-seeking behaviors and consequently
decreasing unnecessary 90-day hospital readmissions.
Common Sense Model
The Common Sense Model (CSM) was proposed as an information-processing model
that holds that individuals (a) interpret the meaning of illness and symptoms, (b) decide how to
respond, (c) take action, (d) evaluate the effectiveness of the action or illness management
strategy, and (e) revise their understanding of the criteria for evaluating the effectiveness of the
action (Leventhal et al., 2003). CSM focuses on how patients shape their health-seeking
behaviors based on their illness beliefs. The issues related to immunization during the ongoing
COVID-19 pandemic clearly illustrate how extreme illness beliefs related to conspiracy theories,
governmental interference, or wholesale fraud in the actual existence of the disease has shaped
health-seeking behaviors related to obtaining the vaccination, with many individuals choosing to
not be immunized despite clear risks to their own health and the health of others. Theories
related to the CSM and over-arching model of self-regulation provide interpretations of illness
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via an explanatory construct of chronic illness representation and focus on how people with
chronic somatic disorders make sense of their illness (Kaptein et al., 2003). Goals and
confidence are key self-regulatory elements that influence action (Scheier & Carver, 2003).
Important aspects of medication adherence have been further described in the perceptual context
of treatment risk versus side effects and are elaborated in the necessity-concerns framework
(Horne, 2003). The effects of culture, gender, personality, cognition, and denial related to the
application of the CSM have been described in detail (Baumann, 2003; Cameron, 2003;
Contrada & Coups, 2003; Martin & Suls, 2003; Wiebe & Korbel, 2003).
In the CSM, illness representations are formed by both individual experience and social
inputs and have (a) an identity, label, or name associated with the condition (HF, HF
exacerbation), (b) a timeline or perceived rate of onset, duration, and decline (progression of HF
stage), (c) consequences or anticipated physical, cognitive and social disruption (decline in
function, death), (d) a cause (heart attack as a cause of HF or idiopathic cause of HF), and (e)
control or the perceived effectiveness of the ability of self or medical interventions to manage
disease (Leventhal et al., 2003). Similar to the previously discussed signal detection theory, in
which the signal must be accurately interpreted as present or absent in the context of background
noise, the CSM provides insight into why patients with HF often misidentify symptoms of
concern. Breathlessness, chronic fatigue, and swollen feet may be clear signs of HF for a
physician but may be misinterpreted by the patient due to their previous experience or illness
prototype and an illness representation that may falsely minimize or exaggerate the identity,
timeline, consequences, cause, and control of HF elements. These result in suboptimal illness
outcomes of excessive hospital readmission or preventable mortality (Leventhal et al., 2016). In
order to successfully manage their disease progression, HF patients must be able to accurately
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and reliably identify symptoms associated with the condition, anticipate the progression of their
disease, understand the consequences of specific medical and self-management choices or
interventions, have knowledge of the cause of worsening symptoms and demonstrate an action
plan exhibiting their ability to control their condition and measure the effectiveness of chosen
self-management or medical interventions (Leventhal et al., 2016).
The CSM was chosen over other models of health behavior, such as the Health Belief
Model and Theory of Planned Behavior because concepts in the CSM are multi-level. The CSM
focuses on not only the antecedent experience of severity (illness prototype) but also concurrent
inputs from the senses and treatment beliefs. It also considers the projected future consequences
and potential for cure or control (illness representation) of the health-seeking behavior
(Leventhal et al., 2016). Moreover, the CSM requires examination beyond the ‘why’ a specific
behavior occurred; it examines the context, what an individual did, and how the behavior is
achieved (Leventhal et al., 2016).
The CSM proposition that guided this dissertation study is that the relationship between
illness representations with inputs from the illness prototype, sensory inputs and treatment
beliefs, and the illness outcome of hospital readmission can be modified by improving coping
procedures developed in the context of palliative care. Health care providers can do little to
influence an individual patients’ illness prototype, sensory inputs, or treatment beliefs. However,
health care providers can provide the patient with coping procedures that may impact the illness
outcome of interest—to decrease hospital readmission. This study evaluated the relationship of
coping procedures, as measured by the presence versus absence of palliative care consultation
with the illness outcome of 90-day hospital readmission.
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It is reasonable to presume that achievement of high patient perception competency in
coping procedures would be more effectively delivered within the physician-driven model of
HFPC. However, the difficulty demonstrated in previous studies is that the observed variation in
HFPC service delivery is high, and determining the threshold of whether HFPC services have
been adequately delivered is difficult. If presence versus absence of an order for HFPC consult is
the differentiator, the consult may occur during the inpatient hospitalization or not; if presence
versus absence of an actual HFPC consult on the medical record is the differentiator, the type of
services delivered is highly variable. Since patient knowledge and competency are at the core of
successful disease management, it is irrelevant where the derived source for HFPC competency
arises. Rather, knowledge and skills are received, understood, and incorporated by the patient to
inform a more accurate and reliable illness representation. Consideration of the need and referral
for palliative care consultation is a reasonable if unvalidated proxy for the intent of the entire
patient care team to provide HFPC competency via a mixed approach with nursing-driven
education; primary care self-care recommendations, future planning with advanced directives,
and designation of health care proxy and coordination of services; subspecialist management
recommendations; case management referrals for available community support services and
ideally, palliative care consultation.
Summary of What is Known and Unknown About HFPC and Hospital Readmission
In summary, what is known and unknown about the relationship between HFPC and
hospital readmissions is that the prevalence of HF is increasing and is unlikely to decrease with
significant and sustained risk factor prevalence of coronary artery disease, hypertension, diabetes
mellitus, obesity, and smoking in the population (Benjamin et al., 2018; Heidenreich et al.,
2013). The economic burden for the management of HF in a model of healthcare designed for
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acute care is unsustainable (Heidenreich et al., 2013). It is unknown whether HFPC is an
effective alternative for patient management to improve outcomes for patients with HF.
The interpretation of symptoms and health-seeking behaviors for HF is complex, difficult
to assess, and exerts a strong influence on the individual’s illness representation, prompting
health-seeking behaviors (Enguidanos et al., 2015; Kaptein et al., 2003; Leventhal et al., 2016;
Turrise, 2016). Research demonstrates that coping mechanisms improve illness outcomes
(Leventhal et al., 2016; Turrise, 2016). It is unknown whether improved coping mechanisms,
represented by the presence of a PC consult, can affect the illness outcome of hospital
readmission in patients with HF.
Research has shown that the HRRP policy that seeks to reduce hospital readmissions was
based on an inherently flawed premise that the hospital may influence health-seeking behaviors
for a 30-day period post-discharge (Chin et al., 2016; National Quality Forum, 2016). In
addition, studies have shown that 30-day hospital readmissions were not impacted by related
hospital process of care indicators but were associated with individual and community factors
such as resource availability, social support, and mental health issues (Barnett et al., 2015; Chin
et al., 2016; Freedland et al., 2016; Pandey et al., 2017). It is unknown whether the acute care
hospital system can reasonably facilitate access to a limited resource, like PC consultation, with a
limited number of PC practitioners to fully serve the HF population in need of services. It is also
unknown whether different modalities of care, service delivery models, or location of service
delivery of PC interventions can deliver comparable outcomes.
Lastly, the HRRP policy has met with a modicum of success in reducing 30-day HF
hospital readmissions, but that reduction has continued controversy with its association with
increases in post-discharge HF mortality. It is unknown whether improved coping mechanisms
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delivered by HFPC can achieve reductions in hospital readmission without an increase in
mortality. In other words, it is unknown if HFPC modifies the relationship between the HF
illness representation and the illness outcome of hospital readmission without an increase in
mortality.
Contribution
Practical application of the findings generated will:


Contribute to the existing knowledge gap identified as a research priority by the NIH,
NPCRC to better characterize and address the needs of providers managing the care
of advanced HF patients.



Contribute to the evidence evaluating the effectiveness of palliative care referral to
reduce hospital readmissions for HF.



Contribute to the evidence evaluating the relationship between a PC consult and 90day hospital readmissions in a propensity-matched HF cohort, with adequate controls
for the assessment of bias arising from differential mortality, an element that has been
poorly assessed in the previous literature.
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Chapter 3: Methodology
Research Methods
The approach to this research is a concurrent cohort design with a prospective
ascertainment of 90-day hospital readmission, HFPC consult and mortality. To ensure the
capture of all discharges and readmissions, all live discharges with a primary diagnosis of HF,
codified in Appendix A4, were abstracted from the AdventHealth data warehouse. Data
abstraction included patient identifiers to enable future contact, all coded administrative ICD-10
diagnosis codes, palliative care consult code, and mortality status and elements required to
achieve propensity matching. The outcome of interest is hospital readmission for any cause
within 90 days of index HF hospitalization. Readmission was assessed by medical record review
and patient contact (if needed) conducted at 90-120 days post-discharge. IRB approval of the
research plan, ascertainment of readmission, and mortality at 90 days post-discharge were
ascertained in a stepwise manner:
1. All 90-day hospital readmissions captured within the AdventHealth Tampa database
were supplemented with additional metrics abstracted from the electronic medical
record to enable propensity matching.
2. Patients with an unascertained status at 90 days post index HF discharge were
reviewed in the AdventHealth Tampa electronic medical record to determine
readmission, palliative care consult, and mortality status.
3. Any remaining patients with an unascertained status at 90 days post-HF discharge
were contacted directly with the contact information provided at the time of the index
admission with a single query: “Has ‘patient name’ had any hospital admissions since
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the discharge from AdventHealth Tampa on ‘discharge date’?” after introductions
defined by the IRB.
4. Any remaining patients with an unascertained status at 90 days post-HF discharge
were determined to be lost to follow-up (Lorenz et al., 2008). Ascertainment of status
at 90-day post HF discharge was high, with only one patient excluded as lost to
follow-up.
CONSORT
The CONSORT flow diagram template was developed for standardized reporting of
randomized clinical trials. It has been adapted to illustrate the research plan for this investigation
(Schulz et al., 2010). Table 1 shows the index hospitalization for live HF discharges between
October 1, 2019, and December 31, 2019.
Table 1
Index Hospitalization for Live HF Discharges
Index Hospitalization for Live HF Discharges
Oct 1 - Dec. 31, 2019
N=150 (estimated)
Exclusions:

Age < 18
Transfer to another acute care / psychiatric hospital
Left hospital against medical advice
Hospitalizations for the same condition within 30 days of an index hospitalization
were not considered an index event.
Patients alive but without at least 90 days of post-discharge follow-up.

Palliative Care Consult

No Palliative Care Consult

n=

n=

Propensity-matched cohort

Propensity-matched cohort

n=

n=
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Excluded criteria used by Centers for Medicare & Medicaid Services (CMS) to calculate hospital
mortality and readmission performance, but not used in this study:
1. Exclusion of patients who did not have a full year of pre-admission enrollment in
Medicare.
2. Exclusion of patients alive but without at least 30 days of post-discharge follow-up.
Specific Methodological Procedures
Specific procedures defined herein make the analytic choices transparent to the reader
and include a description of the specific plan to achieve propensity matching, the plan for logistic
regression analysis, and the formats for the final presentation of results.
Analytic Choices
A key aspect of this investigation is the choice of analytic approach that was used. A
review of the literature related to mortality and HF readmissions illustrated how different
analytical choices can yield divergent results. Silberzahn et al. (2018) quantified the potential
variability in the analytic approach with 32 equivalently competent research teams presented
with the same dataset and research question and asked to determine a valid analytic approach and
final result. The teams selected from one to seven covariates from the 14 covariates available; 15
(52%) chose a Logistic approach, six (20%) teams chose a Linear approach, six (20%) chose a
Poisson approach, and two (7%) chose a miscellaneous approach. Results varied from OR 0.89
to 2.93; the theoretical approach, operationalization of the theory, statistical analytic choices, and
the assumptions made during analysis can result in sizable variation in effect sizes even with a
valid statistical methodological approach (Silberzahn et al., 2018). The authors recommended
approaches that increase transparency in the analytic choices made and decrease the opportunity
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for selective reporting. The description of research methods employed in this study ensured
transparency of analytic choices with the aim to decrease the opportunity for selective reporting.
Logistic Regression
To answer the primary research question of interest, whether palliative care consultation
can impact 90-day hospital readmission in a propensity-matched, mortality-adjusted HF
population, the propensity-matched cohorts were compared in a logistic regression with the
dependent variable of 90-day readmission and independent variables:


Palliative care consult (Y or N)



Propensity score (Continuous)



90-day mortality (Y or N)

The relationship between 90-day hospital readmission and PCHF consult was further
explored with a graphical analysis of time to readmission with a Kaplan-Meier survival analysis
regression evaluating the presence/absence of differential survival time to readmission predicted
by palliative care consult, including only those patients who had an ascertained status of alive at
90 days, exclusive of the contribution of propensity.
Propensity Matching. Propensity matching has been used frequently in the HF literature
to ensure appropriately matched cohorts (Brian Cassel et al., 2016; Chuang et al., 2017; Wiskar
et al., 2017). Propensity-matched cohorts were formed based on the development of a propensity
score for each HF index hospitalization case. The propensity score is the conditional probability
of receiving an exposure (e.g., palliative care consult) given a vector of measured covariates. It
can be used to adjust for selection bias when assessing causal effects in observational studies
(Andrey et al., 2011). The propensity score is defined as the probability of receiving treatment
based on measured covariates e(x) =P(Z =1 | X) where e(x) is the abbreviation for propensity
score, P a probability, Z =1 a treatment indicator with values 0 for control and 1 for treatment,
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the "|" symbol stands for conditional on, and X is a set of observed covariates (Thoemmes,
2012). The calculated propensity score enables matching on demographic characteristics and
severity to ensure that patients who receive HFPC are matched to patients with a similar
demographic and severity profile (O'Connor et al., 2015).
Propensity scores for receiving palliative care consult were calculated using a nonparsimonious multi-variable logistic regression model with the treatment variable of palliative
care consult as the dependent variable and independent variable covariates (Chuang et al., 2017;
Garrido et al., 2014; Gupta et al., 2017; National Consensus Project, 2018):
● age
● gender
● DNR status (Y or N)
● insurance coverage
○ Medicare
○ Medicaid
○ private
○ dual eligible
● last known cardiac ejection fraction
○ preserved
○ borderline
○ reduced < 25%
● ICD implant
○ ICD only
○ CRT-D only
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○ ICD or CRT-D
● all administratively coded ICD-10 diagnosis codes to identify comorbidities identified
in Appendix A5 (Elixhauser et al., 1998)
○ cardiac arrhythmias
○ valvular disease
○ pulmonary circulation disorders
○ peripheral vascular disorders
○ hypertension, uncomplicated
○ hypertension, complicated
○ paralysis
○ other neurological disorders
○ chronic pulmonary disease
○ diabetes, uncomplicated
○ diabetes, complicated
○ hypothyroidism
○ renal failure
○ liver disease
○ peptic ulcer disease, excluding bleeding
○ AIDS or HIV
○ lymphoma
○ metastatic cancer
○ solid tumor without metastasis
○ rheumatoid arthritis or collagen vascular diseases
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○ coagulopathy
○ obesity
○ weight loss
○ fluid and electrolyte disorders
○ blood loss anemia
○ deficiency anemia
○ alcohol abuse
○ drug abuse
○ psychoses
○ depression
● severity of HF index hospitalization at time of admission
○ systolic blood pressure
○ heart rate
○ Na
○ BUN
○ creatinine
○ hemoglobin
○ parenteral inotrope therapy (dopamine hydrochloride, dobutamine
hydrochloride, milrinone lactate)
○ intra-aortic balloon pump use during index hospitalization
○ current smoking
● adherence to guideline directed medical therapy determined by chart review
○ NYHA class I-IV —> ACEI or ARB
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○ If NYHA class II-III with adequate BP control on ACE/ARB and no C/I to
ARB or sacubitril —> D/C ACEI or ARB; initiate ARNI
○ If NYHA class II-III, LVEF <=35% (caveat: >1 year survival, >40d post
MI) —> ICD
○ If NYHA class II-IV, LVEF <=35%, NSR & QRS >=150ms with LBBB
pattern —> CRT or CRT-D
○ If NYHA class II-III, NSR< HR>=70 bpm on maximally tolerated dose
beta blocker —> Ivabradine
● length of stay, days
● discharge destination
○ home
○ skilled nursing facility
○ inpatient rehabilitation facility
○ intermediate care facility
○ long-term care facility
○ hospice, home
○ hospice, inpatient
A logit of the propensity score enabled calculation of ORs for obtaining palliative care
consultation for individual covariates (MedCalc Version 15.1, 2018).

In the final analysis, the use of a propensity score as a continuous variable will enable matching
on demographic characteristics and severity. To ensure the inclusion of the maximum number of
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observations, nearest neighbor-matching was employed because it reduces bias due to
incomplete matching (Austin, 2013). The mean propensity score for the resulting palliative care
and non-palliative care group before and after propensity matching was calculated, and a
standardized difference was calculated. Residual imbalances in baseline covariates between
treatment groups after propensity score matching was assessed by estimating the absolute
standardized differences of the mean propensity scores (Austin, 2009). Standardized differences
quantify the bias in the means (or proportions) of covariates across the groups, expressed as a
percentage of the pooled standard deviation (Andrey et al., 2011). A t-test p-value was calculated
to test statistically significant differences between the HFPC and non-HFPC groups before and
after propensity-matching.
Demographic Characteristics. Additional demographic characteristics that were
abstracted include:


telephone contact information provided at the time of index HF admission.

Formats for Presentation of Results
CONSORT flow diagram summarizes the observed allocation of propensity matching,
success with follow-up, and net cases included in the final analysis (Schulz et al., 2010). The
resulting analysis is presented as tables demonstrating logistic regression of the primary research
question of interest, whether 90-day readmissions can be influenced by HFPC consult after
controlling for mortality and severity. The validity of this analysis is supported by tables of
demographic characteristics before and after propensity-matching and calculated odds ratios for
HFPC consult. Sub-analysis of time to readmission included calculated means and time to
readmission. Survival curves demonstrate differential time to readmission for HFPC versus noHFPC consult cohorts.
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Logistic Regression


table of the outcome of a logistic regression of 90-day hospital readmission after
controlling for mortality and severity (propensity-scoring) in the propensity-matched
population



table of the outcome of a logistic regression of 90-day hospital readmission after
controlling for mortality and severity (propensity-scoring) in the total un-matched
population

Demographic Characteristics and Propensity Scoring of HFPC Versus Non-HFPC Cohorts


table of demographic characteristics of HFPC versus non-HFPC cohorts before and
after propensity-matching



table of means and standardized differences of HFPC versus non-HFPC cohorts
before and after propensity-matching



box and whiskers plot of propensity scores stratified by HFPC versus non-HFPC
cohorts

Odds Ratio
As a logit transformation of the individual 𝐵 obtained from the logistic regression
equation to demonstrate the effect size of the relationship, OR will be calculated.


Odds ratio of 90-day hospital readmission predicted by the presence versus absence
of a palliative care consult in propensity-matched, mortality adjusted cohort.



Odds ratio of HFPC consult predicted by demographic characteristics, markers of
acuity at the time of hospital admission, and other comorbidities.

Kaplan-Meier Survival Curve


table of mean time to readmission



histogram of time to readmission by cohort
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distribution of time to readmission by cohort



Kaplan-Meier survival curve showing time to readmission for HFPC and non-HFPC
patients in the total un-matched population (Chuang et al., 2017)



Kaplan-Meier survival curve showing time to readmission for HFPC and non-HFPC
patients in the propensity-matched population

Resource Requirement
The research relied solely on the effort of the investigator to develop and execute the
approach, rationale, study design, data collection, and data analysis. The data warehouse required
for data abstraction is maintained by AdventHealth Tampa, consistent with their current standard
practice. Access to the data was pursuant to the procedures defined respectively by the State of
Florida and AdventHealth and specifically interpreted for this study by the AdventHealth Tampa
Institutional Review Board. A computer with Windows 10 operating system that utilized
Endnote 8.0 software to support reference management, Scrivener software to support
manuscript development, access to Grammarly.com to support editing, a current subscription for
SPSS software to analyze the data, and Microsoft Office to support final publication.
Reliability and Validity
A strength of the approach outlined in this proposal is that this investigation assessed the
outcomes of a cohort comprising 100% of individuals admitted for HF in the time period, preCOVID Oct 1 - Dec 31, 2019, assessing the outcome of 90-day hospital readmission and
accounting for mortality, minimizing the risk of ascertainment bias, and enhancing study validity
and reliability. The impact of differential mortality between groups receiving and not receiving
palliative care has been recognized as a significant risk of ascertainment bias in previous studies
(Chuang et al., 2017; Desai et al., 2016; Hua et al., 2017; Wiskar et al., 2017).

76
Propensity scores assigned from the use of the validated Elixhauser comorbidity scoring
system enabled the assignment of a propensity score based on a validated weighting of
comorbidities and validated metrics of HF severity taken from the index hospitalization. The use
of a validated scoring system to derive the propensity score creates the best opportunity to ensure
the greatest homogeneity of each cohort, creating the best opportunity to observe differential
outcomes between cohorts should they, in truth, exist.
Timeline
The execution of this investigation from the time of IRB submission was estimated to be:


four weeks

IRB submission.



four weeks

IRB clarifications and edits.



four weeks

Execute electronic data request to site.



six weeks

Data abstraction from medical records.



six weeks

Compilation of all data into analysis file.



six weeks

Data analysis.



six weeks

Preparation of dissertation results and discussion.

The actual timeline required approximately one year compared to the estimated six months,
primarily due to the need to obtain multiple IRB approvals and unanticipated delays with
compiling the data abstraction.
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Chapter 4: Results
Chapter Introduction
This chapter reviews the compilation of the final dataset, provides a detailed review of the
data analysis procedures and findings of the a priori data analysis plan, and discusses the findings
of this investigation. The primary outcome of the propensity-matched, mortality-adjusted logistic
regression showed that for every unit reduction in 90-day hospital readmission, there was a
statistically significant 1.468 increase in no HFPC consult (reduction in HFPC consult), p =.001.
Compilation of Final Dataset
The final dataset used for analysis was compiled from multiple data output files that were
compiled into a comprehensive dataset through a process of linking variables on four different
patient identifiers. This compilation resulted in an n =268. After exclusion of an additional 18
cases that were expired (8), left the hospital against medical advice (AMA; 5), ineligible
hospitalization (4), and discharged to Psychiatry (1), left a dataset n =250 for the index
hospitalization period Oct. 1 - Dec. 31, 2019.
Multiple transformation and recoding of variables were required to transform individual
vital signs and laboratory values that were output list-wise as a ‘value’ field, identified by case
and specific test in the original data file into separate variables for each case. Likewise, selected
comorbidities were organized as a subset of all comorbidities and transformed from unsorted
lists into variables that defined the presence/absence of each selected condition for each
respective identified index case. Lastly, the identification of the presence/absence of a 90-day
hospital readmission was incorporated into the final dataset. Multiple readmissions were
common in the original dataset and had to be de-selected, as they were not pertinent to this
investigation. It is notable that at this juncture, when palliative care consults from the original
datafile abstraction were matched to index hospitalization cases, no palliative care events
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matched to the index hospitalization cohort. Despite employing validated methods for identifying
palliative care consult occurrence, there were no coded PC events or any listed PC consults for
this cohort of hospitalized HF patients. All PC consults listed were attributed to hospitalized
cancer patients exclusively.
With a full cohort of index hospitalizations defined (n =254), data abstraction proceeded
with the planned chart review abstraction of mortality events, ejection fraction (EF%),
ACE/ARB use, presence/absence of ICD or CRT device implant, and IABP at the time of index
hospitalization. It was at this juncture that insight was gained into the reason that there were no
palliative care events listed in the abstracted data file. Due to the unique nature of the physician
consult note naming convention, there is no standardized name for a “Palliative Care,”
“Cardiology,” or any other type of consult. Each consult note is named according to the
individual naming convention determined by the consulting physician. Thus, a cardiology
consult may be listed as “Cardiology,” but it also may be listed as “Florida Heart.” All HFPC
consults were consistently named “Palliative Care” and were thus available for abstraction as a
part of chart review but could not be abstracted through automated means, as a standardized
naming convention did not exist. Lastly, the final determination of mortality events at 90 days
was largely determined by chart review and pharmacy utilization. Patient contact was required to
determine mortality status in only two cases; one patient had moved out of the area, and the
other’s family represented the patient as both alive and deceased.
Transformation of Variables
All vital sign and laboratory values were normally distributed, including initial systolic
blood pressure (SBP), initial heart rate (HR), initial sodium (Na), initial blood urea nitrogen
(BUN), initial BUN/Creatinine ratio (BUN/Cr), initial Creatinine (Cr), initial hemoglobin (Hgb),
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and initial hemoglobin A1C (Hgb A1C; see Appendix A7). Despite the presence of normal
distributions for each of these variables, it was important to stratify these variables on established
laboratory normals, which provided a greater level of clinical meaningfulness. While both
continuous and stratified values are equivalent for the purposes of statistical analysis, the
creation of clinically meaningful strata facilitates clinically applicable interpretation of results.
For example, outcomes for patients that are hypotensive versus normotensive versus
hypertensive are more clinically applicable than the statistically equivalent but less meaningful
outcomes for single gradations of blood pressure or any other vital sign or laboratory value
metric included in the model. In addition, directionality may not always be implicit in a
continuous variable and would be a source of confusion in the interpretation of results. In this
dataset, a very low or very high SBP or Na is clinically meaningful; that same interpretation does
not apply to Hemoglobin (low is bad) or Cr (high is bad).
Stratification enables analysis against a pre-defined ‘normal.’ Categorical variable coding
enabled the specification of a defined reference population and will allow the reader to draw
meaningful conclusions more easily about the interpretation of the statistical associations with
the outcome of interest. For example, mid-range or normal range of SBP was defined as the
reference population, while the high range of values for EF% was defined as the ‘normal’
reference, and the low range of values for Cr was defined as the ‘normal’ reference group (See
Appendix A8).

80
CONSORT
An overview of the data collection process and resulting population (n) is best reviewed
with the CONSORT diagram. The CONSORT flow diagram template was developed for
standardized reporting of randomized clinical trials (Schulz et al., 2010). It was adapted to
illustrate the research plan and outcomes for data collection in this investigation. Table 2 shows
the index hospitalization for live HF discharges between October 1, 2019, and December 31,
2019.
Table 2
Index Hospitalization for live HF Discharges: Oct. 1 – Dec. 31, 2019
Index Hospitalization for Live HF Discharges: Oct 1 - Dec. 31, 2019
n=250
Exclusions:

Age < 18
Transfer to another acute care hospital / psychiatric
hospital
Left hospital against medical advice
Hospitalizations for same condition within 30 days
of an index hospitalization were not considered
index events.
Patients alive but without at least 90 days of postdischarge follow-up.

30

Palliative Care Consult - Yes

Palliative Care Consult - No

n=92

n=142

Propensity-matched cohort30

Propensity-matched cohort

n=36

n=96

This procedure excluded those that were so low on propensity scoring that likelihood to
receive a PC consult was nil, and conversely excluded the population that scored so high on
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Excluded criteria used by Centers for Medicare and Medicaid Services (CMS) to calculate
hospital mortality and readmission performance, but not used in this study:


exclusion of patients who did not have a full year of pre-admission enrollment in
Medicare



exclusion of patients alive but without at least 30 days of post-discharge follow-up.

Data Analysis
Data analysis was conducted in accordance with the a priori outlined data analysis plan.
Logistic regression was used to assess the association of the independent variables of 90-day
mortality, HFPC consult, and propensity score (severity) against the primary outcome of interest,
90-day hospital readmission. The analysis yielded statistically significant findings in the
propensity-matched cohort; there were similar statistically significant findings in the overall
unmatched study population. Key steps in this final analysis included:
1. Logistic regression of the primary research question of interest, whether 90-day
hospital readmissions are influenced by HFPC consult after controlling for mortality
and severity.
2. An analysis of demographic characteristics of the overall unmatched study population
demonstrated statistically significant population differences that could confound the
outcome of interest.
3. Propensity-matching enabled the creation of cohorts that were similar in severity and
eliminated the potentially confounding population differences.

propensity scoring that likelihood of PC consult was a certainty, n=132 was the final number
included in the propensity-matched model.
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4. Demographic characteristics of the propensity-matched population demonstrated
similarity across a broad array of characteristics, with no residual demographic
statistical differences.
5. A more in-depth analysis of risk factors predicting the occurrence of an HFPC consult
was conducted with logistic regression of the individual predictor study variables for
the outcome of HFPC.
6. A more in-depth analysis of time to readmission with survival analysis found
statistically significant differences in the survival curve of time to readmission
between patients who received an HFPC consult and those that did not. Findings were
statistically significant in both the overall unmatched study population as well as the
propensity-matched cohort.
Logistic Regression
Logistic regression was employed to assess the primary research question of this
investigation. The primary outcome of interest, 90-day hospital readmission, was predicted by
the independent variables of 90-day mortality, HFPC consult and propensity score (severity; see
Table 3). Logistic regression was most applicable with a binary outcome of 90-day readmission
(Y/N) and predictors that were binary (90-day mortality and HFPC consult), while propensity
score was a continuous variable.
Propensity Matched Model. Outcomes of the logistic regression of the propensitymatched model found that for every unit reduction in 90-day hospital readmission,
contributing factors were a:


Statistically significant 1.468 increase in no HFPC consult (reduction in HFPC
consult), p =.001
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.482 increase in mortality (no survivorship at 90-day), p =.36



-0.631 reduction in severity, p =.50



Palliative Care OR 4.3, 95% CI [1.8 - 10.6]

Table 3 shows the logistic regression of propensity-matched 90-day readmissions.
Table 3
Logistic Regression of Propensity-Matched 90-Day Readmissions

Palliative Care Consult (No)
Survivor @ 90-day (No)
Propensity_Match
Constant

B

S.E.

Wald

df

Sig. Exp(B)

1.468
.482
-.631
-.779

.455
.531
.944
.537

10.418
.827
.447
2.105

1
1
1
1

.001
.363
.504
.147

4.342
1.620
.532
.459

This analysis indicates that after controlling for mortality and severity, there is a
statistically significant association between no HFPC consult and no 90-day hospital
readmission. In other words, HFPC consultation is statistically significantly associated with
hospital readmission within 90-day of discharge, after controlling for both mortality and severity.
For every 1.5 HFPC consults performed, one 90-day hospital readmission will be predicted by
this B trendline (e.g., if 30 HFPC consults are performed each month, 20 of those patients can be
expected to have a hospital readmission within 90 days). The OR of 90-day hospital readmission
for the HFPC consult cohort was OR 4.3, 95% CI [1.8 - 10.6], or patients who are appropriately
targeted for an HFPC consult are four times more likely to have a 90-day hospital readmission
than a patient who does not qualify for an HFPC consult.
Non-propensity Matched Model. To assess the robustness of the model without
propensity-matching, a calculation of logistic regression for the total population was performed.
Similar findings were noted with a logistic regression of the total unmatched population (see
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Table 4). Results were similar in that for every unit reduction in 90-day hospital readmission,
contributing factors were:


statistically significant 1.44 increase in no HFPC consult (reduction in HFPC
consult), p =.001



0.611 increase in mortality (no survivorship at 90-day), p =.12



.460 increase in severity (propensity score), p =.44



Palliative Care OR 4.2, 95% CI [1.8 - 10.1].

Table 4
Logistic Regression of Un-Matched 90-Day Readmissions
B

S.E.

Wald

df

Sig. Exp(B)

Palliative Care Consult (No)

1.442

.444

10.546

1

.001

4.231

Survivor @ 90-day (No)

.611

.388

2.486

1

.115

1.843

Propensity_Match

.460

.596

.594

1

.441

1.584

Constant

-.944

.491

3.701

1

.054

.389

This analysis demonstrated the robustness of the model in that even when the broader
non-propensity matched population is used, statistically significant negative associations persist
between HFPC consult and 90-day hospital readmission. In other words, HFPC consultation
remains statistically significantly associated with hospital readmission within 90-day of hospital
discharge after controlling for mortality and severity, even when outliers that were initially
restricted from the propensity-matched analysis are included.
Demographics -Total Population. Evaluation of the demographic characteristics of
populations to be compared in a statistical analysis is important to ensure that there are no
significant differences in the two populations that could confound the outcomes of the analysis.
At the very least, these population differences may call into question whether the existing
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demographic differences are the primary cause of observed outcomes. There are numerous
statistically significant differences between the cohort that had an observed palliative care
consult compared to the cohort that did not. Table 5 demonstrates these differences.
Table 5
Demographic Characteristics - Total Un-Matched Study Population
Palliative Care Consult
___________________________
No
Yes
Column

*p31

Column

Count

N%

< 55

35

23.0%

17

17.3%

55-75

70

46.1%

38

38.8%

75+

47

30.9%

43

43.9%*

Female

71

46.7%

56

57.1%

Male

81

53.3%

42

42.9%

Do Not

.

148

97.4%*

85

86.7%

.001

Resuscitate

DNR

4

2.6%

13

13.3%*

.001

Primary

Commercial

102

67.1%

55

56.1%

Insurance

Medicaid

6

3.9%

1

1.0%

Medicare

44

28.9%

42

42.9%*

.024

Secondary

None

76

50.0%*

34

34.7%

.017

Insurance

Commercial

47

30.9%

40

40.8%

Medicaid

26

17.1%

23

23.5%

Medicare

3

2.0%

1

1.0%

Age cohort

Gender

Ejection Fraction % (Low)

Mean Count

N%

.41

Mean

.037

.43

Ejection

.25 Reduced

39

26.0%

24

25.0%

Fraction cohort

.25-.50

58

38.7%

30

31.3%

Borderline

31

Tests are adjusted for all pairwise comparisons within a row of each innermost sub-table
using the Bonferroni correction.
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Table 5 continued
Demographic Characteristics - Total Un-Matched Study Population
Palliative Care Consult
___________________________
No
Yes
Column

.50+ Preserved

Count

N%

53

35.3%

Ejection Fraction % (High)

*p31

Column
Mean Count
42

N%

Mean

43.8%

.46

.47

AICD or CRT-

No

111

73.0%

74

75.5%

D Implant

Yes

41

27.0%

24

24.5%

ACE or ARB

No

55

36.2%

57

58.2%*

.001

Prescribed

Yes

97

63.8%*

41

41.8%

.001

Guideline

No

63

41.4%

60

61.2%*

.002

Adherence

Yes

89

58.6%*

38

38.8%

.002

Length of Stay

5

8

Hospitalization

Admission

57

37.5%

36

36.7%

duration

Observation

60

39.5%*

19

19.4%

.001

Prolonged

35

23.0%

43

43.9%*

.001

Discharge

Home

101

66.4%*

38

38.8%

.000

disposition

Home w

28

18.4%

21

21.4%

0

0.0%

3

3.1%

0

0.0%

8

8.2%

1

0.7%

2

2.0%

Services
Hospice –
Home
Hospice –
Facility
Inpt Rehab
Facility

31

Tests are adjusted for all pairwise comparisons within a row of each innermost sub-table
using the Bonferroni correction.
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Table 5 continued
Demographic Characteristics - Total Un-Matched Study Population
Palliative Care Consult
___________________________
No
Yes
Column

*p31

Column

Count

N%

Mean Count

N%

Mean

LTC Hospital

2

1.3%

2

2.0%

Short Term

1

0.7%

1

1.0%

19

12.5%

23

23.5%*

99

65.1%*

39

39.8%

.000

Yes

53

34.9%

59

60.2%*

.000

Survivor @ 90-

No

19

12.5%

26

26.5%*

005

day

Yes

133

87.5%*

72

73.5%

.005

BP

Hypertension

87

57.2%

59

60.2%

Hypotension

0

0.0%

2

2.0%

Normal

65

42.8%

37

37.8%

Normal

108

71.1%

64

65.3%

Bradycardia

9

5.9%

3

3.1%

Tachycardia

35

23.0%

31

31.6%

Hypernatremia

4

2.7%

3

3.1%

Hyponatremia

26

17.4%

18

18.4%

Normal

119

79.9%

77

78.6%

Low

20

13.4%

11

11.2%

Normal

83

55.7%

54

55.1%

Renal

46

30.9%

33

33.7%

High

26

17.6%

13

13.7%

Inpatient
SNF -Skilled
Nurse
90-day Readmit No

HR.

Na

BUN/Cr

Cr

31

.024

Tests are adjusted for all pairwise comparisons within a row of each innermost sub-table
using the Bonferroni correction.
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Table 5 continued
Demographic Characteristics - Total Un-Matched Study Population
Palliative Care Consult
___________________________
No
Yes
Column

Hgb

Hgb A1C

*p31

Column

Count

N%

Mean Count

N%

Elevated

38

25.7%

37

38.9%*

Normal

84

56.8%

45

47.4%

Anemia

79

53.0%

58

59.2%

Normal

69

46.3%

40

40.8%

Polycythemia

1

0.7%

0

0.0%

Normal

21

42.0%

18

60.0%

Poor Control

17

34.0%

12

40.0%

Very Poor

12

24.0%

0

0.0%

Mean
.029

Control
Pressors

No

145

95.4%

95

96.9%

required

Yes

7

4.6%

3

3.1%

Intra Aortic

No

152

100.0%

97

99.0%

Balloon Pump

Yes

0

0.0%

1

1.0%

Tobacco Use

Cognitive Def

0

0.0%

0

0.0%

Never

81

54.7%

57

58.8%

Last Tobacco

22

14.9%

10

10.3%

37

25.0%

24

24.7%

5

3.4%

4

4.1%

Use <30d
Last Tobacco
Use >1yr
Last Tobacco
Use >30d <1yr

31

Tests are adjusted for all pairwise comparisons within a row of each innermost sub-table
using the Bonferroni correction.
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Table 5 continued
Demographic Characteristics - Total Un-Matched Study Population
Palliative Care Consult
___________________________
No
Yes
Column

*p31

Column

Count

N%

3

2.0%

2

2.1%

No

151

99.3%

96

98.0%

Yes

1

0.7%

2

2.0%

No

151

99.3%

96

98.0%

Yes

1

0.7%

2

2.0%

Alcohol abuse

No

152

100%

98

100%

w mild liver dz

Yes

0

0.0%

0

0.0%

Deficiency

No

117

77%*

64

65.3%

.044

Anemias

Yes

35

23.0%

34

34.7%*

.044

Arthropathies

No

145

95.4%

94

95.9%

Yes

7

4.6%

4

4.1%

Chronic blood

No

151

99.3%

97

99.0%

loss anemia

Yes

1

0.7%

1

1.0%

Leukemia

No

152

100.0%

97

99.0%

Yes

0

0.0%

1

1.0%

No

150

98.7%

96

98.0%

Yes

2

1.3%

2

2.0%

Metastatic

No

151

99.3%

97

99.0%

cancer

Yes

1

0.7%

1

1.0%

Unable to

Mean Count

N%

Mean

answer
AIDS
Alcohol abuse

Lymphoma

31

Tests are adjusted for all pairwise comparisons within a row of each innermost sub-table
using the Bonferroni correction.
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Table 5 continued
Demographic Characteristics - Total Un-Matched Study Population
Palliative Care Consult
___________________________
No
Yes
Column

*p31

Column

Count

N%

Solid tumor w/o No
metastasis,insitu Yes

152

100%

98

100%

0

0.0%

0

0.0%

Solid tumor w/o No

149

98.0%

96

98.0%

mets, malignant Yes

3

2.0%

2

2.0%

Cerebrovascular No

148

97.4%

95

96.9%

4

2.6%

3

3.1%

152

100%

96

98.0%

0

0.0%

2

2.0%

151

99.3%*

91

92.9%

.014
.014

disease - POA

Yes

Cerebrovascular No
disease - seq

Yes

Cerebrovascular No

Mean Count

N%

dz - paralysis

Yes

1

0.7%

7

7.1%*

Congestive

No

16

10.5%

8

8.2%

heart failure

Yes

136

89.5%

90

91.8%

CHF w HTN,

No

42

27.6%

18

18.4%

complicated

Yes

110

72.4%

80

81.6%

144

94.7%

91

92.9%

CHF w HTN, w No
renal failure

Yes

8

5.3%

7

7.1%

Coagulopathy

No

143

94.1%*

83

84.7%

Yes

9

5.9%

15

15.3%*

No

142

93.4%

88

89.8%

Yes

10

6.6%

10

10.2%

No

139

91.4%

84

85.7%

Dementia
Depression

31

Mean

Tests are adjusted for all pairwise comparisons within a row of each innermost sub-table
using the Bonferroni correction.
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Table 5 continued
Demographic Characteristics - Total Un-Matched Study Population
Palliative Care Consult
___________________________
No
Yes
Column

Column

Count

N%

Yes

13

8.6%

14

14.3%

Diabetes w

No

87

57.2%

58

59.2%

chronic comp

Yes

65

42.8%

40

40.8%

Diabetes w/o

No

137

90.1%

88

89.8%

chronic comp

Yes

15

9.9%

10

10.2%

Drug abuse

No

145

95.4%

94

95.9%

Yes

7

4.6%

4

4.1%

Drug abuse w

No

152

100.0%

98

100.0%

psychoses

Yes

0

0.0%

0

0.0%

Hypertension,

No

132

86.8%

91

92.9%

complicated

Yes

20

13.2%

7

7.1%

151

99.3%

98

100.0%

Hypertension, w No

Mean Count

N%

renal failure

Yes

1

0.7%

0

0.0%

Hypertension,

No

124

81.6%

88

89.8%

uncomplicated

Yes

28

18.4%

10

10.2%

Liver disease,

No

148

97.4%

92

93.9%

mild

Yes

4

2.6%

6

6.1%

Liver disease,

No

151

99.3%

96

98.0%

mod to severe

Yes

1

0.7%

2

2.0%

Chronic

No

100

65.8%

54

55.1%

pulmonary dz

Yes

52

34.2%

44

44.9%

31

*p31
Mean

Tests are adjusted for all pairwise comparisons within a row of each innermost sub-table
using the Bonferroni correction.
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Table 5 continued
Demographic Characteristics - Total Un-Matched Study Population
Palliative Care Consult
___________________________
No
Yes
Column

Neurological dz No

*p31

Column

Count

N%

Mean Count

N%

151

99.3%

95

96.9%

Mean

affecting mvmt

Yes

1

0.7%

3

3.1%

Other neuro-

No

137

90.1%

85

86.7%

logical disorders Yes

15

9.9%

13

13.3%

Seizures and

No

149

98.0%

96

98.0%

epilepsy

Yes

3

2.0%

2

2.0%

Obesity

No

89

58.6%

56

57.1%

Yes

63

41.4%

42

42.9%

No

151

99.3%

95

96.9%

Yes

1

0.7%

3

3.1%

No

139

91.4%

90

91.8%

vascular disease Yes

13

8.6%

8

8.2%

Psychoses

No

149

98.0%

97

99.0%

Yes

3

2.0%

1

1.0%

Pulmonary

No

140

92.1%*

74

75.5%

.000

circulation dz

Yes

12

7.9%

24

24.5%*

.000

Renal failure,

No

117

77.0%*

64

65.3%

.044

moderate

Yes

35

23.0%

34

34.7%*

.044

Renal failure,

No

135

88.8%

84

85.7%

severe

Yes

17

11.2%

14

14.3%

131

86.2%

75

76.5%

Paralysis
Peripheral

Hypothyroidism No

31

Tests are adjusted for all pairwise comparisons within a row of each innermost sub-table
using the Bonferroni correction.
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Table 5 continued
Demographic Characteristics - Total Un-Matched Study Population
Palliative Care Consult
___________________________
No
Yes
Column

*p31

Column

Count

N%

Yes

21

13.8%

23

23.5%

Other thyroid

No

151

99.3%

98

100.0%

disorders

Yes

1

0.7%

0

0.0%

Peptic ulcer

No

148

97.4%

96

98.0%

with bleeding

Yes

4

2.6%

2

2.0%

121

79.6%*

60

61.2%

.002

Yes

31

20.4%

38

38.8%*

.002

No

146

96.1%*

82

83.7%

.001

Yes

6

3.9%

16

16.3%*

.001

Valvular disease No
Weight loss

Mean Count

N%

Mean

These statistically significant population differences are likely to confound the outcome of
interest; thus, it is important to create cohorts that are matched on their likelihood or propensity
to receive a palliative care consult.
Propensity-Matching. The population cohort was matched on propensity or the
likelihood that two individuals who did and did not receive HFPC consult were otherwise
similarly matched on other markers of acute illness severity (lab values and vital signs),
prevention (HF guideline adherence), demographic characteristics, and comorbidities. A
propensity score was calculated in SPSS version 27 for each case as a regression of all
demographic characteristics thus far described (see Figure 1). SPSS version 27 was used to

31

Tests are adjusted for all pairwise comparisons within a row of each innermost sub-table
using the Bonferroni correction.
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perform a regression of all variables collected, including demographic characteristics of age,
gender, and insurance; prevention characteristics of adherence to evidence-based HF treatment,
including tobacco use, drug therapy, and electrical therapy; index hospitalization severity
markers, including selected laboratory values and vital signs present on arrival, DNR status,
hospitalization duration, advanced interventions required, discharge disposition, and
comorbidities. This regression analysis generated a propensity score that enabled matching of the
HFPC and non-HFPC cohorts. The propensity score was then used as a continuous variable to
match patients in the non-HFPC consult cohort. Multiple non-HFPC consult patients could be
matched to HFPC consult patients with similar characteristics, preserving as much of the data as
possible.
At the extremes of scoring, there were a sizable number of patients (n =102) that could
not be matched to similar peers in the non-HFPC consult cohort because their score was so low
(indicating minimal severity markers) that no HFPC consult was a certainty. Likewise, at the
other end of the spectrum, there was a sizable (n =102) number of patients who could not be
matched to a similar peer in the non-HFPC consult cohort because their score was so high
(indicating numerous severity markers), predicting a certain likelihood of HFPC consult. Thus,
propensity matching helped to achieve a more homogeneous population with less variability,
ensuring a greater likelihood of observing an accurate and valid assessment of the outcome of
interest.
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Figure 1
Propensity Score by HFPC Consult

Demographics - Propensity-Matched Cohort. The resulting matched cohort (n =132) is
more homogeneous, and both HFPC and non-HFPC cohorts are equivalently matched on
demographic characteristics (see Table 4). One hundred and two patients were eliminated as
unmatched, which is a significant loss of data but reflects the extremes of propensity scoring.
Those at the extremes did not exhibit sufficient variability to contribute to a meaningful answer
in the final analysis. (For example, all patients that did not match at the low end of propensity
had no palliative care consult, while all patients that did not match at the high end of propensity
scoring had a palliative care consult. Chi-square testing of the total population demographic
characteristics demonstrated statistically significant differences between the population receiving
HFPC consult and the population not receiving HFPC consult p <.0001 prior to matching and p
=.077 after matching (see Appendix 10). Likewise, after matching, the range of propensity scores
was minimized, and standard deviations were likewise minimized compared to the total
population cohort, creating a more homogeneous population and limiting the ability of extreme
values to affect the mean.
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Table 6
Demographic Characteristics of Propensity-Matched Cohort

Cohort Demographics
Matched 32(132)

Unmatched 33(102)

Palliative Care Consult

Palliative Care Consult

No

Yes

Column

No

Column

Yes

Column

Column

Count

N%

Count

N%

Count

N%

Count

N%

< 55

23

24.0%

7

19.4%

10

21.7%

9

16.1%

55-75

40

41.7%

14

38.9%

25

54.3%

20

35.7%

75+

33

34.4%

15

41.7%

11

23.9%

27

48.2%

Female

46

47.9%

17

47.2%

21

45.7%

36

64.3%

Male

50

52.1%

19

52.8%

25

54.3%

20

35.7%

Do Not

.

95

99.0%

34

94.4%

44

95.7%

46

82.1%

Resuscitate

DNR

1

1.0%

2

5.6%

2

4.3%

10

17.9%

Primary

Commercial

67

69.8%

21

58.3%

29

63.0%

31

55.4%

Insurance

Medicaid

6

13.0%

Age cohort

Gender

Medicare

29

30.2%

15

41.7%

11

23.9%

25

44.6%

Ejection Fraction

.25 Reduced

25

26.0%

10

27.8%

10

21.7%

14

25.0%

cohort

.25-.50 Borderli

35

36.5%

12

33.3%

21

45.7%

16

28.6%

.50+ Preserved

36

37.5%

14

38.9%

15

32.6%

26

46.4%

AICD or CRT-D

No

70

72.9%

25

69.4%

34

73.9%

43

76.8%

Implant

Yes

26

27.1%

11

30.6%

12

26.1%

13

23.2%

Guideline

No

41

42.7%

15

41.7%

18

39.1%

40

71.4%

Adherence

Yes

55

57.3%

21

58.3%

28

60.9%

16

28.6%

Hospitalization

Admission

37

38.5%

14

38.9%

16

34.8%

20

35.7%

duration

Observation

33

34.4%

11

30.6%

21

45.7%

7

12.5%

32

No statistically significant differences
Unmatched demographics reflect those at the extremes of the propensity scoring scale such
that matching was not feasible. As such it is not appropriate to test population statistically
significant differences as they are by definition at opposite extremes.
33
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Table 6 continued
Demographic Characteristics of Propensity-Matched Cohort

Cohort Demographics
Matched 32(132)

Unmatched 33(102)

Palliative Care Consult

Palliative Care Consult

No

Yes

Column

No

Column

Yes

Column

Column

Count

N%

Count

N%

Count

N%

Count

N%

Prolonged

26

27.1%

11

30.6%

9

19.6%

29

51.8%

Discharge

Home – 01

58

60.4%

20

55.6%

35

76.1%

13

23.2%

disposition

Home w

21

21.9%

6

16.7%

6

13.0%

15

26.8%

3

5.4%

7

12.5%

2

3.6%

1

1.8%

Services
Hospice –
Home
Hospice –
Facility
Inpt Rehab

1

1.0%

2

2.1%

Facility
LTC Hospital

1

2.8%

Short Term

1

2.2%

1

1.8%

Inpatient
SNF -Skilled

14

14.6%

9

25.0%

4

8.7%

14

25.0%

59

61.5%

22

61.1%

23

50.0%

35

62.5%

2

3.6%

Nurse
BP

Hypertension
Hypotension

HR.

32

Normal

37

38.5%

14

38.9%

23

50.0%

19

33.9%

Normal

71

74.0%

26

72.2%

30

65.2%

36

64.3%

Bradycardia

2

2.1%

1

2.8%

6

13.0%

2

3.6%

Tachycardia

23

24.0%

9

25.0%

10

21.7%

18

32.1%

No statistically significant differences
Unmatched demographics reflect those at the extremes of the propensity scoring scale such
that matching was not feasible. As such it is not appropriate to test population statistically
significant differences as they are by definition at opposite extremes.
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Table 6 continued
Demographic Characteristics of Propensity-Matched Cohort

Cohort Demographics
Matched 32(132)

Unmatched 33(102)

Palliative Care Consult

Palliative Care Consult

No

Yes

Column

Na

BUN/Cr

No

Column

Yes

Column

Count

N%

Count

N%

Count

Hypernatremia

4

4.2%

1

2.8%

Hyponatremia

13

13.5%

6

16.7%

12

Normal

79

82.3%

29

80.6%

Low

10

10.4%

3

Normal

53

55.2%

Renal

33

N%

Column
Count

N%

2

3.6%

26.1%

9

16.1%

34

73.9%

45

80.4%

8.3%

8

17.4%

4

7.1%

20

55.6%

25

54.3%

33

58.9%

34.4%

13

36.1%

13

28.3%

19

33.9%

14

14.6%

6

16.7%

10

21.7%

6

10.7%

Elevated

25

26.0%

9

25.0%

10

21.7%

28

50.0%

Normal

57

59.4%

21

58.3%

26

56.5%

22

39.3%

Anemia

52

54.2%

21

58.3%

24

52.2%

32

57.1%

Normal

44

45.8%

15

41.7%

22

47.8%

24

42.9%

Normal

12

38.7%

5

50.0%

6

40.0%

13

68.4%

9

29.0%

5

50.0%

7

46.7%

6

31.6%

10

32.3%

2

13.3%

No

94

97.9%

42

91.3%

53

94.6%

Yes

2

2.1%

4

8.7%

3

5.4%

No

96

100%

46

100%

55

98.2%

compromise
Cr

Abnormal –
High

Hgb

Hgb A1C

Poor Control
Very Poor
Control
Pressors required

Intra Aortic

36
36

100%
100%

Balloon Pump
32

No statistically significant differences
Unmatched demographics reflect those at the extremes of the propensity scoring scale such
that matching was not feasible. As such it is not appropriate to test population statistically
significant differences as they are by definition at opposite extremes.
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Table 6 continued
Demographic Characteristics of Propensity-Matched Cohort

Cohort Demographics
Matched 32(132)

Unmatched 33(102)

Palliative Care Consult

Palliative Care Consult

No

Yes

Column
Count

N%

No

Column
Count

N%

Yes

Column
Count

N%

Yes
Tobacco Use

Column
Count

N%

1

1.8%

Cognitive
Deficits
Never

53

55.2%

18

50.0%

25

54.3%

36

64.3%

Last Tobacco

13

13.5%

4

11.1%

9

19.6%

6

10.7%

27

28.1%

13

36.1%

8

17.4%

9

16.1%

2

2.1%

1

2.8%

2

4.3%

3

5.4%

1

1.0%

2

4.3%

2

3.6%

96

100%

46

100%

54

96.4%

2

3.6%

55

98.2%

1

1.8%

Use <30d
Last Tobacco
Use >1yr
Last Tobacco
Use >30d <1yr
Unable to
answer
AIDS

No

36

100%

Yes
No

95

99.0%

Yes

1

1.0%

Alcohol abuse w/

No

96

100%

36

100%

46

100%

56

100%

mild liver disease

Yes

Deficiency

No

72

75.0%

26

72.2%

37

80.4%

37

66.1%

Anemias

Yes

24

25.0%

10

27.8%

9

19.6%

19

33.9%

Alcohol abuse

32

36

100%

46

100%

No statistically significant differences
Unmatched demographics reflect those at the extremes of the propensity scoring scale such
that matching was not feasible. As such it is not appropriate to test population statistically
significant differences as they are by definition at opposite extremes.
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Table 6 continued
Demographic Characteristics of Propensity-Matched Cohort

Cohort Demographics
Matched 32(132)

Unmatched 33(102)

Palliative Care Consult

Palliative Care Consult

No

Yes

Column

No

Column

Yes

Column

Column

Count

N%

Count

N%

Count

N%

Count

N%

No

90

93.8%

35

97.2%

45

97.8%

53

94.6%

Yes

6

6.3%

1

2.8%

1

2.2%

3

5.4%

Chronic blood

No

96

100%

36

100%

45

97.8%

55

98.2%

loss anemia

Yes

1

2.2%

1

1.8%

Leukemia

No

46

100%

55

98.2%

1

1.8%

Arthropathies

96

100%

36

100%

Yes
No

94

97.9%

35

97.2%

46

100%

56

100%

Yes

2

2.1%

1

2.8%

No

95

99.0%

35

97.2%

46

100%

56

100%

Yes

1

1.0%

1

2.8%

Solid tumor w/o

No

96

100%

36

100%

46

100%

56

100%

metastasis, in situ

Yes

Solid tumor w/o

No

95

99.0%

35

97.2%

44

95.7%

55

98.2%

mets, malignant

Yes

1

1.0%

1

2.8%

2

4.3%

1

1.8%

Cerebrovascular

No

disease - POA

94

97.9%

35

97.2%

45

97.8%

54

96.4%

Yes

2

2.1%

1

2.8%

1

2.2%

2

3.6%

Cerebrovascular

No

96

100%

36

100%

46

100%

55

98.2%

disease - seq

Yes

1

1.8%

Cerebrovascular

No

50

89.3%

Lymphoma

Metastatic cancer

95

99.0%

36

100%

46

100%

disease -paralysis

32

No statistically significant differences
Unmatched demographics reflect those at the extremes of the propensity scoring scale such
that matching was not feasible. As such it is not appropriate to test population statistically
significant differences as they are by definition at opposite extremes.
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Table 6 continued
Demographic Characteristics of Propensity-Matched Cohort

Cohort Demographics
Matched 32(132)

Unmatched 33(102)

Palliative Care Consult

Palliative Care Consult

No

Yes

Column

No

Column

N%

N%

Yes

1

1.0%

6

10.7%

Congestive heart

No

9

9.4%

4

11.1%

5

failure

10.9%

3

5.4%

Yes

87

90.6%

32

88.9%

41

89.1%

53

94.6%

CHF with

No

21

21.9%

6

16.7%

16

34.8%

8

14.3%

hypertension,

Yes

75

78.1%

30

83.3%

30

65.2%

48

85.7%

CHF with

No

91

hypertension w

94.8%

34

94.4%

45

97.8%

54

96.4%

Yes

5

5.2%

2

5.6%

1

2.2%

2

3.6%

No

90

93.8%

35

97.2%

44

95.7%

42

75.0%

Yes

6

6.3%

1

2.8%

2

4.3%

14

25.0%

No

89

92.7%

32

88.9%

43

93.5%

51

91.1%

Yes

7

7.3%

4

11.1%

3

6.5%

5

8.9%

No

87

90.6%

32

88.9%

42

91.3%

49

87.5%

Yes

9

9.4%

4

11.1%

4

8.7%

7

12.5%

Diabetes with

No

55

57.3%

22

61.1%

24

52.2%

33

58.9%

chronic comp

Yes

41

42.7%

14

38.9%

22

47.8%

23

41.1%

Diabetes w/o

No

83

86.5%

31

86.1%

46

100%

51

91.1%

chronic comp

Yes

13

13.5%

5

13.9%

5

8.9%

Drug abuse

No

91

94.8%

34

94.4%

54

96.4%

Coagulopathy

Dementia

Depression

32

Count

45

N%

Column
Count

renal failure, sev

N%

Column

Count

complicated

Count

Yes

97.8%

No statistically significant differences
Unmatched demographics reflect those at the extremes of the propensity scoring scale such
that matching was not feasible. As such it is not appropriate to test population statistically
significant differences as they are by definition at opposite extremes.
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Table 6 continued
Demographic Characteristics of Propensity-Matched Cohort

Cohort Demographics
Matched 32(132)

Unmatched 33(102)

Palliative Care Consult

Palliative Care Consult

No

Yes

Column

No

Column

Yes

Column

Column

Count

N%

Count

N%

Count

N%

Count

N%

Yes

5

5.2%

2

5.6%

1

2.2%

2

3.6%

Drug abuse with

No

96

100%

36

100%

46

100%

56

100%

psychoses

Yes

Hypertension,

No

85

88.5%

33

91.7%

38

82.6%

53

94.6%

complicated

Yes

11

11.5%

3

8.3%

8

17.4%

3

5.4%

Hypertension, w/

No

96

100%

36

100%

45

97.8%

56

100%

renal failure, sev

Yes

1

2.2%

Hypertension,

No

78

81.3%

31

86.1%

39

84.8%

51

91.1%

uncomplicated

Yes

18

18.8%

5

13.9%

7

15.2%

5

8.9%

Liver disease,

No

95

99.0%

36

100%

44

95.7%

50

89.3%

mild

Yes

1

1.0%

2

4.3%

6

10.7%

Liver disease,

No

95

99.0%

46

100%

54

96.4%

mod to sev

Yes

1

1.0%

2

3.6%

Chronic

No

59

61.5%

22

61.1%

34

73.9%

29

51.8%

pulmonary dz

Yes

37

38.5%

14

38.9%

12

26.1%

27

48.2%

Neurological dz

No

95

99.0%

35

97.2%

46

100%

54

96.4%

affecting mvmt

Yes

1

1.0%

1

2.8%

2

3.6%

Other neuro-

No

85

88.5%

32

88.9%

44

95.7%

47

83.9%

logical disorders

Yes

11

11.5%

4

11.1%

2

4.3%

9

16.1%

32

36

100%

No statistically significant differences
Unmatched demographics reflect those at the extremes of the propensity scoring scale such
that matching was not feasible. As such it is not appropriate to test population statistically
significant differences as they are by definition at opposite extremes.
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Table 6 continued
Demographic Characteristics of Propensity-Matched Cohort

Cohort Demographics
Matched 32(132)

Unmatched 33(102)

Palliative Care Consult

Palliative Care Consult

No

Yes

Column

No

Column

Yes

Column

Column

Count

N%

Count

N%

Count

N%

Count

N%

56

100%

Seizures and

No

94

97.9%

34

94.4%

45

97.8%

epilepsy

Yes

2

2.1%

2

5.6%

1

2.2%

Obesity

No

53

55.2%

19

52.8%

28

60.9%

34

60.7%

Yes

43

44.8%

17

47.2%

18

39.1%

22

39.3%

No

95

99.0%

35

97.2%

46

100%

54

96.4%

Yes

1

1.0%

1

2.8%

2

3.6%

Peripheral

No

87

90.6%

33

91.7%

43

93.5%

52

92.9%

vascular disease

Yes

9

9.4%

3

8.3%

3

6.5%

4

7.1%

Psychoses

No

94

97.9%

35

97.2%

45

97.8%

56

100%

Yes

2

2.1%

1

2.8%

1

2.2%

Pulmonary

No

84

87.5%

33

91.7%

46

100%

36

64.3%

circulation dz

Yes

12

12.5%

3

8.3%

20

35.7%

Renal failure,

No

73

76.0%

25

69.4%

35

76.1%

35

62.5%

moderate

Yes

23

24.0%

11

30.6%

11

23.9%

21

37.5%

Renal failure,

No

86

89.6%

32

88.9%

42

91.3%

49

87.5%

severe

Yes

10

10.4%

4

11.1%

4

8.7%

7

12.5%

Hypothyroidism

No

83

86.5%

32

88.9%

39

84.8%

39

69.6%

Yes

13

13.5%

4

11.1%

7

15.2%

17

30.4%

Paralysis

32

No statistically significant differences
Unmatched demographics reflect those at the extremes of the propensity scoring scale such
that matching was not feasible. As such it is not appropriate to test population statistically
significant differences as they are by definition at opposite extremes.
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Table 6 continued
Demographic Characteristics of Propensity-Matched Cohort

Cohort Demographics
Matched 32(132)

Unmatched 33(102)

Palliative Care Consult

Palliative Care Consult

No

Yes

Column

No

Column

Yes

Column

Column

Count

N%

Count

N%

Count

N%

Count

N%

96

100%

36

100%

45

97.8%

56

100%

1

2.2%

46

100%

55

98.2%

1

1.8%

Other thyroid

No

disorders

Yes

Peptic ulcer with

No

92

95.8%

35

97.2%

bleeding

Yes

4

4.2%

1

2.8%

Valvular disease

No

72

75.0%

25

69.4%

41

89.1%

31

55.4%

Yes

24

25.0%

11

30.6%

5

10.9%

25

44.6%

No

91

94.8%

34

94.4%

45

97.8%

43

76.8%

Yes

5

5.2%

2

5.6%

1

2.2%

13

23.2%

Weight loss

Table 6 demonstrates that the resulting propensity-matched cohorts exhibit strong
demographic similarities, and no statistically significant differences remain. The residual
unmatched cohort included those that did not match into the propensity-matched cohort and
illustrate characteristics of the outliers that were redacted during the process of propensitymatching from the final propensity-matched cohort used in the final analysis. Importantly,
ANOVA analysis of the total population and matched cohorts showed that even after matching,

32

No statistically significant differences
Unmatched demographics reflect those at the extremes of the propensity scoring scale such
that matching was not feasible. As such it is not appropriate to test population statistically
significant differences as they are by definition at opposite extremes.
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statistically significant differences in the mean remain between the HFPC consult x =.25, 95% CI
[.21 - 29] and non-HFPC consult x =.42, 95% CI [.35-.49] cohorts (see Table 7).
Further analysis continued based on these findings. If the ANOVA had demonstrated a
loss of statistical significance after matching, it would have been interpreted that matching
eliminated all sources of difference, and further analysis would have been futile. Likewise,
calculation of standardized differences (effect size) of the means before and after matching found
a persistently strong effect size of Cohen’s d =0.86 in the unadjusted model and Cohen’s d =0.83
in the propensity-matched model, indicating that there is no substantial loss of predictive ability
after matching.
Table 7
Comparison of Means and Standardized Difference of Total Study Population vs. Propensitymatched Cohort for Presence/Absence of HFPC Consult
Palliative Care Consult – No

Palliative Care Consult - Yes

__________________________________________________
Propensity
Mean 95%
95%
SD
Mean 95%
95%
SD
score
UCL
LCL
UCL
LCL
Total
.16965 .13712 .20218 .19608 .73815 .67685 .79945 .29600
population
cohort
Matched
.24879 .20879 .28759 .19444 .41754 .34612 .48896 .21107
cohort

Cohen’s
d

0.86

0.83

Odds Ratios Predictive of HFPC
While logistic regression was used to answer the primary research question of interest,
whether 90-day hospital readmission is affected by HFPC consult after controlling for mortality
and severity, it was also part of the a priori analysis plan to further evaluate the important
contributing factors to the occurrence of an HFPC consult to gain insight into why a specific
outcome was observed. For example, if patients who received HFPC consult were appropriately
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targeted. Logistic regression of the total population characteristics produced calculated odds or
risk of each individual characteristic to contribute to the overall likelihood of a patient having an
HFPC consult (see Table 8). Odds ratio is a measure of association that provides an indication of
the effect size existing between the predicting factor and the outcome of interest.
Table 8
Odds Ratios Predicting the Likelihood of HFPC Consult

Demographic Categories

Characteristics

Age cohort

<55

Odds Ratio

55-75

.180*

75+

.402

Gender

Gender (Female)

2.943

Do Not Resuscitate

Do Not Resuscitate

2.574

Primary insurance

Commercial

Ejection Fraction cohort

Medicaid

.000

Medicare

3.670*

50%+ Preserved
25% Reduced

3.035

25-50% Borderline

.995

AICD/CRT-D

AICD or CRT-D Implant (Yes)

3.127

Guideline Adherence

Guideline Adherence (No)

2.475

Hospitalization duration

Admission

Discharge disposition

Observation

1.004

Prolonged

.611

Home
Home w/ Home Health
Hospice
Inpatient Rehabilitation Facility
Long Term Care

5.342*
4877036073.909
115.070
2.635
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Table 8 continued
Odds Ratios Predicting the Likelihood of HFPC Consult

Demographic Categories

Blood Pressure on arrival

HR on arrival

Na on arrival

BUN/Cr on arrival

Cr on arrival

Characteristics

Odds Ratio

Short Term Gen Hospital

.000

Skilled Nursing Facility

13.418*

Normal
Hypertensive

3.672*

Hypotensive

74028849642.421

Normal
Bradycardic

.043

Tachycardic

3.569

Normal
Hypernatremic

2.635

Hyponatremic

.358

Low
Normal

3.639

Renal compromise

2.449

Normal
Abnormal

.733

Elevated

7.509*

Hgb on arrival

Anemia

.550

Pressors required

Pressors required (Yes)

.506

IntraAortic Balloon Pump

Intra Aortic Balloon Pump (Yes)

Tobacco Use

Denies

Comorbidities coded

506772158989469180

Tobacco use < 30 d

.158

Tobacco use > 1 yr

.966

Tobacco Use >30d <1yr

.148

Unable to answer

.018

AIDS
Alcohol abuse

376707060855.6
7.5
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Table 8 continued
Odds Ratios Predicting the Likelihood of HFPC Consult

Demographic Categories

Characteristics
Deficiency Anemias
Arthropathies
Chronic blood loss anemia
Leukemia
Lymphoma
Metastatic cancer

Odds Ratio
1.7
.027*
6.9
12130545869000848.0
.028
806628941303.5

Solid tumor w/o mets, malignant

.000

Cerebrovascular disease - POA

9.6

Cerebrovascular dz - sequelae

487343389861.8

Cerebrovascular dz - paralysis

10.4

Congestive heart failure

.047*

CHF with HTN, complicated

4.4

CHF with HTN w renal failure

66.8*

Coagulopathy

7.7

Dementia

.6

Depression

1.1

Diabetes w/ chronic complications

.3

Diabetes w/o chronic complications

19.0*

Drug abuse

3.1

Hypertension, complicated

.2

Hypertension, comp with renal

.000

failure, severe
Hypertension, uncomplicated

.4

Liver disease, mild

9.3

Liver disease, moderate to severe

.2

Chronic pulmonary disease

10.6*
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Table 8 continued
Odds Ratios Predicting the Likelihood of HFPC Consult

Demographic Categories

Characteristics
Neurological disorders affecting

Odds Ratio
.3

movement
Other neurological disorders

.6

Seizures and epilepsy

8.2

Obesity

2.8

Paralysis

16.8

Peripheral vascular disease

.75

Psychoses

.91

Pulmonary circulation disease

8.9

Renal failure, moderate

1.9

Renal failure, severe

1.8

Hypothyroidism

1.0

Other thyroid disorders

.22

Peptic ulcer with bleeding

.2

Valvular disease

4.2*

Weight loss

6.8

Note. Statistically significant factors p <.05 are signified by *
*p <.05
This sub-analysis demonstrates the underlying factors that are statistically significantly
associated with HFPC consult, a key independent variable in the primary research question of
interest, whether 90-day hospital readmission is affected by HFPC consult after controlling for
90-day mortality and severity (propensity score). This sub-analysis provides context and clarity
for interpreting the meaning of the primary study findings. From the primary analysis, it was
shown that HFPC consultation is negatively associated with hospital readmission after
controlling for mortality and severity. This sub-analysis likewise provides a contextual
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understanding of the individual characteristics that are likely to produce an HFPC consult during
an inpatient hospitalization. It includes age 55-75, Medicare insurance, discharge with home
health services and discharge to SNF, hypertensive on admission, and elevated Cr on admission.
Comorbidities likely to result in an HFPC consult include arthropathies, HF, HF with renal
failure, Diabetes without chronic complications, COPD, and valvular disease.
Survival Analysis
A further a priori planned sub-analysis that also provided additional context and clarity to
the primary study findings is an analysis of time to hospital readmission which was used in the
primary analysis as a binary outcome of 90-day hospital readmission (Y/N). However, hospital
readmission can also be viewed as a continuous variable. The a priori plan to include survival
analysis in the data analysis was to take full advantage of the data available on the temporal
patterns of readmission that occur within the 90-day window of hospital readmission. Among the
total unmatched population, the average time to hospital readmission for patients with no HFPC
consult was 5.6 weeks, and 3.6 weeks for patients with an HFPC consult (see Table 9). This
finding further describes the results in the preliminary logistic regression that noted the negative
association between HFPC and no hospital readmission; as HFPC events increased, hospital
readmission events were more frequent.
Table 9
Mean Time to Readmission, Weeks
Palliative Care

Std.

Consult

Mean

N

Deviation

No

5.626

53

3.1240

Yes

3.588

60

2.8264

Total

4.544

113

3.1278
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Hospital-related admissions were those that occurred within seven days of hospital
discharge and were directly related to the hospitalization (Chin et al., 2016). HFPC-related
admissions were those that occurred from 8-30 days post index hospitalization and account for
more predominantly HFPC-related factors of patient management (Chin et al., 2016). While the
majority of patients with no HFPC consult did not require readmission, a more flattened
distribution of patients who received an HFPC consult experienced a readmission within the 90day observation period, perhaps indicating a more significant level of morbidity and
complications requiring hospital readmission than the no HFPC consult cohort (see Figure 2).
Figure 2
Time to Hospital Readmission Stratified by Presence/Absence of HFPC Consult

Likewise, a graphical depiction of the time to readmission (see Figure 3), stratified by HFPC
consult for the entire study population, illustrates a strong tendency for earlier hospital
readmission if the patient had an HFPC consult compared to the cohort that did not have an
HFPC consult.
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Figure 3
Distribution of Time to Readmission by HFPC Consult

Patterns of hospital readmission stratified by cohorts that had an HFPC consult/no HFPC
consult added additional clarity and context to the primary research question of interest that
found a strong statistically significant relationship between 90-day hospital readmission and
HFPC consult. Time to readmission happened more frequently in patients who have an HFPC
consult. Readmissions occurred earlier in the post-discharge period and were strongly skewed to
the immediate 30-day post-discharge period.
Kaplan-Meier Survival Curve of Time to Readmission
To gain further insight into the patterns of hospital readmission, survival analysis was
chosen for this sub-analysis because it enables statistical analysis of time to event data, in this
case, time to hospital readmission, stratified by cohorts, presence/absence of HFPC consult. The
primary research question of interest demonstrated that HFPC consult was statistically
significantly associated with 90-day hospital readmission after controlling for 90-day mortality
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and severity (propensity-score). Survival analysis provides additional insight into the differential
burden of hospital readmission borne by the cohorts and illustrates the difficulties this population
experiences with avoiding 90-day hospital readmission. A survival curve of time to readmission
by HFPC consult was constructed for the entire study population (see Figure 4) and found
statistically significant differences in the time to hospital readmission for the cohorts with Log
Rank (Mantel-Cox) tests significant at <.0001, and Breslow (Generalized Wilcoxon) tests
significant at <.0001.
Figure 4
Kaplan-Meier Survival Curve of Time to Readmission by HFPC Consult

In the second survival curve analysis, results were even more profound with the
population restricted to the propensity-matched cohorts used in the primary logistic regression
analysis of the primary research question of interest. Comparing presence/absence of HFPC
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consult, the difference in the two curves was even greater and remained statistically significant
by Log Rank (Mantel-Cox) tests significant at <.0001 and Breslow (Generalized Wilcoxon) tests
significant at <.0001 (see Figure 5).
Figure 5
Kaplan-Meier Survival Curve of Time to Readmission Restricted to Propensity-matched HF
Discharges

This survival analysis demonstrated that <30% of HF patients who have an HFPC consult
are unable to avoid hospital readmission for >90 days. Over 50% of HF patients who have an
HFPC consult experience a hospital readmission within 30 days of discharge. Over 75% of HF
patients who have an HFPC consult will have a hospital readmission within 90 days of discharge.
Among patients who do not have an HFPC consult, >60% of patients will not require a hospital
readmission within the first 90 days post-discharge.
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Findings
The data analysis of this investigation yielded a breadth of findings. Compilation of the
final dataset identified an average of 83 patients per month with a primary diagnosis of HF. Data
abstraction was facilitated by a robust data architecture that enabled an automated abstraction of
a broad array of data variables. The need to re-sort, re-order and transform data variables from
multiple raw data files to integrate them into a single dataset remains. For example, laboratory
values are output listwise. For example, there is a ‘case’ for every lab value that requires reordering such that all values appear as an individual variable for each case. Likewise, all coded
comorbidities are output listwise and require selection of the comorbidities of interest before the
data can be re-ordered and incorporated into the final dataset.
Lastly, while evidence has previously suggested that the most valid and reliable method
to abstract HFPC consultations was found to be an abstraction of the coded PC consult, it is
important to note that this coded or ‘billed’ visit may not appear in an individual hospital
database if that hospital does not directly bill for the service. Dependent on state regulations,
third-party billing may allow the physician to bill the patient/insurance directly; thus, those codes
do not appear on an abstraction of hospital administrative data. Also, the ease with which highly
customizable data can be abstracted within the existing data architecture is dependent on whether
a field is standardized and abstractable.
In this investigation, zero-coded PC visits were abstracted. Abstraction of consults was
likewise unfeasible because of the absence of standardized data abstraction fields. Within this
data architecture, there were no standardized naming conventions for consults; thus, this
individualization of the consult name meant that the HFPC consult events were not abstractable.
This finding is important as an insight for future investigations to be aware of the subtleties of
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individual hospital data architecture systems that may limit access to the occurrence of the event
and underestimate the event occurrence. It is further offered as a caution to investigations that
primarily rely on administrative coding data to assess the efficacy of HFPC consult interventions.
Transformation of data once incorporated into the final dataset was necessary to enable
clinically meaningful and interpretable data. While continuous data was available for laboratory
and vital sign data, the meaning or clinical applicability of a single unit change in blood pressure
was less important than the meaning and clinical applicability of a comparison of strata of blood
pressure measurements. Comparison of hypertensive or hypotensive values to normal values was
much more clinically meaningful and applicable than comparison of a systolic blood pressure
value that varied from 99 to 100. Likewise, directionality may be a clinically important element
but may not be appropriate for a parameter that exhibits reverse or bi-directionality. For example,
Cr could be evaluated with a continuous measure as a low creatinine is ‘bad,’ and a high Cr is
‘bad.’ Conversely, with BP, low and high values are ‘bad,’ while middle values are ‘normal.
Similarly, EF percentages, with high values are ‘good,’ and low values are ‘bad.’ This insight is
offered as an important finding and caution that it is important not only to use the data that is
available (continuous) and statistically valid but to maintain awareness that transformation or
stratification may be preferred to ensure those resulting findings are clinically meaningful.
The CONSORT study summary format is a helpful tool to summarize important elements
of a study investigation to convey important elements of the study construct. The construct is
helpful to the reader and reviewers to understand the critical elements of the investigation.
Logistic regression to evaluate the primary research question of interest, whether there was a
statistically significant association between the dependent variable of 90-day hospital
readmission and the independent variables of 90-day mortality, HFPC consult and propensity
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score (severity). In this model, no HFPC-consult was statistically significantly associated with no
90-day hospital readmission, B =1.468, p <.001, OR 4.3, 95% CI [1.8-10.6]. Likewise, increased
mortality was associated with no 90-day hospital readmission, although it was not statistically
significant, B =.482, p =.36 (OR 1.8). Decreased severity was also associated with no 90-day
hospital readmission B =-0.631, p =.504 (OR 1.6), but was not statistically significant (see Table
3).
These results reveal that avoidance of 90-day hospital readmission is best achieved by
having no criteria for the performance of an HFPC-consult, experiencing a mortality event, or
having fewer comorbidities. All of these elements: (1) having no criteria for the performance of
an HFPC-consult, (2) experiencing a mortality event, or (3) having fewer comorbidities are all
largely out of the control of any individual patient. Thus, while HFPC may be an important
aspect of continuity of care and care planning for the HF patient, it is not a valid or effective
method for reducing 90-day hospital readmissions. Patients with an acute decompensation of
their HF, evidenced by abnormal key lab indicators on arrival or patients with numerous
comorbidities or approaching end-of-life, are more likely to be referred for HFPC consult. In this
investigation, HFPC consult was predicted by and served as a proxy for the HF patient who has
an acute decompensation with abnormal lab values on admission, with numerous comorbidities,
or approaching end-of-life. HFPC consultation has many values in the care and management of
the HF patient. However, reducing 90-day hospital readmission is not an achievable goal.
Conversely, HFPC consult should serve as a proxy signal to expect the increased frequency of
admissions in a population with high morbidity approaching end-of-life.
To evaluate the robustness of the model, the non-propensity matched model was analyzed
and demonstrated similar statistically significant associations between no 90-day hospital
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readmission and no HFPC consult B =1.442, p <.001 (OR 4.2; see Table 4). Likewise, no 90-day
hospital readmission was associated with a non-statistically significant .611, p =.115 increase in
post-discharge mortality (OR 1.8) after controlling for HFPC consultation and severity. Lastly,
90-day hospital readmission was associated with a non-statistically significant .0.46 increase in
severity (propensity score; OR 1.6) after controlling for mortality and HFPC consult. It is
congruent that avoidance of 90-day hospital readmission would be associated with no HFPC
consult (less sick) and increased mortality (patients died); however, it is incongruent that
increased severity would be associated with no 90-day readmission and perhaps reflect the
influence of the inclusion of outliers redacted in the propensity-matched model.
An important aspect of any statistical analysis is an assessment of underlying
demographic differences that may exist and potentially confound the results of the planned
analysis. The demographic characteristics of the total study population, n =234, after exclusion
of ineligible subjects, clearly illustrated important and statistically significant differences in the
study cohort that received an HFPC consult compared to the cohort that did not (see Table 5).
There were statistically significant differences in age, DNR status, primary insurance, secondary
insurance, adherence to evidence-based guidelines for the treatment of HF, specifically
ACE/ARB use, duration of hospitalization, discharge disposition, 90-day readmission, mortality,
and renal compromise on admission. There were further statistically significant differences in
comorbidities, including deficiency anemias, paralysis as a sequela to cerebrovascular disease,
pulmonary circulation disease, renal failure, valvular heart disease, and weight loss.
Propensity-matching was planned during the initial study plan to ensure comparable
study cohorts of individuals who did and did not have an HFPC consult. Propensity-matching
calculates a score that is derived from a linear regression of characteristics found in the original
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demographic characteristics list. When incorporated in the final analysis, the propensity score
ensures that comparisons are made between subjects who are a best match on all characteristics
with the exception of the outcome of interest, HFPC consultation. Thus, the investigator can be
assured that a comparison is being made between homogeneous populations and not being
influenced by outliers.
The resulting propensity-matched cohort, n =132, demonstrated improved homogeneity
with the absence of statistical significance for any individual characteristic (see Table 6).
However, while propensity-matching achieved population homogeneity, it did not eradicate
statistically significant differences between the HFPC consult and non-HFPC consult cohort with
a mean propensity score of 0.25, 95% CI [0.21-0.29] in the no HFPC consult cohort, and the
HFPC consult cohort demonstrating a mean of 0.42, 95% CI [0.35 - 0.49] (see Table 7).
Likewise, a comparison of the standardized difference in the un-propensity matched cohort and
propensity-matched cohort with Cohen’s d indicates a persistently strong effect size in both
models, suggesting that there is no loss of the predictive ability of the model after matching (see
Table 7). Cohen’s d measures the magnitude of the relationship between the variable measured
(propensity score) and the outcome of interest (HFPC consult).
To further investigate the relationship between HFPC consult and hospital readmission as
part of the a priori analysis plan, a logistic regression of the model variables was performed to
obtain the associated OR or risk of individual demographic characteristics to contribute to the
occurrence of a palliative care consult (see Table 8). Statistically significant and clinically
important associations were found with these characteristics: recipient having Medicare
insurance (OR 3.7), discharge home with home health (OR 5.3), discharge to skilled nursing
facility (OR 13.4), hypertensive on arrival (OR 3.7), elevated Cr on arrival (7.5), CHF with
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hypertension w/severe renal failure (OR 66.8), diabetes without chronic complications (OR
19.0), chronic pulmonary disease (OR 10.6) and valvular disease (OR 4.2). Statistically
significant but clinically meaningless associations were found with the age cohort 55-75
(OR.18); comorbidities of arthropathies (OR .03) and CHF (OR .05) were likely attributable to
collinearity as by definition, all members of the cohort had a primary discharge diagnosis of HF.
To further evaluate the relationship between HFPC consult and hospital readmission,
means were calculated. For the entire cohort that experienced a hospital readmission n =113, the
mean time to hospital readmission for patients who had no HFPC consult was 5.6 weeks, while
the mean for patients who had an HFPC consult was 3.6 weeks (see Table 9). The pattern of
hospital readmissions is likewise significantly different. Patients with an HFPC consult
demonstrated earlier hospital readmission, with 88% of subjects realizing a hospital readmission
within the first 30 days, compared to just 36% of patients with no HFPC consult. Forty percent
of patients in the HFPC consult group had no 90-day readmission, while 75% of patients in the
no-HFPC consult cohort had no 90-day hospital readmission (see Figure 4). Figure 5
demonstrates the almost flat curve of readmissions amongst patients with no HFPC consult while
the patients with an HFPC consult spiked very early in the first 30-days post-discharge and then
tapered to a minimum. Patients with HF targeted for HFPC consult were more likely to
experience not only more frequent hospital readmissions but also earlier times to readmission in
the post-discharge period, the majority within the first 30 days.
This investigation has fully established that there is a statistically significant difference in
90-day hospital readmission between the cohort of subjects with an HFPC consult versus those
with no HFPC consult; thus, it is important to fully appreciate the granularity present within the
dataset. Not only is it important to have established the core difference in 90-day hospital
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readmissions, but the differential trend in hospital readmission is further appreciated with a
survival analysis of time to readmission. The survival analysis of the total study population
identified a statistically significant difference between subjects with and without HFPC consult
(see Figure 4). The propensity-matched survival analysis identified an even greater magnitude of
difference in the curves (see Figure 5). Both analyses were strongly statistically significant by
Log Rank (Mantel-Cox) <.0001 and Breslow (Generalized Wilcoxon) <.0001.
An overview of the entire study population demonstrated that <30% of HF patients who
have an HFPC consult are unable to avoid hospital readmission for >90 days, >50% of HF
patients who have an HFPC consult experienced a hospital readmission within 30 days of
discharge, and > 75% of HF patients who have an HFPC consult will have a hospital readmission
within 90 days of discharge. This survival analysis conveyed the real disparity in the experience
of patients with respect to hospital readmission for subjects with an HFPC consult compared to
those with no HFPC consult.
HF patients receiving appropriately targeted HFPC consultation experience earlier and
more frequent hospital readmissions, higher mortality, and suffer greater severity of their illness.
It is counterproductive to attempt to advocate HFPC to achieve reductions in 90-day hospital
readmissions. If anything, this study has established that once appropriately targeted HF patients
have been referred to HFPC, plans should be implemented to accommodate an expected
increased frequency of hospital readmissions and decreased time to readmission with
accompanying increased mortality.
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Chapter 5: Discussion
Introduction
This section discusses the findings of the study, whether the study has met its specified
objectives, the findings in relation to the existing literature, and the strengths, weaknesses, and
limitations of this investigation. The implications section discusses the impact of this
investigation, contributions to knowledge and professional practice, and the future implications
of this research with recommendations for further/future research. Lastly, the chapter provides a
discussion of limitations and delimitations.
Outcomes of the logistic regression of the propensity-matched model showed that for
every unit reduction in 90-day hospital readmission, there was a statistically significant 1.468
increase in no HFPC consult (reduction in HFPC consult), p =.001. Propensity-matching ensures
that comparisons are made between subjects who are a best match on all characteristics with the
exception of the outcome of interest. The resulting propensity-matched cohort, n =132,
demonstrated improved homogeneity with the absence of statistical significance for any
individual characteristic. To further evaluate the relationship between HFPC consult and hospital
readmission, means were calculated. For the entire cohort that experienced a hospital
readmission n =113, the mean time to hospital readmission for patients who had no HFPC
consult was 5.6 weeks, while the mean for patients who had an HFPC consult was 3.6 weeks.
Survival analysis of the unmatched population identified statistically significant differences
between subjects with and without HFPC consult, p <.001. The propensity-matched survival
analysis identified an even greater magnitude of difference in the curves, p < .001. Less than
30% of HF patients who have an HFPC consult will avoid hospital readmission for over 90 days,
>50% of HF patients who have an HFPC consult will have a hospital readmission within 30 days
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of discharge, and > 75% of HF patients who have an HFPC consult will have a hospital
readmission within 90 days of discharge.
Discussion
The investigation set out to evaluate the association of palliative care consultation in the
hospital setting with hospital readmissions at 90 days post-discharge with statistical controls for
mortality and severity through propensity-matching. Numerous guidelines on ensuring
excellence in HF management have established recommendations that palliative care should be a
part of the multidisciplinary health care team managing patients with HF. Numerous studies have
explored the relationship between palliative care and 30-day hospital readmission to provide
support for these recommendations. Some of the studies found that HFPC consult decreased the
risk of hospital readmission; others found only an equivocal association, while others found a
negative association. Most of these studies were retrospective and relied on administrative
datasets to quantify their results. These studies did not assess the relationship of palliative care
with 90-day hospital readmission with adequate controls for mortality and severity.
Studies that have assessed mortality associated with palliative have done so primarily
with comparisons of pre- and post- HRRP implementation population-based metrics or
comparison to severity-adjusted populations. This investigation aimed to not simply compare
whether mortality rates are the same in HFPC versus non-HFPC consult groups but to control for
mortality and assess the ability of HFPC consult to decrease hospital 90-day readmissions in a
defined hospital population that has actively promoted the adoption of HFPC consults in its HF
population. The findings of this investigation indicate that in a propensity-matched population,
adjusting for mortality, HFPC consultation is positively associated with 90-day hospital
readmission. In other words, patients who received an HFPC consult were statistically
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significantly more likely to have a readmission within 90 days compared to the propensitymatched cohort that did not have an HFPC consult. As such, an HFPC consult may not be causal
for the increased prevalence of 90-day hospital readmissions, as it more than likely reflects a
level of morbidity that cannot be quantified by even the most exhaustive measurement of
covariates. This investigation included an exhaustive list of covariates, and if the relationship
between HFPC consult and 90-day hospital readmission were weak, it would have been
eradicated by ‘overmatching.’ However, this did not occur. Rather, the relationship between
HFPC consult and 90-day hospital readmission remained strong and highly statistically
significant.
An alternative explanation is that care providers in this institution are highly attuned to
the intangible aspects of patient management that predict which individuals are likely to be high
utilizers of health system resources and thus selected for an HFPC consult. Thus, selection bias
may exist at the provider level, embedded within the individualized care management planning
for patients. These study findings may suggest that such high utilizers are being given all the
resources that the health system has at its disposal to attempt to meet the patient’s needs. Such an
aim is intuitively a value-added intervention for the patient. As such, these findings should not
suggest that HFPC has no value, but the findings are clear that as a method to decrease 90-day
hospital readmission, HFPC consultation is not a valid approach.
The hypothesis of this investigation was that the increased level of resources, education,
facilitated decision-making, and future health planning would enable the patient to better
understand their symptoms and improve health behaviors through a better understanding of the
health system and enable them to seek health care services in less hospital-oriented settings,
ultimately decreasing hospital readmissions. While previous studies, primarily based in other
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countries with a greater population-focused system of health care, have demonstrated decreased
hospital readmissions, at best, equivocal findings in reducing hospital readmission have been
found in the United States. This study highlighted those equivocal findings that typically did not
incorporate controls for severity or mortality—there, in truth, is no association between HFPC
consult and 90-day hospital readmission. Due to the nature of the health care system and its
focus on acute care, it may be a plausible alternative that the hospital environment is the best
location of care for patients with end-stage HF who suffer from a significant level of morbidity,
acute decompensation, and limited expertise and find it difficult to access their primary care or
any other alternative care setting in a timely way.
Implications
The implications for this study include that it has identified a significant finding that
improves upon other authors who have found negligible or no association between HFPC consult
and HF readmissions. It also is the first study that provided individual follow-up of a
retrospectively defined cohort (index HF hospitalization Oct 1 - Dec 31, 2019) and prospectively
followed the cohort to observe their experience with HFPC consult, subsequent mortality events,
and 90-day hospital readmission. This study has evaluated this question with substantial
methodological rigor and would likely withstand the criticism of peer review. Limitations to the
success of peer review would be that this study was conducted at a single site with availability
and support for palliative care referrals. Not all hospital systems have similar levels of support or
availability of palliative care practitioners, compromising generalizability. However, if such
findings are reproducible in other settings with the availability and similar support for palliative
care referral, it would be important that the dissemination of palliative care programs not be
based on the flawed premise that installation of such a program will help in the objective to
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decrease hospital 30-day readmissions as advocated by the HRRP. It further supports other
researchers who have questioned the objectives of the HRRP that call for palliative care referral
as a mechanism to decrease hospital 30-day readmissions. HFPC may support other important
aspects of patient care but reducing hospital readmission is not an objective that can be achieved
with HFPC consult.
It is important that hospital resources be utilized in the most useful and efficient ways. If
HFPC resources are tasked with providing an HFPC consult to every patient with end-stage heart
failure, with the primary intention that such referral will minimize hospital readmissions, it is a
clear misuse of HFPC resources. HFPC may provide other necessary supports for decisionmaking and future health planning, which are important aspects of patient management.
However, if the primary aim is to reduce hospital 30-day readmission, HFPC resources are being
misspent.
The best outcome arising out of the implications of this study would be the refocusing
and reallocation of HFPC resources to meet realizable goals and provide meaningful support for
decision-making and future health planning. This may constitute the same population of HF
patients with high morbidity, poor health knowledge, and limited social resources, but the
objectives would be more closely aligned with quality-of-life issues rather than a hospital
operations focus to reduce hospital readmissions, given the current state of the health care system
that often focuses on operational efficiency imperatives that are measurable and have a direct
contribution to the financial bottom line versus quality-of-life imperatives that are very difficult
to measure and do not directly contribute to a financial bottom line.
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Recommendations
Recommendations for future research include testing the reproducibility of this research
at a similar site that supports referral of end-stage HF patients for an HFPC consult and has the
availability of HFPC resources to provide consistent and timely access to those resources. It is
known that there is broad variation in the level of PC services available at health systems across
the country. A cross-sectional study to determine what services are provided in a PC consult
should be conducted to standardize definitions for the level of service.
Likewise, it is important that the PC professional community define what the target
population should be, what the objectives for treatment should be, and what the measurable
outcomes should be. This standardization is necessary to ensure consistent dissemination of PC
interventions that are identified in future research. As an observational study, this study could not
establish causation. A randomized clinical trial would be more likely to provide further insight
into the level of HFPC services that may exert a threshold effect and exert an influence on
hospital readmissions. A cost-effectiveness study would be a value-add to health systems to
explore whether it is more cost-effective to utilize HFPC resources to reduce hospital
readmissions that continue to occur versus creating an alternative care setting that more directly
meets the needs of the end-stage HF patient that may include HFPC but also provide access to
the acute care interventions required by the patient in a timely and accessible way such that they
do not need to seek acute care hospitalization.
Limitations and Delimitations
These findings may represent a hospital system that has developed a robust system for
identifying and referring an HF patient to HFPC in a timely way. Such timely identification may
reflect patients with more advanced disease or poorer medical and social coping mechanisms that
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were not assessed in this study. While patients were matched on severity, health-seeking
behaviors and coping mechanisms were beyond the scope of this study. Indeed, the referral
patterns for this hospital may identify the individuals with the poorest health-seeking behaviors
and the fewest social supports and coping mechanisms. Even though HFPC is appropriately
offered as another aspect of treatment, it should not be viewed as a mechanism to reduce hospital
30-day readmissions.
The underlying natural variation within this investigation lies in the complexity of
clinical care management, associated morbidity and mortality, prevalence and health care costs
of heart failure, and the difficulty in developing reliable solutions that meet the complex and
varied course of disease discussed in the previous sections of this dissertation. The optimal
treatment regimen for HF continues to evolve with a significant body of literature and cannot be
identified as a single best approach at this time, resulting in significant variations in care. Thus,
significant treatment heterogeneity is unavoidable in any HF cohort.
Recent commentary has highlighted the importance of delineating the duration of HF,
with a key aspect being the timing of initiation of HFPC with recommendations for early
initiation to ensure a smooth and timely integration of HFPC services (von Schwarz et al., 2020).
This issue is part of a larger issue, which is defining more specifically not only the timing of
initiation of HFPC consultation but more specifically delineating the services that comprise the
essential services that ensure HFPC effectiveness. While the scope of this question exceeds the
scope of this investigation, it remains an important area for future research.
Insurance providers, including the US government by way of the Medicare program, have
a vested interest in controlling costs associated with treatment, with the result that interventions
to decrease hospital readmissions are likely to continue unless evidence is generated that such
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administrative mandates demonstrate clear futility or harm. More importantly, patients and their
families rely on health care providers and the broader health system to receive optimal, lifepreserving medical care and quality of life. HFPC would appear to be the best option of
addressing complex individualized care needs in an outpatient setting but requires validation.
This research contributes to the development of incremental knowledge specific to the validity of
HFPC interventions to decrease hospital readmissions after controlling for mortality. Also, this
research addressed the underlying barriers and issues by addressing a specific gap in medical
knowledge that has not been assessed (whether the effect of mortality on HFPC readmission
rates is substantive or negligible and whether HFPC is an effective intervention for patients with
end-stage heart disease to reduce 90-day hospital readmissions). Lastly, this investigation fully
established that there is a statistically significant difference in 90-day hospital readmission
between the cohort of subjects with an HFPC consult versus those with no HFPC consult with
individuals with an HFPC consult realizing statistically significant earlier hospital readmission
than their propensity-matched counterparts.
Summary
Recent administrative mandates from the Centers for Medicare and Medicaid Services
(CMS) embodied in the Hospital Readmission Reduction Program (HRRP) have aimed to reduce
the frequency of heart failure (HF) 30-day hospital readmissions. To fill the health care needs of
patients with end-stage heart failure, palliative care (HFPC) and hospice referrals are promoted
to provide additional support to patients in addition to their primary care and specialist
physicians and reduce unnecessary hospital readmission. While HFPC is a plausible and logical
intervention, effectiveness in achieving reductions in readmissions has not been assessed in a
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heart failure population with adequate controls to assess potential sources of confounding and
interaction.
Currently, hospital readmission metrics include in their numerator all patients with a
diagnosis of HF who are readmitted within a 30-day time period with the denominator including
all patients discharged with a diagnosis of HF. If the patient experiences a mortality event in the
30-day period after hospital discharge, there is no opportunity for readmission, and the mortality
event does not accrue to the numerator of the admitting hospital readmission metric. Studies to
date have evaluated the efficacy of palliative care to achieve reductions in hospital readmissions
but have not evaluated this potential for significant differential mortality. This investigation
assessed the mortality-adjusted, propensity-matched (severity-adjusted) relationship between
HFPC consult and 90-day hospital readmission in patients with a diagnosis of end-stage heart
failure (HF) in the current context of administrative mandates that aim to reduce the frequency of
HF hospital readmissions.
Heart failure is the most common discharge diagnosis in the United States, affecting 5.1
million annually (Arora et al., 2017; Fasolino & Phillips, 2016). The Centers for Medicare and
Medicaid Services (CMS) implemented components of the 2010 Affordable Care Act with the
introduction of the Hospital Readmission Reduction Program (HRRP) and began to publicly
report hospital 30-day all-cause risk-standardized mortality rates and 30-day all-cause riskstandardized readmission rates for acute myocardial infarction (AMI), heart failure (HF) and
pneumonia (Krumholz et al., 2013). In October 2012, CMS introduced penalties and began
reducing Medicare payments for excess readmissions in a broad array of inpatient
hospitalizations, specifically HF, based on a ratio of predicted versus expected 30-day
readmissions (Medicare, 2017). A higher-than-expected rate of thirty-day readmissions
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following HF hospitalization can negatively impact hospital performance measures and incur
reimbursement penalties (Davis et al., 2017).
The expansion of palliative care programs beyond cancer to end-stage organ failure
patients is new and has received increasing popular attention worldwide in the last decade (Ng et
al., 2016). A key element of the hospital interest in palliative care is the risk adjustment it affords
the hospital submitting data for CMS readmission metrics. The presence of a coded palliative
care consult (V667) or hospice referral on the electronic medical record of the patient admitted
with HF increases the expected count of HF readmissions in CMS quality calculations and
creates a greater opportunity for the hospital to have a less than the expected count of HF
readmissions which translates into a higher quality score for the admitting hospital (Trivette,
2017).
Research evaluating the effectiveness of an HFPC consult in the setting of acute
hospitalization for HF as an intervention to decrease 30-day hospital readmission has shown
mixed results and methodological limitations. A broad array of guidelines promotes its adoption,
while the literature has demonstrated poor reproducibility of the reliability of a PC consult to
effectively reduce hospital readmissions (Chuang & Fausto, 2014; Chuang et al., 2017; Nelson et
al., 2011; O'Connor et al., 2015; Wiskar et al., 2017). The goal of this research was to assess the
effectiveness of HFPC consult to effect change in 90-day hospital readmissions in a propensitymatched model that adequately controls for mortality at a single-site 526-bed tertiary-care
facility.
This research is relevant to several key health care areas, including heart failure, hospital
readmissions, and palliative care. Heart failure prevalence is increasing, administrative pressures
to reduce hospital readmissions show no sign of weakening, and alternative strategies like
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palliative care require an evidence-based and methodologically rigorous evaluation of outcomes.
The sustained incidence, increasing prevalence, and significant lifetime risk of HF create the
strong imperative to improve all aspects of care associated with the diagnosis of HF. The
prevalence of risk factors in the US population, the increasing prevalence of obesity and
diabetes, the associated cost for care, and potentially significant increases in the future cost of
care for patients with HF indicate a significant imperative to improve the care and management
of individuals with HF. The challenges of a clinical syndrome with high mortality, complex
medical management of multiple comorbidities, and challenges with identifying interventions
with associated mortality benefit create the imperative for identifying new strategies, such as
palliative care to prevent HF hospital readmission and improve management of patients with HF.
The development of readmission metrics is flawed as a measure of hospital quality of care and is
more likely to represent administrative priorities to promote the development of improved
systems of care that incorporate individual and community aspects of care that are more likely to
contribute to improved continuity of care and result in fewer unplanned hospital readmissions
(Barnett et al., 2015; Chin et al., 2016; Freedland et al., 2016; National Quality Forum, 2016;
Pandey et al., 2017). According to Cook et al. (2016), mortality risk increases after hospital
readmission and never returns to pre-admission levels. Palliative care may provide the needed
transition and continuity of care to address the observed increase in mortality risk associated with
hospitalization.
The theoretical approach to this study employed the Common Sense Model in that the
relationship between illness representations with inputs from the illness prototype, sensory
inputs, and treatment beliefs, and the illness outcome of hospital readmission can be modified by
improving coping procedures developed in the context of palliative care. CSM focuses on the
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antecedent experience of severity (illness prototype) and concurrent inputs from the senses and
treatment beliefs. Moreover, it considers the projected future consequences and potential for cure
or control (illness representation) of the health-seeking behavior (Leventhal et al., 2016). The
interpretation of symptoms and health-seeking behaviors for HF is complex, difficult to assess,
and exerts a strong influence on the individual’s illness representation and prompting healthseeking behaviors (Enguidanos et al., 2015; Kaptein et al., 2003; Leventhal et al., 2016; Turrise,
2016). Coping mechanisms have been demonstrated to improve illness outcomes (Leventhal et
al., 2016; Turrise, 2016).
Statistical analysis encompassed:
a) logistic regression and odds ratio calculation of risk of the primary research question
of interest, the dependent variable 90-day hospital readmission against the
independent variables of mortality and severity (propensity-score) in both the
propensity-matched and total unmatched population
b) demographic characterization of the total unmatched population and the resulting
propensity-matched cohort
c) calculation of odds ratios for risk of HFPC consult based on demographic
characteristics, markers of acuity, and comorbidity
d) sub-analysis of time to readmission with histograms and survival curve analysis
Results were statistically significant for a strong association between HFPC consult and
90-day hospital readmission in a propensity-matched population, OR 4.3, 95% CI [1.8-10.6].
Statistically significant differences in the demographic characteristics of the population were
eliminated with propensity-matching but maintained strong model predictive ability with
Cohen’s d =0.83. Calculated ORs for obtaining HFPC consult provided insight into clinically
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meaningful patient characteristics that predict HFPC consult. Time to readmission analysis
demonstrated that patients with an HFPC consult have a different mean time to readmission, and
survival analysis demonstrated the statistically significant differences in the experience of
patients who received an HFPC consult compared to those that did not, p <.0001.


<30% of HF patients who have an HFPC consult are unable to avoid hospital
readmission for >90 days.



>50% of HF patients who have an HFPC consult experience a hospital readmission
within 30 days of discharge.



75% of HF patients who have an HFPC consult will have a hospital readmission
within 90 days of discharge.

This study demonstrated that while HFPC may be an important aspect of continuity of
care and care planning for the HF patient, it is not a valid or effective method for reducing 90day hospital readmissions. In this investigation, HFPC consult was predicted by and served as a
proxy for the HF patient that has an acute decompensation with abnormal lab values on
admission, with numerous comorbidities or approaching end-of-life. HFPC consultation has
many values in the care and management of the HF patient. However, reducing 90-day hospital
readmission is not an achievable goal. Conversely, HFPC consult should serve as a proxy signal
to expect the increased frequency of admissions in a population with high morbidity approaching
end-of-life.
It is important that hospital resources be utilized in the most useful and efficient ways. If
HFPC resources are tasked with providing an HFPC consult to every patient with end-stage heart
failure, with the primary intention that such referral will minimize hospital readmissions, it is a
clear misuse of limited PC resources. HFPC may certainly provide other necessary supports for
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decision-making and future health planning, which are important aspects of patient management.
However, if the primary aim is to reduce hospital 30-day readmission, PC resources are being
misspent.
The best outcome arising out of the implications of this study would be the refocusing
and reallocation of PC resources to meet realizable goals and provide meaningful support for
decision-making and future health planning. This may constitute the same population of HF
patients with high morbidity, poor health knowledge, and limited social resources, but the
objectives would be more closely aligned with quality of life issues rather than a hospital
operations focus to reduce hospital readmissions, given the current state of the health care system
that too often focuses on operational efficiency imperatives that are measurable and have a direct
contribution to the financial bottom line versus quality of life imperatives that are more difficult
to measure.

136
Appendices

137
Appendix A1
Table A1
Summary of Findings Pertaining to HF Readmission Rates
______________________________________________________________________

Author

Time span

n

All-cause 30-day HF
readmission rate

Comment

______________________________________________________________________
(Krumholz et al., Jul 2005 - Jun 1,430,053
2009)
2008

Median 24.4% (range 15.9% to
34.4%; 25th to 75th percentile
23.4% to 25.6%)

(DeVore et al.,
2016)

100,189

2006 - 7 21.5%
2007 - 8 21.8%
2008 - 9 22.2%
2009 - 10 22.2%
2010 - 11 22.1%
2011 - 12 22.5%

21,264

2009 20.0% (SD, 1.3%)
Get With the Guidelines is
2012 19.0% (SD, 1.2%) (p =0.001) a voluntary program
Trend in relative HRR by quartile
of performance Q1(best),
Q4(worse)
Q1 -0.9% (13.1 to 4.8)
Q2 -4.9% (-7.4 to 0.5)
Q3 -7.0% (-10.4 to -2.6)
Q4 -8.7% (-12.9 to -5.0)

2006 - 2012

(Bergethon et al., 2009 - 2012
2016)

(Wasfy et al.,
2017)

Jan 2000 - Nov 2868 hospitals Risk-standardized rates
30, 2013
per 10,000 discharges per year
Pre-ACA law 5.1 (4.8 to 5.3)
Post-ACA law -84.7 (-83.9 to 85.4)

(Zuckerman et al., Oct 2007 2016)
May 2015

(Desai et al.,
2016)

3387
hospitals

2007 - 08 21.5%
2014 - 15 17.8%
Slope of change:
Oct 2007 - Apr 2010 -0.017
Apr 2010 - Oct 2012 -0.103
Oct 2012 - Apr 2015 -0.005

Jan 2008 - Jun 48,137,102
Penalty hospitals
2015
hospitalizations 2008 27.5% mean HRR
Difference in annualized rate of
20,351,161
change:
Medicare
2008 - 2010 0.10% (-0.12 to 0.32)
enrollees
2010 - 2012 -0.50% (-1.18 to 0.62)
2012 - 2015 0.72% (0.40 to 0.95)

Adjusted trend
Before public reporting
0.0% (-1.4 to 1.5)
After public reporting 1.8% (-3.3 to -0.2)

Averted admissions by
quartile of performance
Q1(best) Q4(worse)
Q1 77.6 (76.4 to 79.2)
Q2 86.8 (85.6 to 88.0)
Q3 100.8 (98.4 to 102.8)
Q4 112.0 (108.0 to 115.6)
Aggregate HRR for all
target conditions inclusive
of AMI, HF, and
pneumonia

2010 - 2012 Penalty
hospitals had a -1.25%
difference in annualized
rate of change as
compared to non-penalty
hospitals.
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No penalty hospitals:
2008 24.2% mean HRR
2008 - 2010 -0.26% (-0.56 to 0.04)
2010 - 2012 0.08% (-0.30 to 0.46)
2015 - 2015 0.14% (-0.17 to 0.46)
(Sukul et al.,
2017)

2014

98,315 index HF Younger patients 18 - 64 had
admits
higher rates of readmission (21.4%)
compared to elderly patients
21,054 HF
(20.7%) p < 0.001
readmissions

(Gilotra et al.,
2017)

Jul 2014 - Mar 93
2015

29 (30%)

HF 30-day readmission
rate 17 (18%)
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Appendix A2
Table A2
Summary of Findings Pertaining to HF Readmission Rates and Mortality

Author

Dates

n

30-day
mortality
before public
reporting

30-day
Comment
mortality after
public
reporting

____________________________________________________________________________________________
_
(Krumholz et al., Jul 2005 - Jun 1,161,165
Median 11.1%
2009)
2008
(range, 6.6 to
19.8%)
(Krumholz et al.,
2013)

Jul 2005 - Jun 4767 hospitals
2008
1,161,179 patients

Correlation
between mortality
rates and
readmission rates
was
r2 =-0.17, 95% CI
[-0.20 to -0.14]

(Arundel et al.,
2016)

1998 - 2001

12-month
mortality for
patients with 30day readmit 41%

7578

HR 1.68, p <
0.001, 95% CI
[1.48 - 1.90]

With no 30-day
readmission, 27%
(Cook et al., 2016) 2003 - 2006

3993

37% net increase in
mortality risk
subsequent to 30day hospital
readmission.
p =0.15

(DeVore et al.,
2016)

2006 - 2012

100,189

(Bergethon et al.,
2016)
(Dharmarajan et
al., 2017)

2009 - 2012

21,264

2008 - 2014

2,962,554
hospitalizations
4772 hospitals

2008 8.4%
30-day post
discharge
mortality

2014 9.2%

Trend increased
0.008% (0.007% to
0.010%) monthly

(Fonarow et al.,
2017)

2008 - 2014

Reanalysis of
Dharmarajan 2017

2008
Observed 7.9%

2014
Observed 9.2%

Delta 2.6%
mortality increase

Adjusted all-cause Adjusted allmortality trend - cause mortality
2.4% (-6.2 to 1.6) trend 3.1% (-1.3
to 7.6)
2009 7.8%
2012 7.6%
p =0.71
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Expected 7.9%

Expected 6.6%

(Gupta et al., 2017) Jan 1, 2006 Dec 31, 2014

115,245 pts
416 hospitals

7.2%
30-day postdischarge
mortality

9.2%
30-day HR 1.15,
95% CI [1.08 1.24]
1-yr HR 1.10,
95% CI [1.07 1.14]
30-day HF
30-day HF
mortality
mortality
decreased -0.12% increased 0.17%
per year among
per year among
baseline poor
all other hospitals
performers

(Chatterjee & Joynt 2009 - 2015
Maddox, 2018)

2009 - 2751
2015 - 3796
hospitals

(Wadhera, Joynt
Maddox, Wang,
Shen, & Yeh,
2018)

Jul 1,2011 Jun 30, 2014

1,343,792 pts, 2948 High versus Low
hospitals
30-day episode
payments
associated with
Mortality OR
0.969,
p < 0.001

Cautionary for
programs that
incentivize reduced
payments like
HRRP

(Khera,
Dharmarajan, &
Krumholz, 2018)

Jan 1, 2006 Dec 31, 2014

4,000,000 HF
hospitalizations

Combines
divergent inhospital and postdischarge trends to
report overall
nonsignificant
mortality trend.

Trend increasing Trend for in0.004% per month hospital mortality
pre-HRRP
decreased from
4.3% to 3.5%,
post-discharge
mortality
increased from
7.4% to 9.2%.

Population subset
from AHA Get
With the
Guidelines
voluntary registry
p < .001
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Appendix A3
Table A3
Summary of Findings Pertaining to HF Readmission Rates and Palliative Care

Study

Dates

n

(Rabow et al., Not
n=90
2004)
reported 40 usual
primary care
50 PC
intervention

Intervention

Outcomes

Interdisciplinary PC team Physical
meetings led by PC MD UCSD SOB p =0.01
providing:
Brief Pain Inventory
(a) written
(ns)
recommendations to PCP Sleep items from MOS
in five domains of PC at p =0.05
study entry, midway, and Psychological
end.
Profile of Mood States
(b) Social work case
(ns)
management
CES Depression scale
(c) RN led family
(ns)
caregiver training
Spiritual
(d) Pharmacist
Spiritual well-being
medication review
scale p =0.007
(e) Chaplain offered
Social
spiritual and
QoL scale-Cancer (ns)
psychological support
Health care satisfaction
(f) Monthly patient and
GHAA survey (ns)
family support groups
Advanced care planning
(g) Weekly telephone
p =0.03 in one of three
contact, monthly visits
outcomes
providing communication Utilization
with PC team about
Clinic visits p =0.03
patient needs.
Urgent care p =0.04
Specialist, ED visits,
hospital admissions,
hospital days, and
charges (ns)
Mortality (ns)

(Aiken et al., Jul 1999 N=192
PhoenixCare intervention
2006)
- Mar
91 usual care with service delivery by
2001
101 PC
RN case managers
intervention conducting home visits,
phone calls, and
accompanying patients to
MD visits

Risk of bias
assessment (Higgins
et al., 2011; Savovic
et al., 2018)
Moderate risk of bias.
Site randomized, no
subject randomization.
Unblinded
Mixed subject
population with HF
minority (34 - 35%).
Selection bias with 58%
(intervention) to 65%
(control) refused to
enroll because they were
“too ill.”
N.B. Pain and
depression
recommendations were
rarely implemented.

Receipt of sufficient
High risk of bias.
information or education
p < 0.05 for four of 12 Mixed subject
outcomes
population affecting
Preparation for end-of- generalizability to HF
life p < 0.05 for two of patients.
10 outcomes.
Subjective outcomes
Symptom burden p <
using non-validated
0.05 for one of six
instruments
outcomes.
Unblinded
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(Brumley et
al., 2007)

(Pantilat,
O'Riordan,
Dibble, &
Landefeld,
2010)
(Brannstrom
& Boman,
2014)

Sep 2002 n=298
- Mar
155 usual
2004
care
155 PC
intervention

Terminally ill
participants randomized
to usual care or in-home
palliative care with an
assigned coordinating PC
physician preventing
service fragmentation.

High loss to follow-up,
retaining 43% of
intervention pts. and
33% of control pts.

Satisfaction with care p
< .05, decreased use of
medical services (ED
visits) p =.01, site of
death at home p < .001,
lower costs of care p
=.03

High risk of bias.
Unblinded
Population not
representative of HF
population (33% HF).
Intervention
representative of hospice
not palliative care.

Jan 2002 n=107
Daily inpatient PC visits Symptom rating 0 - 10
- Dec
53 usual care and phone call two weeks of pain (ns), dyspnea
2003
54 PC
after discharge.
(ns), and anxiety (ns).
intervention

High risk of bias.

Jan 2011
- Oct
2012
Sweden

High risk of bias.

n=72
PREFER 36 usual care Multidisciplinary in36 PC
home disease
intervention management and PC
services
Nurse visits p =0.0001
MD phone calls or Rx
meds (ns)
MD visits (ns)

(Sidebottom
et al., 2015)

SF-36 physical and
mental functioning p <
0.05 for two out of eight
domains for HF subset.
ED visits (ns)

Apr 2012 n=232
- Feb
116 usual
2013
care
US
116 PC
intervention

Symptom burden
(ESAS) (ns)
Quality-of-life
EuroQol (EQ-5D) p
=0.05
(KCCQ) (ns)
Survival at six months.
(ns)
Total Readmissions p
=0.009

Single center, unblinded
(blinded assessments)

Single center, unblinded
Core health system
differences limit
generalizability to the
US.
Differential allocation to
control or intervention
by age

Standard process of
Quality-of-life
High risk of bias
hospital PC team and
(MLHFQ) p <
survey responses to
0.0001 at one Single center, unblinded
MLHFQ, ESAS, and
or three
Selection bias - enrolled
PHQ-9 acquired at
months.
subjects not ordered for
baseline interview and no Symptom management standard of care PC
patient cost for initial PC
(ESAS) p <
referral
consult.
0.0001 at one
or three
Financial compensation
months.
to intervention subjects
Depression (PHQ-9) p < providing free initial PC
0.0001 at one consult.
or three
months.
Differential loss to
Advance care planning p follow-up with 80% of
=0.033 at six individuals in the
months
intervention arm
30-day readmission (ns) receiving only one
Hospice use (ns) at six initial visit.
months
Mortality (ns) at six
months
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(Bekelman et May
al., 2015)
2009 Jun 2011
US

n=392
197 usual
care
187
intervention

Multidisciplinary
collaborative care HF
disease management:
Screening for and
treatment of depression
Telemonitoring with
patient self-care support

Quality-of-life (KCCQ)
(ns)
Mortality p =0.04
1-year hospital
Readmission (ns)

Equivocal risk of bias

Very high variance in
KCCQ trajectories
(range 0 - 100)
Unblinded patient
Subgroup analysis of HF intervention (blinded
patients with Depression outcome assessments)
(PHQ-9) p =0.01

(Hopp et al., Sep 2006 n=85
At least one inpatient PC Election versus nonHigh risk of bias
2016)
- Jun
43 usual care consultation, with the
election of comfort2008
42 PC
opportunity for additional oriented care (hospice or Unblinded
US
intervention meetings.
“do not resuscitate”
92% African American
order) (ns)
patient population and
Quasi-qualitative
predominantly White
reasons for noncaregivers providing
participation abstracted service.
from medical record.
(Wong et al., May
2016)
2013 Dec
2014
Hong
Kong

n=84
MD supported RN case Readmission at four
41 usual care managers provided
weeks (ns)
43 PC
patient visits, training,
and 12 weeks (p
intervention home visits and
=0.009)
telephone visits weekly Symptom intensity
for the first four weeks,
(ESAS)(ns)
then monthly through 12 Functional status (PPS)
weeks.
(ns)
Quality-of-life
MQOL-HK p <
0.001 at
12 weeks,
CHHQ p < 0.001 at
12 weeks)
Satisfaction with care
(ns)

High risk of bias

(Rogers et al., Aug
2017)
2012 Jun 2015
US

n=150
Interdisciplinary,
Quality-of-life
75 usual care guideline-driven,
KCCQ, FACIT-PAL
75 PC
multicomponent PC
p =0.021
intervention intervention with
Anxiety and depression
contemporary HF
HADS p =0.063
management. PC MD led Spiritual well-being
team with PC NP
FACIT-Sp p =0.031
collaborating with
Hospitalizations (ns)
cardiology and a focus on Mortality (ns)
shared goal setting. After
discharge NP participated
in ongoing patient
management.

Low-Moderate risk of
bias

Differential loss-tofollow-up (25% control,
14% intervention (I)
Differential allocation to
control or intervention
by HF class (I)
Differential allocation to
control or intervention
for advanced HF
interventions (CRT and
Pacemaker) (I)
Core health system
differences limiting
generalizability.

Unblinded intervention
Single center
12% loss to follow-up
Selection bias - subjects
recruited from
established HF program
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(Bekelman et Aug
N=314
al., 2018)
2012 - 157 usual
Apr 2015 care
157 PC
intervention

Psychosocial care model
- Collaborative Care to
Alleviate Symptoms and
Adjust to Illness (CASA)
RN symptom evaluation
Social worker providing
psychosocial care
Consulting team,
including PC, PCP, and
Cardiology providing
orders for tests and
medications to patients’
PCP for review and
signature.

Quality-of-life (KCCQ)
(ns)
Depression (PHQ-9) p
=0.02
Anxiety (GADQ) (ns)
Global symptoms
(GSD)(ns)
Specific symptoms: pain
(ns), fatigue p =0.02,
shortness of breath (ns)
Hospitalizations (ns)
Mortality at three and
six months(ns)

Low risk of bias
Multi-site
Single blind
SOC PC consultation
delivered to usual care
arm.
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Table A4
2020 ICD-10-CM Heart Failure Diagnostic Codes
__________________________________________________________________________
Code
Description
__________________________________________________________________________
I09.81
I11.0
I50
I50.1
I50.2
I50.20
I50.21
I50.22
I50.23
I50.3
I50.30
I50.31
I50.32
I50.33
I50.4
I50.40
I50.41
I50.42
I50.43
I50.8
I50.81
I50.810
I50.811
I50.812
I50.813
I50.814
I50.82
I50.83
I50.84
I50.89
I50.9

Rheumatic heart failure
Hypertensive heart disease with heart failure
Heart failure
Left ventricular failure, unspecified
Systolic (congestive) heart failure
Unspecified systolic (congestive) heart failure
Acute systolic (congestive) heart failure
Chronic systolic (congestive) heart failure
Acute on chronic systolic (congestive) heart failure
Diastolic (congestive) heart failure
Unspecified diastolic (congestive) heart failure
Acute diastolic (congestive) heart failure
Chronic diastolic (congestive) heart failure
Acute on chronic diastolic (congestive) heart failure
Combined systolic (congestive) and diastolic (congestive) heart failure
Unspecified combined systolic (congestive) and diastolic (congestive) heart
failure
Acute combined systolic (congestive) and diastolic (congestive) heart failure
Chronic combined systolic (congestive) and diastolic (congestive) heart failure
Acute on chronic combined systolic (congestive) and diastolic (congestive) heart
failure
Other heart failure
Right heart failure
Right heart failure, unspecified
Acute right heart failure
Chronic right heart failure
Acute on chronic right heart failure
Right heart failure due to left heart failure
Biventricular heart failure
High output heart failure
End stage heart failure
Other heart failure
Heart failure, unspecified

Excluding:
__________________________________________________________________________
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000 - 007, 008.8 Heart failure complicating abortion or ectopic or molar pregnancy
008.8
Other complications following an ectopic and molar pregnancy
075.4
Heart failure complicating obstetrical procedure or delivery
I13.0
Hypertensive heart and chronic kidney disease with heart failure and stage one
through four chronic kidney disease, or unspecified chronic kidney disease
I13.2
Hypertensive heart and chronic kidney disease with heart failure and with stage
five chronic kidney disease, or end stage renal disease
I46
Cardiac arrest
I97.13
Postprocedural heart failure
P29.0
Heart failure originating in the perinatal period
R57.0
Cardiogenic shock
R57.9
Shock, unspecified
Including MS-DRG v37.0:
__________________________________________________________________________
222
223
291
292
293

Cardiac defibrillator implant with cardiac catheterization with ami or hf or shock
with mcc
Cardiac defibrillator implant with cardiac catheterization with ami or hf or shock
without mcc
Heart failure and shock with mcc
Heart failure and shock with cc
Heart failure and shock without cc or mcc

Excluding MS-DRG v37.0:
__________________________________________________________________________
791
793

Prematurity with major problems
Full term neonate with major problems
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Appendix A5
Table A5
ICD-10-CM Comorbidities Pertaining to HF Propensity-Matching (Quan et al., 2005)
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Appendix A6
Figure A6
Palliative Care Automatic Consult Criteria
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Appendix A7
Figure A7
Variable Histograms Demonstrating Normal Distribution of Values and Transformed Strata
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Appendix A8
Table A6
Dependent Variable Encoding
Original Value
No
Yes

Internal Value

0
1

Categorical Variables Codings

Parameter coding
Frequency

(1)

(2)

(3)

(4)

(5)

(6)

Discharge

Home - 0

126

.000

.000

.000

.000

.000

.000

disposition

Home W/

48

1.000

.000

.000

.000

.000

.000

Hospice

10

.000

1.000

.000

.000

.000

.000

Inpt Reh

3

.000

.000

1.000

.000

.000

.000

Long Ter

4

.000

.000

.000

1.000

.000

.000

Short Te

2

.000

.000

.000

.000

1.000

.000

Skilled

41

.000

.000

.000

.000

.000

1.000

Denies

132

.000

.000

.000

.000

Tob<30d

32

1.000

.000

.000

.000

Tobuse1+

57

.000

1.000

.000

.000

Tobuse30

8

.000

.000

1.000

.000

Unable t

5

.000

.000

.000

1.000

Hospitalization

Admissio

87

.000

.000

duration

Observat

72

1.000

.000

Prolonge

75

.000

1.000

Primary

Commerci

148

.000

.000

Insurance

Medicaid

6

1.000

.000

Medicare

80

.000

1.000

.25 Redu

59

1.000

.000

Tobacco Use

153
Ejection

.25-.50

84

.000

1.000

Fraction cohort

.50+ Pre

91

.000

.000

Age cohort

< 55

49

.000

.000

55-75

99

1.000

.000

75+

86

.000

1.000

Hyperten

139

1.000

.000

Hypotens

2

.000

1.000

Normal

93

.000

.000

0 Normal

163

.000

.000

1 Bradyc

11

1.000

.000

2 Tachyc

60

.000

1.000

Hypernat

7

1.000

.000

Hyponatr

40

.000

1.000

Normal

187

.000

.000

Abnormal

36

1.000

.000

Elevated

72

.000

1.000

Normal

126

.000

.000

Low

25

.000

.000

Normal

131

1.000

.000

Renal co

78

.000

1.000

Guideline

No

114

1.000

Adherance

Yes

120

.000

Gender

Female

120

1.000

Male

114

.000

Do Not

.

219

.000

Resuscitate

DNR

15

1.000

Hgb

Anemia

129

1.000

Normal

105

.000

Intra Aortic

No

233

.000

Balloon Pump

Yes

1

1.000

AICD or CRT-

No

172

.000

D Implant

Yes

62

1.000

No

225

.000

BP

HR.

Na

Cr

BUN/Cr

154
Pressors
required

Yes

9

1.000

155
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Table A7
Classification Tablea
Predicted
Palliative Care Consult
Observed
Step 1

Percentage

No

Yes

Correct

Palliative Care

No

126

16

88.7

Consult

Yes

20

72

78.3

Overall Percentage

84.6

a. The cut value is .500
Variables in the Equation
B

S.E.

Step Age cohort
1

a

Wald

df

Sig.

4.132

2

.127

Exp(B)

Age cohort(1)

-1.716

.876

3.839

1

.050

.180

Age cohort(2)

-.911

.928

.963

1

.326

.402

Gender(1)

1.079

.634

2.899

1

.089

2.943

Do Not

.945

1.939

.238

1

.626

2.574

3.799

2

.150

13055.527

.000

1

.999

.000

.667

3.799

1

.051

3.670

2.558

2

.278

1.910

1

.167

Resuscitate(1)
Primary
Insurance
Primary

-

Insurance(1)

23.386

Primary

1.300

Insurance(2)
Ejection
Fraction cohort
Ejection
Fraction
cohort(1)

1.110

.803

3.035

156
Ejection

-.005

.656

.000

1

.994

.995

1.140

.670

2.898

1

.089

3.127

.906

.582

2.420

1

.120

2.475

.581

2

.748

Fraction
cohort(2)
AICD or CRTD Implant(1)
Guideline
Adherance(1)
Hospitalization
duration
Hospitalization

.004

.691

.000

1

.996

1.004

-.493

.670

.542

1

.462

.611

11.830

6

.066

4.116

1

.042

5.342

22.308 10366.699

.000

1

.998

4877036073.909

4.746

3.552

1.785

1

.182

115.070

.969

2.224

.190

1

.663

2.635

-

40192.970

.000

1

1.000

.000

.896

8.399

1

.004

13.418

4.199

2

.123

4.199

1

.040

3.672

.000

1

.999

74028849642.421

6.102

2

.047

duration(1)
Hospitalization
duration(2)
Discharge
disposition
Discharge

1.676

.826

disposition(1)
Discharge
disposition(2)
Discharge
disposition(3)
Discharge
disposition(4)
Discharge
disposition(5)

16.778

Discharge

2.597

disposition(6)
BP
BP(1)

1.301

.635

BP(2)

25.028 24543.706

HR.
HR.(1)

-3.141

1.700

3.414

1

.065

.043

HR.(2)

1.272

.779

2.670

1

.102

3.569

2.324

2

.313

Na

157
Na(1)

.969

1.419

.467

1

.495

2.635

Na(2)

-1.027

.783

1.718

1

.190

.358

1.854

2

.396

BUN/Cr
BUN/Cr(1)

1.292

1.040

1.543

1

.214

3.639

BUN/Cr(2)

.896

1.141

.616

1

.432

2.449

11.075

2

.004

Cr
Cr(1)

-.311

1.248

.062

1

.804

.733

Cr(2)

2.016

.693

8.462

1

.004

7.509

Hgb(1)

-.598

.581

1.059

1

.303

.550

Pressors

-.681

2.542

.072

1

.789

.506

.000

1

.999

506772158989469180.000

7.070

4

.132

required(1)
Intra Aortic

40.767 56841.443

Balloon
Pump(1)
Tobacco Use
Tobacco Use(1)

-1.848

.914

4.086

1

.043

.158

Tobacco Use(2)

-.035

.630

.003

1

.956

.966

Tobacco Use(3)

-1.908

1.660

1.320

1

.251

.148

Tobacco Use(4)

-4.021

2.251

3.189

1

.074

.018

AIDS

26.655 23895.083

.000

1

.999

376707060855.558

Alcohol abuse

2.020

5.497

.135

1

.713

7.536

Deficiency

.542

.747

.526

1

.468

1.719

Arthropathies

-3.616

1.442

6.290

1

.012

.027

Chronic blood

1.924

6.860

.079

1

.779

6.851

Anemias

loss anemia
Leukemia

37.035 46700.500

.000

1

.999

12130545869000848.000

Lymphoma

-3.563

2.849

1

.091

.028

Metastatic

27.416 23779.443

.000

1

.999

806628941303.526

.000

1

.999

.000

2.111

cancer
Solid tumor
without

20.120

23779.443

158
metastasis,
malignant
Cerebrovascular

2.263

2.197

1.060

1

.303

9.609

.000

1

.999

487343389861.793

disease - present
on admission
Cerebrovascular 26.912 40192.970
disease –
sequelae
Cerebrovascular

2.339

2.321

1.015

1

.314

10.366

-3.053

1.111

7.549

1

.006

.047

1.479

1.136

1.693

1

.193

4.388

4.202

2.084

4.065

1

.044

66.789

Coagulopathy

2.040

1.371

2.214

1

.137

7.690

Dementia

-.529

1.010

.274

1

.601

.589

Depression

.121

.923

.017

1

.896

1.129

-1.130

.675

2.802

1

.094

.323

2.945

1.003

8.631

1

.003

19.019

Drug abuse

1.136

1.326

.733

1

.392

3.113

Hypertension,

-1.509

1.161

1.689

1

.194

.221

disease sequelae
paralysis
Congestive
heart failure
CHF with
hypertension,
complicated
CHF with
hypertension w
renal failure,
severe

Diabetes with
chronic
complications
Diabetes
without chronic
complications

complicated

159
Hypertension,

40192.970

.000

1

1.000

.000

-.833

.889

.879

1

.348

.435

2.230

2.407

.858

1

.354

9.299

-1.861

4.643

.161

1

.689

.156

2.357

.690

11.668

1

.001

10.555

-1.350

1.950

.479

1

.489

.259

-.475

.981

.234

1

.628

.622

2.109

1.632

1.669

1

.196

8.238

Obesity

1.037

.597

3.017

1

.082

2.820

Paralysis

2.821

2.902

.945

1

.331

16.801

Peripheral

-.289

.948

.093

1

.761

.749

Psychoses

-.096

1.901

.003

1

.960

.908

Pulmonary

2.181

1.049

4.318

1

.038

8.854

.650

.797

.666

1

.415

1.916

complicated

14.252

with renal
failure, severe
Hypertension,
uncomplicated
Liver disease,
mild
Liver disease,
moderate to
severe
Chronic
pulmonary
disease
Neurological
disorders
affecting
movement
Other
neurological
disorders
Seizures and
epilepsy

vascular disease

circulation
disease
Renal failure,
moderate

160
Renal failure,

.573

1.293

.197

1

.657

1.774

.032

.829

.002

1

.969

1.033

-1.527 42260.166

.000

1

1.000

.217

-1.615

1.620

.994

1

.319

.199

1.427

.645

4.886

1

.027

4.165

Weight loss

1.917

1.172

2.678

1

.102

6.803

Constant

-5.363

1.896

7.999

1

.005

.005

severe
Hypothyroidism
Other thyroid
disorders
Peptic ulcer
with bleeding
Valvular
disease

161
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Table A8
Predicted probability * Palliative Care Consult
Chi-Square Tests
Asymptotic
Significance (2Value
Pearson Chi-Square
Likelihood Ratio

df

sided)

a

232

.451

313.626

232

.000

234.000

N of Valid Cases

234

a. 466 cells (100.0%) have expected count less than 5. The
minimum expected count is .39.

PVar_Match * Palliative Care Consult
Chi-Square Tests
Asymptotic
Significance (2Value
Pearson Chi-Square
Likelihood Ratio
N of Valid Cases

Df

sided)

a

131

.459

154.691

131

.077

132.000

132
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